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Oxygen (O2) insufficiency (hypoxia), either in response to environmental exposure 
or pathological states is a driver of metabolic remodelling, the details of which are ill- defined. 
This work aimed to further understanding of metabolic responses to environmental hypoxia. 
In the first study, plasma metabolite changes were measured in 198 human subjects upon 
ascent to Everest Base Camp (5300m) using metabolomic and lipidomic techniques. 
Results were indicative of a shift towards anaerobic glycolysis, a mobilisation of fat stores 
and alterations to fat lipoprotein transport with ascent. In the second study, a pilot study, 
subjects (n=5) were examined pre and post an attempted winter crossing of Antarctica, 
including a 24 week stay above 2,500m. Metabolomics analysis of serum samples alongside 
whole body physiological and exercise measurements were indicative of a shift in metabolic 
signature, including an increased reliance upon carbohydrate metabolism during exercise.  
Developing a means of attenuating the metabolic stress of hypoxia would be highly 
beneficial for aiding human adaptation and ameliorating the effects of disease states where 
hypoxia is a comorbidity. An additional aim was to explore the potential of dietary nitrate for 
this purpose. In the third study, the potential for nitrate supplementation to aid hypoxic 
acclimatisation of skeletal muscle mitochondria and the role of PPARα (a master regulator 
of fat oxidation) were assessed using a mouse model of wild type (n=42) and PPARα-/- 
strains (n=42). Nitrate supplementation (0.7mM) recovered hypoxic induced decreases in 
fatty acid and carbohydrate oxidation in response to prolonged, severe hypoxic exposure 
(10% O2, 28 days) and did so independently of PPARα. In the fourth study, the effects of 
acute dietary nitrate supplementation (12mM nitrate vs. placebo ingested 3 hours pre-
exercise) upon exercise endurance and related metabolite changes were investigated in 
chronic obstructive pulmonary disease (COPD) patients (n=21, age 68+7 years). Whilst 
neither median endurance time nor targeted plasma metabolites differed between 
treatments, O2 consumption was significantly lower following nitrate treatment vs. placebo. 
The absence of plasma lactate changes between treatments indicates this effect was not 
mediated through increased reliance upon anaerobic metabolism.   
In conclusion, this work highlighted several potential biomarkers of interest in healthy 
humans exposed to environmental hypoxia, including alterations to carbohydrate and lipid 
metabolism. Dietary nitrate demonstrated potential for recovering metabolic function in vitro, 
yet failed to illicit beneficial effects in a clinical population in vivo.   
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1H-NMR Proton nuclear magnetic resonance 
HOAD  3-hydroxyacyl-CoA dehydrogenase 
HRE  Hypoxic response element 
iCa2+  Intracellular calcium 
KTM  Kathmandu 
LCAD  Long chain acyl CoA 
LC-MS  Liquid chromatography-mass spectrometry 
LPC  Lyso-phosphatidylcholine 
LDN  London 
LDL   Low density lipoprotein 
LEAK  Leak state respiration 
LPL  Lipoprotein lipase 
MFN2  Mitofusin 2 
MiR  Mitochondrial respiration medium  
MS  Mass spectrometry 
MyHC  Myosin heavy chain 
m/ z Mass to charge ratio 
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NAD+  Nicotinamide adenine dinucleotide 
NADH  Reduced nicotinamide adenine dinucleotide 
NAM  Namche 
NO  Nitric oxide 
NO3-  Inorganic nitrate 
NO2-  Nitrite 
NOS  Nitric oxide synthase 
O2  Oxygen 
OAA  Oxaloacetate 
OCE  Oxidative phosphorylation coupling efficiency 
OXPHOS Oxidative phosphorylation 
PB  Barometric pressure 
PCA  Principal component analysis  
PC  Phosphatidylcholine 
PCr  Phosphocreatine 
PDK  Pyruvate dehydrogenase kinase 
PHE  Pheriche 
Pi  Inorganic phosphate 
PIO2  Partial pressure of inspired oxygen 
PKG  Protein kinase G 
31P-MRS  31-phosphorus magnetic resonance spectroscopy  
31P-NMR 31-Phosphorus nuclear magnetic resonance 
PO2  Partial pressure of oxygen  
PGC1α Proliferator-activated receptor gamma coactivator 1-alpha 
PPARα Peroxisome proliferator-activated receptor alpha 
PS  Phosphatidylserine 
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QC  Quality control 
ROS  Reactive oxygen species 
SERCA Sarcoplasmic reticulum Ca2+ ATPase 
SCD1  Stearoyl-CoA desaturase 1 
SD  Standard deviation 
SM  Sphingomyelin 
SpO2  Arterial O2 saturation 
sGC  Soluble guanylyl cyclase 
TCA  Tricarboxylic acid 
Tfam  Mitochondrial transcriptional factor A 
TG  Triglyceride 
UCP  Uncoupling protein  
VE  Minute ventilation 
VEGF  Vascular endothelial growth factor 
VLDL  Very low density lipoprotein 
VO2  Pulmonary oxygen uptake 
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1 Chapter 1: Introduction and literature 
review 
1.1 Introduction 
The entire macro and micro-anatomy of large animals is constrained by the need for 
an adequate provision of O2 (Koch et al., 2008). The constant O2 requirement has 
necessitated the evolution of an extensive cardiovascular and respiratory system in higher 
animals to ensure adequate oxygenation of all tissues. The transferral of O2 from the 
atmosphere, across the alveoli and to the tissues, ending at the mitochondria occurs via a 
process termed the O2 cascade. In this cascade, O2 moves from areas of high O2 pressure 
(air) to regions of low O2 pressure (mitochondria). The partial pressure of O2 (PO2) falls in a 
stepwise fashion down this cascade. Within mitochondria, O2 is essential for the generation 
of adenosine triphosphate (ATP) via oxidative phosphorylation (OXPHOS). A sufficient 
supply of O2 to the tissue is thus required to maintain oxidative metabolism, and so both 
energetic and redox homeostasis, within complex organisms. 
Disruption of any part of the O2 cascade can result in an insufficient supply of O2 to 
the tissues, termed hypoxia.  This occurs in healthy humans upon exposure to high altitudes, 
whereby the fall in barometric pressure (PB), or the downwards force exerted by the 
atmosphere, leads to a decrease in inspired partial pressure of O2 (PIO2). This compromises 
the transfer of O2 down the O2 cascade resulting in hypobaric hypoxia.  
A plethora of disease states are also associated with disruptions to the O2 cascade. 
This includes chronic obstructive pulmonary disease (COPD), a leading cause of death 
worldwide that is associated with progressive airflow limitation (Lozano et al., 2013). The 
resultant hypoxic state is a key component of disease pathology (Pauwels et al., 2012).  
In these hypoxic states, oxidative metabolism and so ATP production, becomes 
compromised in turn impairing cellular function. Metabolic remodelling is therefore required 
to enable the maintenance of order and homeostasis. However, the details of remodelling 
processes remain ill-defined.   
In the instance of hypobaric hypoxia in healthy humans, current evidence suggests 
that acclimatisation involves a shift towards anaerobic ATP generation alongside alterations 
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to mitochondrial oxidative processes including tricarboxylic acid (TCA) cycle function and 
electron transfer chain/system (ETS) activities, as well as suppression of β-oxidation 
(Horscroft et al., 2014). However, a significant lack of consensus exists between studies, 
making this a highly contentious field. This is likely a result of discrepancies in study design, 
with large degrees of variation in the duration and degree of hypoxic exposure apparent in 
both human and rodent models. Particularly in the case of investigations into human 
physiology, this is further confounded by low subject numbers as the majority of high altitude 
studies are performed on fewer than 20 subjects. In addition, many previous studies focus 
on specific aspects of complex metabolic pathways such as activities of select enzymes, as 
opposed to metabolic profiles, which have the potential to provide far greater insight and 
may highlight biomarkers for hypoxic exposure (Sreekumar et al., 2009, Nicholson et al., 
2008).   
Despite the utmost importance of metabolic remodeling in enabling acclimatisation 
to hypoxic states, the details of this process thus remain ill-defined. Furthering our 
understanding of these changes has implications clinically for those disease states in which 
hypoxia plays an integral part and also for the growing numbers of healthy humans 
sojourning to, or residing at, high altitudes (Woolcott et al., 2015). By gaining a more 
complete picture of the healthy human metabolic remodelling response, it thus becomes 
feasible to further the development of potential strategies that lessen the impact of 
pathological hypoxia. There is a clear need for studies that better define responses across 
differing durations and severities of hypoxia using more sophisticated techniques and, where 
possible, larger subject numbers.   
Developing a means of attenuating the metabolic stress of hypoxia would be highly 
beneficial for aiding human adaptation either in response to environmental exposure or 
pathological states. A candidate for such an intervention is dietary nitrate supplementation.  
At the level of the mitochondria, this intervention has been associated with enhancing 
mitochondrial efficiency (Larsen et al., 2011) and β-oxidation capacity, the latter of which 
was an effect shown to be reliant upon the master regulator of β-oxidation, peroxisome 
proliferator activated receptor α (PPARα) (Ashmore et al., 2015b). At the whole-body level, 
this intervention has been associated with decreasing the O2 cost of submaximal exercise 
in both normoxic and hypoxic conditions (Larsen et al., 2007, Bailey et al., 2009, Larsen et 
al., 2010, Vanhatalo et al., 2010, Lansley et al., 2011). Evidence thus suggests that dietary 
nitrate is a prime candidate for alleviating hypoxic induced metabolic stress. However, this 
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potential is yet to be greatly explored in a hypoxic context. Particularly, mechanisms of 
nitrate action in hypoxia are yet to be sufficiently investigated. In addition, little is known 
about the potential for nitrate supplementation to act as a therapeutic intervention in disease 
states associated with hypoxia.    
In this thesis, two key aims are addressed. The first overarching aim was to better 
define the metabolic responses of healthy humans to hypobaric hypoxia. This involved 
examination of the metabolic and lipid profiles of a large cohort of subjects in response to 
acute, progressive high altitude exposure to 5,300m. In addition, the examination of a small 
cohort in response to chronic exposure to 2,500m was conducted. The second overarching 
aim was to investigate the potential of dietary nitrate supplementation to alleviate metabolic 
stresses of hypoxia. This involved exploration into the mechanisms of nitrate action at the 
level of the mitochondria in an animal model, as well as translation to a disease population, 
whereby the effects of dietary nitrate on metabolism and exercise performance of COPD 
patients were investigated.  
A common theme that persists through each study presented in this thesis is 
examination of metabolic responses to hypoxic perturbation. This is with and without dietary 
nitrate intervention, explored at the level of the blood in healthy humans and COPD patients 
and at the level of skeletal muscle mitochondria in an animal model. As a prelude to the 
detailed report of these investigations, it is therefore appropriate to firstly delve into the 
intricacies of mammalian metabolic systems. The literature review begins with an overview 
of cellular respiration. The effects of hypoxia upon this complex process is then considered 
and the current consensus on adaptive remodelling explored. Following this, detail upon 
dietary nitrate supplementation is presented, along with proposed mechanisms of action and 
effects upon O2 delivery and utilisation.   
1.2 Literature review  
1.2.1 Cellular respiration 
Life is a complex phenomenon that is dependent upon a high degree of activity and 
order among constitutent components of an organism. In terms of thermodynamics, the 
entropy of the universe, being a measure of disorder, must increase over time. Maintenance 
of the ordered structures composing an organism thus relies upon a positive entropy 
change. This requires reactions with a negative entropy to be coupled to those with a positive 
entropy change. A total positive entropy change in turn provides energy, being the ability of 
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a system to do work. In other words, neither activity nor order can be maintained without a 
continuous input of energy and this energy results from a positive entropy change (Nicholls 
et al., 2013).  
For the majority of protozoa and metazoa alike, this energy is derived from 
combustion of organic macromolecules including carbohydrates, fats and proteins. The 
energy released from this process is transferred into the phosphoanhydride bonds of 
adenosine triphosphate (ATP), a process termed phosphorylation. Hydrolysis of these 
bonds results in the production of adenosine diphosphate (ADP) as follows in Equation 1.1.  
 
 𝑨𝑻𝑷 ↔ 𝑨𝑫𝑷 + 𝑷𝒊 
Equation 1.1. ATP synthesis and breakdown.  
This reaction is catalysed by ATP synthase. ATP synthesis or hydrolysis takes place on the 
F1 sector of this enzyme, being the catalytic domain, located at the matrix side of the inner 
mitochondrial membrane (Stock et al., 2000).  
 
The breakdown of ATP in this manner is almost solely responsible for providing the 
free energy required for thermodynamically unfavourable reactions, and so maintenance of 
order, within mammalian cells. ATP thus acts as the energy currency of the cell (Weibel, 
1984, Nicholls et al., 2013). However, ATP itself is not a high energy compound. The reason 
it is part of the energy system is because the ATP hydrolysis reaction, and so the ratio of 
ATP:ADP, lies very far from equilibrium (Nicholls et al., 2013). In essence, this reaction can 
be depicted as a highly compressed spring, with the degree of compression being relative 
to the distance from equilibrium.   
The main site of ATP production is within the ‘furnaces’ of the cell, the mitochondria. 
Here, organic compounds are broken down via a series of oxidation and reduction reactions 
involving the passage of electrons through coenzymes and proteins associated with 
mitochondrial membranes, otherwise termed the ETS. Energy released in this process is 
required for the generation of ATP from its precursor ADP through the action of the final 
complex of the ETS, ATP synthase. This rotary motor enzyme utilises the proton motive 
force, generated from movement of electrons into the inter membrane space, to drive ATP 
synthesis (Stock et al., 2000).  
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 The close relationship between the components and the mechanisms of both 
oxidation and phosphorylation allow these processes to be studied together. The enzymatic 
dependent breakdown of organic compounds and subsequent capture of the energy 
released into phosphate bonds is therefore termed OXPHOS. Briefly, this process is initiated 
by the generation of acetyl coenzyme A (CoA) from the catabolism of substrates including 
carbohydrates, fatty acids, amino acids and ketone bodies. Within the mitochondrial matrix, 
acetyl CoA enters the TCA cycle through a reaction catalysed by citrate synthase (CS), 
involving the condensation of the acetyl group with oxaloacetate forming citrate. The TCA 
cycle proceeds through a series of enzymatically driven oxidation reactions, crucially 
producing hydrogen ions/protons (H+) and electrons that are accepted by the redox 
coenzymes nicotinamide adenine dinucleotide (NAD+) and flavin adenine dinucleotide 
(FAD). The reduced forms of these enzymes, NADH and FADH2, transfer these reducing 
equivalents to the ETS, thus becoming oxidised. The ETS complexes contain both electron 
exchangers and proton pumps. Transferral of electrons through these complexes via a 
series of redox reactions thus transduces the energy required to pump H+ into the 
intermembrane space. The rate of electron transport in this manner in turn determines the 
rate of proton pumping, with the transfer of two electrons stimulating the transport of ten 
protons (Nicholls et al., 2013).  
Accumulation of H+ in the intermembrane space generates an electrochemical 
proton gradient, also termed the proton motive force (ΔµH+), which drives flux of H+ back 
across the inner mitochondrial membrane. In other words, the mitochondrial complexes can 
be envisaged as batteries creating a voltage, being ΔµH+, which when connected to the 
circuit generates a proton current. Passage of protons back across the membrane, driven 
by ΔµH+, occurs by the pathway of least resistance, being ATP synthase.  Transferral of 
eight protons through this motor protein is required to drive the synthesis of three molecules 
of ATP (Nicholls et al., 2013). Coupling of phosphorylation to electron and hydrogen transfer 
in this manner is termed chemiosmosis (Mitchell, 1961).    
Oxygen (O2) has a central role in driving this series of reactions by being the final 
acceptor of electrons in the ETS.  The rate of mitochondrial O2 consumption is equivalent to 
the current of electrons and so the rate of proton pumping. The end result of mitochondrial 
OXPHOS is a highly efficient generation of ATP.  O2 is thus among those elements whose 
reduction provides the largest energy release per electron transfer.  
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Dissipation of the H+ electrochemical potential proton gradient can also occur through 
the movement of H+ back across the inner mitochondrial membrane through routes other 
than ATP synthase. In doing so, the proton circuit becomes short-circuited, meaning the 
coupling of respiration to ADP phosphorylation is partially loose or uncoupled (Nicholls et 
al., 2013). This can occur via endogenous leak, which is thought to result from H+  movement 
across the junction between the adenine nucleotide translocator protein and lipid bilayer, 
contributing to a high proportion of basal metabolic rate in some tissues (Nicholls et al., 
2013). In addition, the proton gradient can be dissipated by the action of uncoupling proteins 
(UCPs).  
UCPs belong to the family of anion carriers, or solute exchangers, present in the 
inner mitochondrial membrane. The action of UCPs that has been best described is that 
specific to brown adipose specific UCP1, which is known to dissipate the energy of substrate 
oxidation as heat, making it essential to non-shivering thermogenesis (being the production 
of heat from cellular respiration) (Rousset et al., 2004). Homologues of UCP1 have been 
identified: UCP2 and 3, with UCP2 expressed ubiquitously and UCP3 predominantly in 
skeletal muscle (Rousset et al., 2004). This naming is perhaps misleading, given that both 
have roles that differ quite considerably from UCP1 as neither is thought to contribute 
towards adaptive thermogenesis. Instead, both UCP2 and 3 have links to regulation of 
metabolism, specifically to fatty acid metabolism.  It has been suggested that UCP2/3 
regulate free fatty acid levels by exporting fatty acid anions out of the mitochondrial matrix 
when they are in excess (Schrauwen et al., 2002, Garlid et al., 1998, Harper et al., 2002). 
Indeed, fatty acids are thought to be essential cofactors for UCP proton transport (Rousset 
et al., 2004). The lateral binding of fatty acids to the UCP2 peripheral site is thought to be 
essential for the UCP2-catalyzed fatty acid flipping action required for proton translocation 
across the membrane (Berardi et al., 2014). Fatty acids are also known to upregulate UCP3 
(Schrauwen et al., 2002). Beyond relations to fatty acid metabolism, UCP2 has also been 
linked to decreasing insulin secretion in pancreatic β-cells and restoring glucose sensing 
(Zhang et al., 2001). In addition, both UCP2/3 are thought contribute towards the resting 
metabolic rate.  
Basal proton leak, whether endogenous or UCP mediated, is linked to restricting 
oxidative damage. O2 is capable of accepting an additional electron to create the superoxide 
ion, a more reactive form of O2. Respiration is thus associated with production of reactive 
O2 species (ROS). Modest increases in proton leak cause reductions in superoxide 
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generation via a lowering of membrane potential, thus acting as a key defence mechanism 
(Nicholls et al., 2013).   
Second to OXPHOS is the synthesis of ATP from the cytosolic breakdown of glucose 
into two molecules of pyruvate via glycolysis. ATP is produced in the phosphoglycerate 
kinase and pyruvate kinase reactions by direct phosphorylation from ADP. This process, 
termed substrate level phosphorylation, can occur independently of O2, so anaerobically, 
and produces a far lower yield of ATP in comparison to OXPHOS.  Despite this, the capacity 
of glycolysis in providing ATP is seemingly great in certain conditions. Most cancerous cells, 
for instance, ‘ferment’ glucose into lactate even in the presence of an ample supply of O2, a 
phenomenon termed the Warburg effect (Vander Heiden et al., 2009). Additionally, human 
lung fibroblast populations have been shown to demonstrate normal functioning without the 
presence of a mitochondrial network, with reliance on ATP generation shifting to glycolysis 
(Correia‐Melo et al., 2016). Dependence upon glycolytic mechanisms may therefore be a 
feature apparent in proliferating cell types, particularly those cultured in high glucose media. 
However, the capacity of glycolysis to support life at the whole organism level over long 
periods of time is inconceivable. A sufficient level of mitochondrial oxidative metabolism is a 
vital requirement for metazoans.  Indeed, impairments in the OXPHOS system as 
demonstrated through mitochondrial defects markedly impair physiological function and can 
be fatal. For instance, knockouts of proteins essential for fundamental dynamic processes 
such as mitochondrial fusion are shown to cause death in early gestation (Youle et al., 2012).   
As already stated, the role of O2 as a terminal electron acceptor is crucial for driving 
the series of reactions that constitute mitochondrial OXPHOS. A sufficient O2 supply is thus 
required to maintain both energetic and redox homeostasis and so normal physiological 
functioning. For O2 dependent lifeforms, the ability to adapt to changing O2 availability 
through adjustment and remodelling of metabolic processes offers a crucial advantage to 
survival.  A summary of ATP production via glycolysis and mitochondrial oxidative 





Figure 1.1. A diagrammatic representation of ATP production via glycolysis and 
mitochondrial oxidative metabolism. 
Where: ATP = adenosine triphosphate, ADP = adenosine diphosphate, CoA = coenzyme A; 
Pi = inorganic phosphate, F0/F1 = ATP synthase; NADH = nicotinamide adenine 
dinucleotide; FADH2 = flavin adenine dinucleotide; ETS = electron transfer system; I,II,III,IV 
= ETS complexes; ETF = electron transfer flavoprotein, e- = electrons, Q = ubiquinol, c = 
cytochrome c; ΔµH+ =  proton motive force, OXPHOS = oxidative phosphorylation, LEAK = 





As already stated, hypoxia can be experienced in healthy humans in response to high 
altitude exposure. At high altitudes, the atmospheric pressure falls as atmospheric mass is 
reduced. This causes the PB to also decrease and it continues to fall as the altitude 
increases. The air at high altitudes is therefore less compressed and so thinner. At sea level, 
the atmospheric pressure is at 760mmHg compared to 253mmHg at the top of Mount 
Everest, which is 8848m (29,029 ft) (Grocott et al., 2007b) . This means that, although the 
fraction of O2 remains the same at 0.21, the partial pressure of O2 is reduced.  
A fall in PIO2 generates a smaller diffusion gradient in the lungs, which in turn impairs 
alveolar gas exchange. PO2 is decreased further as inspired O2 is mixed with the contents 
of the lung and as gases cross the alveolar blood barrier due to the effects of ventilation-
perfusion mismatch. A reduced PIO2 therefore interferes with the O2 cascade Figure 1.2. 
leading to impaired oxygenation and a decrease in arterial O2 tension.  O2 content of the 
capillaries in turn falls, meaning an inadequate O2 supply reaches the tissues. This fall in 
PIO2 resulting from a low atmospheric pressure is termed hypobaric hypoxia (Rainford, 
2006). The changes in PB and PIO2 with increasing altitude are displayed in context of a 
climb to the summit of Mount Everest in Figure 1.3. 
Hypoxia can also result from a plethora of clinically important conditions, both acute 
and chronic that can affect those of all ages. This encompasses any clinical condition where 
either convective or diffusive O2 transport is impaired. Examples include lung disease, heart 
failure, anaemia and regional vascular diseases (Tuder et al., 2007, Giordano, 2005, 
Semenza, 2001, Forristal et al., 2013, Pe'er et al., 1995). A pathological consequence of the 
airway limitation in COPD, for instance, is alveolar hypoxia. This leads to an abnormally low 
level of O2 in arterial blood, termed hypoxaemia, so in turn tissue hypoxia. This becomes 
particularly prominent in the more progressed stages of the disease and after exercise in 
patients with the milder form. A state of chronic hypoxia is thus common for COPD sufferers, 
the degree of which depends upon disease severity (Raguso et al., 2004).   
Understanding the mechanisms that underpin mammalian adaptation to O2 insufficiency 
and ways that may aid adaptation are areas of intense investigation worldwide.  This is both 
in relation to high altitude exposure, which is becoming more common as travel to high 
altitude destinations becomes more accessible, also in clinical settings where physiological 





Figure 1.3. Alterations in barometric pressure and the corresponding changes in 
inspired partial pressure of oxygen (O2) upon ascent to the summit of Mount 
Everest. 
Values begin at sea level, followed by key checkpoints upon ascent, being: Kathmandu, 
Namche, Pheriche, Everest Base Camp, Camp 2, Camp 3, Camp 4, the balcony and the 
summit.  
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Figure 1.2. A model of the O2 cascade. 
Describing the flow of oxygen (O2) from ambient air through arterial blood to tissues. At 
the cellular level, O2 is consumed by mitochondria, which are thus referred to as the O2 
‘sinks’.  The partial pressure of O2 (PO2) falls progressively from environmental values to 
close to zero at the sink. The O2 flow is driven by this gradual reduction in PO2 and, in 
particular, O2 consumption at the mitochondria. Waste products from cellular respiration, 







1.2.3 Physiological adjustments to hypoxia in healthy 
humans 
Physiological adjustments need to occur upon hypoxic exposure to enable ATP 
production to continue without compromising the redox balance of the cell. This ensures cell 
survival and enables the body to undergo additional stresses such as exercise in hypoxic 
conditions. 
 Oxygen (O2) delivery 
Certain aspects of these adjustments are well understood, including: increased 
ventilation, heart rate, erythropoiesis and a possible enhanced vascularisation of tissues 
(Sutton et al., 1988, Rainford et al., 2006, Martin et al., 2010). These changes are geared at 
improving O2 delivery and enabling maintenance of arterial O2 saturation and O2 content. In 
the context of high altitude exposure, these adjustments can be sufficient to maintain arterial 
O2 saturation at values comparable to those taken at sea level up to an altitude of ~7100m 
(Grocott et al., 2007b). Following acclimatisation to high altitude, cardiac output  also 
remains unchanged from sea level values for a given work load during submaximal exercise, 
implying the O2 delivery system is maintained (Pugh, 1964, Sutton et al., 1988).  
In spite of these observations, exercise capacity is severely limited at altitude, a 
phenomenon that appears to be worsened in elite athletes (Grover et al., 1985, Gore et al., 
1996). There is also a considerable degree of inter-individual variation to hypoxic adaptation 
(Thompson et al., 2007). Changes at the tissue level, so at the level of O2 utilisation, must 
therefore play a pivotal role in the adaptive process (Martin et al., 2010). Central to tissue 
adaptations is alteration in protein levels mediated by changes to gene expression.  
 Hypoxic inducible factor (HIF) 
An array of gene expression changes are induced by prolonged hypoxic exposure. 
Master regulators of the adaptive responses at both cellular and tissue levels are hypoxic 
inducible factors (HIFs). HIFs are heterodimeric basic helix-loop-helix transcription factors 
that are members of the PAS family (Wang et al., 1995).  
HIFs consist of an O2 sensitive α subunit (HIF-α) and a constitutively expressed β 
subunit (HIF-β); interaction of both subunits is required for activation (Ratcliffe et al., 1998, 
López-Barneo et al., 2001). In normoxic conditions, HIF-α subunits are tagged for 
proteasomal degradation through von Hippau Lindau protein dependent polyubiquitination.  
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This constant degradation of HIF-α is a process reliant on O2 dependent hydroxylation of 
proline residues by prolyl hydroxylase 2, which utilises O2 and α-ketoglutarate as co-
substrates (Ivan et al., 2001, Kaelin et al., 2008). It thus follows that the rate of HIF 
hydroxylation is suppressed in hypoxia, so HIF-α is stabilised and accumulates 
spontaneously in the hypoxic cell. It enters the nucleus, where it binds the stable subunit 
HIF-β. The resulting complex binds hypoxia response elements in the regulatory regions of 
hundreds of genes (~200 in the case of HIF-1α), the levels of which are precisely controlled 
in response to cellular O2 levels (López-Barneo et al., 2001, Kaelin et al., 2008). 
Three isoforms of the HIF-α subunit have been identified: HIF-1α, HIF-2α and HIF-3α. 
The HIF-1α and HIF-2α responses are well defined, both acting to regulate a unique set of 
target genes to improve O2 delivery through angiogenesis (e.g. vascular endothelial growth 
factor) and erythropoiesis (via erythropoietin), as well as cell proliferation (Suzuki et al., 
2014, Semenza et al., 1992, Forsythe et al., 1996). In addition, HIF-1α regulates a host of 
genes that influence cellular metabolism including glycolytic enzymes, whereas HIF-2α is 
an inducer of antioxidant genes (e.g. superoxide dismutase 2) (Suzuki et al., 2014).  
Far less certainty surrounds the roles of HIF-3α. The HIF-3α gene gives rise to multiple 
variants of HIF-3α, which are differentially expressed across different tissues and have 
varying responses to hypoxic exposure (Duan, 2016). Whilst HIF-3α lacks a transactivation 
domain, and so is considered to be transcriptionally inactive, its actions appear to regulate 
HIF-1/2α, with some variants inducing inhibitory effects (Duan, 2016, Suzuki et al., 2003) 
Although much controversy exists with regards to the effects of changing HIF 
expression, for instance upon fatty acid oxidation (Cole et al., 2016), it is clear that the  HIF 
pathway plays a central role in regulating the transcriptional response to changing O2 
availability, including mediation of metabolic responses (Kaelin et al., 2008).    
1.2.4 Metabolic remodelling  
The metabolic response of healthy humans to hypoxia is complex and remains 
incompletely resolved. As previously described, in a rested state in normoxia, the majority 
of ATP is produced from mitochondrial OXPHOS. Few cells are able to rely solely upon 
anaerobic means of ATP generation (Weibel, 1984). Survival in the face of reduced O2 
availability thus requires a profound shift in metabolic processes including changes in O2 
dependent processes. This is crucial in those oxidative tissues critically dependent upon a 
sufficient supply of O2 to maintain oxidative and redox homeostasis, such as skeletal muscle. 
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A range of techniques can be utilised to assess metabolic changes within an organism. 
In this thesis, frequently utilised measures were metabolomic and lipidomic techniques. 
Specifically, both techniques were adopted in Chapter 2, whilst only metabolomic methods 
employed in Chapters 3 and 5. In addition, in depth examination of mitochondrial function 
was assessed through respirometry in Chapter 4.  
A brief introduction to metabolomic and lipidomic techniques is given below, with further 
detail provided in Chapter 2. As mitochondrial respirometry measures are restricted to 
Chapter 4, detail on this approach is provided in the relevant chapter.   
Metabolomics  
Recent technological advances have allowed for the unbiased detection, 
identification and semi-quantification of many low molecular weight (<1500 Da) compounds 
in cells, tissues, biofluids or organisms, in a single experiment. These compounds are 
metabolites, being the reactants, intermediates or products of enzymatic reactions in the 
body. They represent the final products of key cellular processes including mRNA and 
protein activity, and are key components of oxidative mitochondrial processes such as the 
tricarboxylic acid (TCA) cycle and β-oxidation. Investigation into the metabolic phenotype, 
or metabolome, in response to a physiological stimulus or genetic modification is termed 
metabolomics. It is a functional level of systems biology (Sauer et al., 2007).  
The metabolome is highly dynamic and subject to fluxes over a period of seconds or 
less. This thus sets it apart from proteome or transcriptome changes, which are usually 
measured over minutes to hours. The metabolome is therefore an extremely sensitive 
measure of biological phenotype and can unmask seemingly silent phenotypic changes that 
have no frank physiological or characteristic behaviour  (Dunn et al., 2011b, Griffin, 2006), 
particularly when used alongside other -omics approaches (Gulston et al., 2008, Mukherjee 
et al., 2014, Waterman et al., 2010).  
 Lipidomics 
 An extension of metabolomics is the specific measurement of the lipid complement 
of a cell, tissue or organism termed the lipidome. This focused approach, termed either 
lipidomics or lipid profiling with both terms being used interchangeably, has become 
necessary due to the complex nature of lipid classes and their variable yet distinct chemical 
properties (Roberts et al., 2008). Lipids are functionally and structurally a highly diverse 
group of compounds. This is partly due to the many possible variations of lipid building 
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blocks, mainly originating from combinations of fatty acids with variable chain lengths and 
possible head groups. This is coupled with possible non-covalent linkages both with variable 
fatty acid and non-lipid moieties such as carbohydrates (Yetukuri et al., 2008).   
The extensive role lipid species play within the cell is fast becoming apparent. 
Previously, the majority of lipids were considered either as components of a homogenous, 
fluid membrane or an energy store. Whilst their function as structural compounds and energy 
stores are essential, the diversity of their roles, for instance in signalling processes and as 
biomarkers, is also becoming clear.  It is now understood that lipid domains within cellular 
membranes, termed lipid rafts, partake in a variety of dynamic cellular processes including 
trafficking, signal transduction and regulation of the activity of membrane proteins (Niemelä 
et al., 2007). Maintenance of membrane composition is thus paramount to the preservation 
of normal cellular physiology. Even minor changes in lipid composition have been 
demonstrated to affect elastic and dynamic properties of membranes, whilst also likely 
having effects upon the regulation of membrane proteins (Niemelä et al., 2007). In addition, 
lipids have roles in mediation of cell-cell interactions as well as transcriptional and 
translational processes (Roberts et al., 2008).   
Recognition of the diverse functioning of lipids has thus driven interest towards 
defining changes in lipid profile, which has in turn become a powerful means for investigating 
the role of lipids in pathophysiological states such as diabetes (Kraegen et al., 2001). 
Examination of the lipid profile can act as an indication of change within a cell or organism 
over time in response to environmental alterations (Roberts et al., 2008).  





Figure 1.4. An outline of metabolomic and lipidomic techniques on human subjects. 
This can include assessment of tissue, cells or a biofluid, such as blood, using a combination 
of nuclear magnetic resonance spectroscopy and mass spectrometry. These analytical 
platforms give a readout of the metabolome and lipidome, which provide detailed insight into 






In line with the focus of this thesis, the following summary of metabolic remodelling in 
hypoxia includes those studies using metabolomic techniques and on those assessing 
specific markers of skeletal muscle metabolic processes alongside the wider field. The latter 
of these measurements is covered far more extensively in the literature than the former. The 
extant metabolomics experiments investigating the physiology of high altitude have focused 
on profiling plasma, serum or urine from hypoxia-exposed individuals. To the author’s 
knowledge, lipidomic assessment has not been explored in this context. For the studies 
discussed below, both the degree and duration of hypoxic exposure is highly variable.  
Glycolysis 
A switch in cellular metabolite usage from the predominant breakdown of fatty acids, as 
occurs at rest in normoxia, to an increase in carbohydrate metabolism appears to be a logical 
adaptive process when considering the O2 requirement of these essential metabolic 
processes. In comparison to fats, carbohydrates require less O2 to breakdown (Opie, 2004). 
In theory, metabolism of free fatty acids requires ~13% more O2 to generate the same 
amount of ATP in comparison to glucose (Opie, 2004). Shifting towards an increasing 
carbohydrate metabolism thus has the potential to maximise the yield of ATP per molecule 
of O2, allowing cells to utilise metabolites more efficiently in low O2 conditions.  
Indeed, this concept is supported by a number of studies demonstrating that glycolytic 
capacity is enhanced in response to hypoxic exposure through HIF-1α mediated up-
regulation of glucose transporters and degradation enzymes (López-Barneo et al., 2001, 
Roberts et al., 1996).  
Glucose transport is a key rate-controlling step in glucose metabolism and hypoxia is a 
well-established stimulator of glucose uptake (Behrooz et al., 1999). This is a complex 
process involving an array of transporters, including a highly homologous group of facilitative 
Na+ independent transmembrane sugar transporters, the GLUT family (Wood et al., 2003). 
This family is thought to consist of three subclasses (I-III), with class I containing GLUT1-4.  
Particularly of interest in hypoxia is the stimulation of  GLUT-1 and 4  (Behrooz et al., 1999). 
The former is expressed ubiquitously and mediates non-insulin dependent transport of 
glucose in mammals, whereas the latter is insulin responsive and is found primarily in 
adipose tissue and striated (cardiac and skeletal) muscle. Translocation of GLUT1 and 4 
from intracellular vesicles to the plasma membrane in response to hypoxic exposure has 
been demonstrated in mammalian striated muscle and numerous cell lines (e.g. L6 
myotubes and 3T3-L1 adipocytes) (Behrooz et al., 1999). The protein levels of both 
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transporters were demonstrated to rise in rat skeletal muscle in reaction to hypoxic 
exposure, a response regulated by HIF-1α (Xia et al., 1997, Semenza, 1999). 
HIF-1α has also been shown to up-regulate RNA expression for a host of glycolytic 
enzymes in human skeletal muscle and hepatocyte cell lines, including: aldolase A, 
phosphoglycerate kinase 1 and pyruvate kinase  (Semenza et al., 1994, Green et al., 1989). 
This appears to occur alongside a shunting of pyruvate away from entry into the TCA cycle 
towards lactate production, as HIF-1α induces pyruvate dehydrogenase kinase (PDK) in 
mouse embryo fibroblasts, which blocks the activity of pyruvate dehydrogenase and so 
inhibits conversion of pyruvate to acetyl CoA (Kim et al., 2006). This is coupled with a 
reported up-regulation of lactate dehydrogenase by HIF-1α in human skeletal muscle and 
HeLa cells, which enhances the anaerobic conversion of pyruvate to lactate (Firth et al., 
1995, Green et al., 1989). These gene expression changes induced by HIF-1α activation 
thus appear both to enhance the capacity for glycolysis and actively suppress the catabolism 
of pyruvate within the mitochondria. This hypoxic induced shift from fatty acid metabolism 
towards a more O2 efficient metabolism of carbohydrates is an effect demonstrated to 
preserve cardiac function (Essop, 2007, Cole et al., 2016). 
However, the evidence assessing glycolytic changes upon hypoxic exposure is far from 
conclusive and there are numerous human skeletal muscle studies that demonstrate a 
decrease in markers of glycolysis. This includes decreases both in protein levels and activity 
of glycolytic enzymes, such as α-enolase, phosphofructokinase and hexokinase (Viganò et 
al., 2008, Green et al., 1989, Green et al., 1992). Other studies demonstrate glycolytic 
markers to be unchanged (Levett et al., 2012, Young et al., 1984).  
This lack of consensus extends to rodent skeletal muscle, with some studies 
demonstrating unchanged activity levels of glycolytic enzymes, such as lactate 
dehydrogenase and hexokinase (Abdelmalki et al., 1996, Ou et al., 2004). However, this is 
coupled with reported increases in phosphofructokinase and hexokinase activity as well as 
increasing levels of pyruvate kinase (Abdelmalki et al., 1996, De Palma et al., 2007, 
Daneshrad et al., 2000).  In addition, decreases have been reported in the membrane 
proteins that facilitate the transport of lactate, monocarboxylate transporters, and in levels 
of β-enolase, phosphoglycercomutase 2 and triose phosphate isomerase (McClelland et al., 
2002, De Palma et al., 2007).   
The literature thus suggests that there is more to the acclimatisation story than a simple 
shift towards glycolysis.  It may be that specific steps within glycolysis are altered, or that 
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the changes vary depending on the severity and duration of hypoxia. However, currently no 
clear patterns have emerged. To complicate matters further, metabolic plasticity during 
acclimatisation appears to vary depending upon tissue type. For instance, the heart and 
plantaris have been suggested to have a greater metabolic plasticity compared to the liver, 
gastrocnemius and soleus (McClelland et al., 2002).   
The seemingly discordant data presented in the literature may be partly explained, or 
further complicated, by the ‘lactate paradox’ (Hochachka et al., 2002).  This phenomenon is 
defined as a  lower-than-expected accumulation of blood lactate in VO2 max tests in native 
highlanders compared to lowlanders and also in acclimatised lowlanders compared to 
unacclimatised (Hochachka et al., 2002). It was first recorded in high altitude acclimatised 
lowland native subjects displaying lower peak and post exercise blood lactate 
concentrations with increasing altitude (West, 1986).  The observation that less lactate 
production occurs under more O2 limiting conditions may initially appear perplexing. 
However, numerous functional advantages for this have been recognised including: 
maintenance of metabolite homeostasis at fatigue, quicker recovery periods and avoidance 
of ATP generation through metabolically inefficient anaerobic pathways. The mechanisms 
behind this so called ‘paradox’ may result from tighter coupling between muscle ATP 
demand and supply pathways (Hochachka et al., 2002), a concept that has been 
demonstrated in Andean high altitude natives and lowlanders through the use of in vivo 31-
phosphorus magnetic resonance spectroscopy (31P-MRS) (Matheson et al., 1991). 
Measurements of  phosphocreatine (PCr), free phosphate (Pi) and muscle pH in response 
to a maximal calf strength test indicated a closer coupling between ATP supply and demand 
in the working muscle (Matheson et al., 1991).  
TCA cycle 
Biomarkers of TCA cycle function include the activity and expression levels of its 
constituent enzymes. Amongst those enzymes studied include: CS, succinate 
dehydrogenase, aconitase, malate dehydrogenase, pyruvate dehydrogenase and α-
ketoglutarate. Studies examining these factors in human skeletal muscle in response to high 
altitude exposure demonstrate either a decrease in enzyme activity and expression (Levett 
et al., 2012, Viganò et al., 2008, Green et al., 1989), or report no change (Levett et al., 2012, 
Jacobs et al., 2012, Green et al., 1992, Green et al., 2000) , with none demonstrating an 
increase (Horscroft et al., 2014). This appears to be true both for human and rodent studies 
alike, with some rodent studies demonstrating decreases in TCA cycle enzyme activities 
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and levels (Abdelmalki et al., 1996, De Palma et al., 2007, Pastoris et al., 1995)  and some 
demonstrating no change (Abdelmalki et al., 1996, Morash et al., 2013, Pastoris et al., 1995, 
Daneshrad et al., 2000).  
Unlike glycolytic changes, the loss of TCA activity in skeletal muscle appears to 
depend upon the severity of hypoxic exposure, with a greater degree of hypoxia being in 
turn associated with a greater loss in TCA function (Horscroft et al., 2014). This effect 
appears to be unrelated to the particular type of enzyme assay used (Horscroft et al., 2014). 
Insight into TCA cycle functioning can also be gained from metabolic profiling, as 
demonstrated by Tissot van Patot and colleagues (Tissot van Patot et al., 2009). In this 
study, metabolomic profiling was performed on samples taken from human subjects 
following 8hrs exposure to 12% O2 (equivalent to ~4300m) in a hypobaric chamber. 
Assessment of plasma using proton nuclear magnetic resonance (1H-NMR) spectroscopy 
revealed an increase in L-lactic acid (HMDB00190) and succinic acid (HMDB00254) 
concentrations, by 29% and 158% respectively in response to hypoxia (Tissot van Patot et 
al., 2009). These findings thus align with those studies suggesting that hypoxia prompts a 
shift towards anaerobic means of ATP generation through an active shunting of pyruvate 
away from entry into the TCA cycle towards lactate production as well as inhibition of TCA 
cycle activity (Firth et al., 1995, Hoppeler et al., 2001, Kim et al., 2006). The consequences 
of increasing succinic acid concentrations are discussed below in relation to mitochondrial 
OXPHOS and the ETS.    
Oxidative phosphorylation (OXPHOS) 
 OXPHOS rate is determined by flux of electrons through the complexes that 
constitute the ETS. Investigation in both humans and rodents into protein levels, gene 
expression and activity of these complexes, the latter being indicative of OXPHOS capacity,  
present a confusing picture. The majority of evidence appears to point towards a decrease 
in these parameter (Viganò et al., 2008, Levett et al., 2012, Pastoris et al., 1995, McClelland 
et al., 2002, De Palma et al., 2007, Gamboa et al., 2010) although some studies also present 
no change (Pastoris et al., 1995, Morash et al., 2013, Levett et al., 2012). An increase in 
complex V (ATP synthase) activity was demonstrated in mice, although this occurred 




Investigation into mitochondrial O2 consumption in response to the addition of 
various substrates, termed mitochondrial respirometry, reveal little change in complex I and 
II function in human skeletal muscle in response to an altitude (4,559m) exposure for 
between 9-11 days (Jacobs et al., 2013). However, a significant decrease in these measures 
was recorded in human skeletal muscle following 28days exposure to 3,454m (Jacobs et 
al., 2012) and specifically in complex I dependent OXPHOS in rodents (Gamboa et al., 
2012).  
Given that the succinate dehydrogenase is also complex II of the ETS, insight into 
OXPHOS capacity can also be gained from assessment of the levels of the substrate of this 
enzyme, succinate.  The accumulation of succinate in response to  8 hrs exposure to 12% 
O2, as reported by Tissot Van Patot and colleagues, may be indicative of a concerted 
downregulation of both TCA cycle and ETS activity (Tissot van Patot et al., 2009). 
Interestingly, succinate is also suggested to have a toxic effect in the heart in response to 
ischemia, as its accumulation has been directly linked to mitochondrial ROS production from 
complex I (Chouchani et al., 2014). 
Alongside repression of OXPHOS are reports of an increasing efficiency of complex 
IV of the ETS under hypoxic conditions through a switch in the composition of this complex. 
Complex IV, or cytochrome c oxidase (COX), belongs to a superfamily of multi-subunit 
terminal oxidases that catalyse the reduction of O2, the final electron acceptor in the ETS, 
to H2O. It comprises of 13 polypeptide COX subunits, some of which are subject to 
regulation.  In mammalian cells, hypoxia has been shown to induce a shift from COX 4-1 
subunit isoform utilisation to the more efficient COX 4-2 isoform, an effect coordinated by 
HIF (Fukuda et al., 2007).  
β-oxidation 
The literature examining fatty acid catabolism, otherwise termed β-oxidation, 
indicates a suppression in skeletal muscle in response to hypoxic exposure (Horscroft et al., 
2014). Biomarkers include activity of enzymes, such as 3-hydroxyacyl-CoA dehydrogenase 
(HOAD), which is shown to be decreased (Galbès et al., 2008, Abdelmalki et al., 1996, 
Levett et al., 2012), with some studies demonstrating no change (Green et al., 1992, Morash 
et al., 2013, Daneshrad et al., 2000, Sterne et al., 1997, Green et al., 1989, Abdelmalki et 
al., 1996). Levels and activity of transport proteins that control fatty acid import are another 
commonly assessed parameter. This includes carnitine palmitoyltransferase and, to a lesser 
extent, carnitine-acylcarnitine translocase. Again, these parameters appear to be decreased 
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in response to hypoxic exposure in rat and human skeletal muscle (Galbès et al., 2008, 
Morash et al., 2013, Viganò et al., 2008).   
Alongside examination of expression or activity of components of the β-oxidation 
pathway are functional mitochondrial respirometry measurements that assess OXPHOS of 
β-oxidation substrates. Hypoxic induced downregulation of β-oxidation is supported through 
evidence of suppressed palmitoyl carnitine OXPHOS in rodents (Morash et al., 2013, Galbès 
et al., 2008). Conversely, octanoyl carnitine measurements were unaffected by hypoxic 
exposure in human studies (Jacobs et al., 2012, Jacobs et al., 2013).  This thus indicates 
that species specific responses may exist.   
Peroxisome proliferator activator receptor alpha (PPARα) 
The mechanisms behind the reported hypoxic induced suppression of β-oxidation 
remain to be fully elucidated, but evidence suggests it involves the ligand activated 
transcription factor peroxisome proliferator activator receptor alpha (PPARα) (Willson et al., 
2000). This is a member of a family of nuclear hormone receptors discovered in the 1990’s, 
first named by virtue of their activation by peroxisome proliferators in rodents (Issemann et 
al., 1990). Since then, the most prominent ligands of these receptors have been identified 
as natural fatty acids, preferably of a chain length above 10 carbons, fatty acid derivatives 
including eicosanoids such as leukotriene B4, as well as synthetic compounds such as the 
fibrate class of hypolipidaemic drugs (e.g. clofibrate) (Wahli et al., 1995, Barbier et al., 2002, 
Willson et al., 2000). The PPARs thus enable nutrient derivatives to act upon gene regulation 
in a similar way as steroid or thyroid hormones act on their nuclear receptors.  
 Ligand binding facilitates the heterodimerisation of PPARs with the retinoic acid 
receptor. The resulting heterodimer complex binds to the peroxisome response element in 
the promoter region of target genes, which consists of a specific direct repeat element, DR-
1 (Wahli et al., 1995, Gearing et al., 1993). This process is aided by ligand mediated 
recruitment of cofactors alongside histone acetylase activity (Kota et al., 2005) and results 
in a change in the mRNA expression level of these target genes. This includes regulation of 
several genes encoding for proteins that control fatty acid metabolism, such as medium-
chain acyl-coenzyme A dehydrogenase (MCAD), and glucose metabolism, including 
pyruvate dehydrogenase kinase 4 (PDK4) and glucose transporter 4 (GLUT4) (Gulick et al., 
1994, Finck et al., 2002).  
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Three distinct subtypes of PPAR have been identified: PPARα, PPARγ and PPARδ. 
Each demonstrates a particular tissue distribution and ligand specificity. Distinction between 
the biological function of the subtypes is thought to result from variation in the N-terminal 
region of the receptor (Willson et al., 2000). The importance of PPARα in hypoxic adaptation 
has become evident in high altitude native populations (Simonson et al., 2010) and through 
various links between the HIF system regulating PPARα  (Huss et al., 2001, Aragonés et 
al., 2008, Ferguson et al., 2015). Much debate exists in the literature regarding the links 
between HIF and PPARα expression and activity and also tissue specific responses of 
PPARα in hypoxia.  
The role of PPARα in hypoxia has been explored in the most depth in the heart.  Cole 
and colleagues (Cole et al., 2016) observed a decrease in cardiac PPARα expression in 
response to hypoxic exposure in mice (11% O2 for ~3 weeks), coupled with suppression of 
β-oxidation and UCP3 levels. These responses were linked to a preservation of cardiac 
function, reflected in the maintenance of normoxic [ATP] and contractile function. They 
occurred alongside upregulated carbohydrate metabolism, shown through increased 
expression of PDK4 and GLUT4. This suggests that in the heart, PPARα plays a key role in 
regulating the balance between fatty acid and glucose metabolism. This conclusion was 
further supported through the effects of PPARα genetic ablation, which was shown to induce 
a similar shift in metabolic preference. This adaptation was lost in high fat feeding conditions 
that provoked PPARα upregulation (Cole et al., 2016).  Along with this, a prior study reported 
PPARα activity to be deactivated in hypoxic rat cardiomyocytes through a reduction in its 
co-factor, retinoid x receptor; a process suggested to be regulated by HIF-1α (Huss et al., 
2001). 
Contrary to these findings, an earlier study by Morash and colleagues demonstrated 
an increase in PPARα protein levels in the mouse heart by 30% in response to 7 days 
hypoxic exposure (13% O2), occurring alongside a 30% decrease within mouse skeletal 
muscle.  Interestingly, these seemingly opposing responses were accompanied by 
decreases in levels and activity of the PPARα target CPT1 in both tissues (Morash et al., 
2013).  
However, other studies support an increase in skeletal muscle PPARα activity in 
response to hypoxia. For instance, findings in human skeletal muscle demonstrate an 
increase in PPARα protein levels in subjects returning from the summit of Mount Everest 
(Levett et al., 2012). Indeed, dependence upon PPARα activity for inducing hypoxia 
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tolerance has been demonstrated in mouse skeletal muscle myofibres. The loss of O2 
sensing HIF prolyl hydroxylase (Phd1) in mouse skeletal muscle induced a reduction in O2 
consumption and a reprogramming of the metabolic pathway from oxidative to anaerobic 
ATP production through activation of PPARα. The increase in PPARα activity was thus 
related to HIF accumulation, the resultant effects mediated specifically though HIF-2α., 
(Aragonés et al., 2008). Whilst this mechanism impaired oxidative performance in normoxic 
conditions, it reduced oxidative stress, conferring protection against ischemic injury 
(Aragonés et al., 2008).  
 Links between PPARα and HIF-2α have extended to the liver. Through constitutive 
activation of HIF-2α, Rankin and colleagues demonstrated a HIF-2α dependent onset of 
severe hepatic steatosis. This was associated with impaired β-oxidation, including 
downregulated expression of PPARα target genes and downstream mRNA levels, 
suggesting impairment in PPARα signalling. This occurred alongside substantial decreases 
in  OXPHOS of fatty acid substrates that was recovered with the addition of glutamate and 
succinate, suggesting a β-oxidation specific defect (Rankin et al., 2009).   
Fat storage and synthesis 
Key to the breakdown of fatty acids via β-oxidation is the control of fat store 
mobilisation. Triglycerides (TGs), made up of free fatty acids esterified to the 3-carbinol O2 
atoms of glycerol, act as a benign form of fatty acid storage. Although cells of most tissues 
are capable of TG synthesis, few are capable of high levels of TG storage. Those that are 
include skeletal and cardiac muscle, with the most prominent store in mammals being the 
liver and adipose tissue. Prior to their usage as an energy source, TGs are mobilised via 
lipolysis. This process can be initiated by catecholamine stimulated phosphorylation of 
hormone sensitive lipase (Nilsson, Strålfors et al. 1980), the activity of which stimulates 
lipolysis and so the mobilisation of adipose tissue TG stores (Gibbons, Islam et al. 2000). 
Given that hypoxic exposure has been linked to increasing release of catecholamines, 
particularly noradrenaline (Young et al., 1989, Siervo et al., 2014), it likely acts as a 
stimulator for mobilising adipose TG stores. Indeed, changes in circulating TGs have been 
reported in numerous altitude studies, with some demonstrating moderate increases and 
some decreases (Wee et al., 2015, Wagner, 2010).  
Systemic transport of TGs is mediated by soluble lipoproteins. Fatty acids released 
from the adipose tissue act as the predominant substrate for the production of hepatic very 
low density lipoproteins (VLDL), to be transported systemically (Gibbons, Islam et al. 2000). 
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In turn, the fatty acids carried by VLDL can be returned to adipose tissue via the action of 
lipoprotein lipase.  The action of lipoprotein lipase has been shown to be strongly inhibited 
by acute hypoxia in differentiated adipocytes (Mahat et al., 2016a). This may result from a 
hypoxic induced increase in activity of a major post-translational regulator of lipoprotein 
lipase, ANGPT4, causing inactivation at the plasma membrane of adipocytes (Wood et al., 
2011).  Together, this suggests that hypoxia may impair the uptake of lipids in adipose 
tissue.  
Another lipoprotein generated during TG transport is high density lipoprotein (HDL). 
This acts both as a site for cholesterol esterification and as a transporter of cholesterol from 
peripheral tissues to the liver (Eisenberg, 1984). HDL levels were reported to undergo a 23% 
increase in response to hypobaric hypoxic exposure (Young et al., 1989), however, this is 
not the case across all high altitude studies with some showing decreases in HDL and others 
no change (Wee et al., 2015).   
Beyond the transport of lipids is import from serum and regulation of the balance in 
availability of saturated and unsaturated fatty acids. This latter point is partially mediated 
through the activity of stearoyl-CoA desaturase 1 (SCD1). This catalyses an oxidative 
reaction converting saturated fatty acids to unsaturated, a key step in lipogenesis from 
acetyl-CoA that is essential for cell growth (Hess et al., 2010). Given the dependence of 
SCD1 upon O2, its activity is suppressed in hypoxic conditions (Kamphorst et al., 2013, 
Matschke et al., 2016). In an attempt to compensate for impaired SCD1 activity, it appears 
that fatty acid import from serum particularly that sourced from lysolipids is enhanced 
through serum and glucocorticoid-inducible kinase in hypoxic cancer cell lines  (Matschke 
et al., 2016, Kamphorst et al., 2013). This thus decreases requirement for de novo fatty acid 
synthesis (Kamphorst et al., 2013).  
At the transcriptional level, HIF-1/2α appear to play a key role in the hypoxic 
mediation of fatty acid homeostasis. HIF-1α signalling has been suggested to increase 
adiposity, serum TGs and free fatty acids as well as induce insulin resistance in high fat 
feeding mouse models (Sun et al., 2013, Jiang et al., 2013, Jiang et al., 2011). This is in 
addition to enhanced secretion of a suggested inhibitor of de novo lipogenesis adiponectin, 
a process mediated through HIF-1α via the SOC3-STAT3 pathway (Jiang et al., 2013, 
Suzuki et al., 2014). Alongside this is an upregulation of fatty acid synthase, a key enzyme 
in lipogenesis that catalyzes the condensation of acetyl CoA and malonyl Co-A to produce 
palmitic acids. This was upregulated in hypoxia via sterol regulatory-element binding protein 
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(SREBP) through activation of Akt and HIF-1α in hypoxic human breast cancer cells (Furuta 
et al., 2008).  
The importance of HIF-2α activity has been highlighted through genome-wide scans 
of high altitude native Tibetan populations, whereby the HIF-2α subunit associated with the 
PPARα gene (Simonson et al., 2010). As aforementioned, the activity of HIF-2α  has also 
been associated with enhanced lipid storage capacity, with constitutive expression of HIF-
2α leading to hepatic steatosis (Rankin et al., 2009).  
Together, these results suggest that hypoxic exposure affects transportation, uptake 
and utilisation of lipids. This inevitably disrupts the finely tuned regulation of this cycle, 
potentially exposing tissues to the toxic effects of high levels of circulating free fatty acids 
(Gibbons, Islam et al. 2000, Kennedy, Martinez et al. 2009, Mayer and Belsham 2010, Shen 
and McIntosh 2016). Particularly in the case of palmitate, prolonged exposure is associated 
with glucose intolerance, as well as inflammation and apoptosis (Mayer et al., 2010, 
Vazquez-Jimenez et al., 2016, Kennedy et al., 2009). Together with HIF induced effects, 
increases in circulating fatty acids may go to explaining why high altitude exposure has been 
associated with insulin resistance in humans (Siervo et al., 2014, Young et al., 1989).  
Despite the progress made in the area of fat storage and synthesis in hypoxia, details 
of this response remain ill-defined, particularly in healthy subjects. Studies assessing 
changes in full lipid profile in response to hypobaric hypoxia are currently lacking, yet would 
provide extensive insight into systemic lipid changes.    
Mitochondrial network dynamics 
The O2 dependent processes discussed above are intimately related to 
mitochondrial morphology.  Mitochondria form part of a highly dynamic tubular network, the 
structure of which is highly responsive to changes in cellular energy state (Youle et al., 
2012). In the face of stressful, energy demanding conditions, maintenance of energy output 
can be achieved through mitochondrial fusion. This process involves sharing of components 
between mitochondria, in effect enabling mitochondria to compensate for one another’s 
defects. Alternatively, the most seriously damaged mitochondria can be segregated through 
a process termed fission. In instances where the degree of mitochondrial damage is beyond 
a certain threshold, a process of autophagy is initiated, whereby old and damaged 
mitochondria are removed. Fusion and fission are closely linked to autophagy. The end goal 
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of these interlinked processes is to maintain a healthy mitochondrial network in the face of 
metabolic or environmental stresses (Youle et al., 2012).    
 Given that modifications to the mitochondrial network are initiated in response to the 
changing metabolic state of the cell, it is not surprising that O2 limiting conditions appear to 
have significant effects upon mitochondrial dynamics.  
 A number of studies have investigated alterations in mitochondrial density of skeletal 
muscle in response to hypoxic exposure using various biochemical measures of 
mitochondrial components as biomarkers. This includes cardiolipin content and the activities 
of CS and complex I, which show strong correlations with mitochondrial content as assessed 
by transmission electron microscopy in human skeletal muscle (Larsen et al., 2012).  
The number of studies demonstrating a decrease in skeletal muscle mitochondrial 
biomarkers in comparison to baseline measurements increases with increasing severity of 
hypoxia, with 57% showing a decrease in extreme hypoxia (PO2 ≤ 10, ca. 6250m), compared 
to 31% at milder exposures (11.7 < PO2 ≤15kPa, ca. 3000-5000m) (Horscroft et al., 2014).  
It thus appears that a loss in mass specific mitochondrial function in the short term may be 
followed by a loss in mitochondrial density with longer term exposure (Horscroft et al., 2014).   
The loss in mitochondrial density has been reported to total ~30% of the total 
mitochondrial mass in human skeletal muscle, with the greatest loss occurring in the 
subsarcolemmal population (Hoppeler et al., 2001). It is in this region of the muscle that 
accumulation of lipofuscin occurs. This is a product of lipid oxidation thought to originate 
from mitochondrial breakdown. Biopsies taken from the vastus lateralis of seven subjects 
following 8-10 week exposure to altitudes above 5000m showed close to a three-fold 
increase in levels of lipofuscin, predominantly around the subsarcolemmal region (Martinelli 
et al., 1990).  
Numerous factors are associated with inducing such changes in the mitochondrial 
network, yet effects of hypoxia upon their regulatory effects remains uncertain. The main 
driver for a reduction in mitochondrial density is likely autophagy, driven in part by HIF-
dependent up-regulation of the pro-apoptotic protein BCL2/adenovirus E1B 19kDa 
interacting protein (BNIP3) (Zhang et al., 2008). BNIP3 increased in response to hypoxic 
exposure in mice, an effect shown to be mediated by HIF-1α , alongside a decrease in 
mitochondrial mass and respiration (Zhang et al., 2008). On the one hand, this response 
has been shown to enable survival of mouse embryonic fibroblasts for long periods in 
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hypoxia (Zhang et al., 2008). Conversely, it has been associated with promoting 
mitochondrial defects and cell death of rat ventricular myocytes (Regula et al., 2002).  
Alterations to mitochondrial morphology have also been shown in cardiac derived 
cells in response to ischemia. This was demonstrated to induce mitochondrial fragmentation, 
a process dependent upon the mitochondrial fission protein dynamin-related protein- 1 
(Drp1). Inhibition of Drp1 reduced myocardial infarct size following coronary artery occlusion 
(Ong et al., 2010).   
Mitochondrial biogenesis may be restricted by a downregulation of mitobiogenesis 
factors such as peroxisome proliferator activated receptor γ co-activator alpha or beta 
(PGC1α/β). This is in addition to downregulation of protein synthesis through inhibition of 
the cell growth regulator mTOR, an effect transduced by HIF via REDD proteins in 
Drosophila (Wullschleger et al., 2006). Along with PGC-1α, mTOR is a necessary 
component of the transcriptional complex controlling mitochondrial biogenesis (Cunningham 
et al., 2007).  
 The effect of O2 insufficiency on morphology of the mitochondrial network, and the 
mechanisms inducing any observed changes remain unclear. This again is likely due to a 
lack of consensus between studies with relation to the severity and duration of hypoxic 
exposure.  
Reactive Oxygen Species (ROS)  
Aside from the requirements of energy production is the paradoxical increase in 
oxidative stress in hypoxia, caused by an enhanced generation of ROS, such as superoxide. 
The mechanisms of the ETS are such that single electrons can be lost at various points to 
O2, in turn forming ROS. This leak, accounting for ~3% loss in electron flux through the ETS, 
predominantly occurs at complexes I and III (Ward, 2008). Production of ROS in transient 
low levels is recognised to be a key signalling mechanism. In hypoxia however, ROS 
production is reported to increase, with complex III acting as a major donator of electrons, 
resulting from a highly reduced respiratory chain (Ward, 2008, Murray, 2009). Whilst the 
release of ROS from complex III appears to be an essential step in HIF stabilisation in human 
derived cell lines (Guzy et al., 2005),  this seemingly vital signalling function is coupled with 
the harmful capability of ROS to oxidise proteins, lipids and nucleic acids, causing cell 
dysfunction. Excessive production, as occurs in hypoxia, can be toxic and induce apoptosis.  
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Harmful effects of ROS production have been examined through the effects upon 
oxidative stress.  Human plasma analysis by Tissot van Patot and colleagues, for instance, 
revealed a reduction in the levels of the antioxidant glutathione along with an increase in 
urinary prostane excretion (Tissot van Patot et al., 2009). In a study by Lundy et al (2003), 
two weeks of altitude exposure at 4100m resulted in an increase in DNA strand breaks. 
Together, this thus goes along with previous reports of hypoxia increasing oxidative stress 
(Magalhaes et al., 2005). However, this response may be ameliorated with longer term 
exposure. Lundby and colleagues found DNA strand breaks reduced back to sea level 
values after 8 weeks exposure, suggesting certain adaptations are occurring to reduce 
oxidative stress. As antioxidant levels weren’t increased, this indicates changes elsewhere 
act to restore redox homeostasis (Lundby et al., 2003). 
Further evidence that oxidative stress can be ameliorated following sufficient 
acclimatisation time is presented through metabolic analysis of human placentas taken 
following labour birth, from subjects either at altitude (3,100m) or sea level (van Patot et al., 
2010).  1H-NMR and 31P-NMR spectroscopic analysis suggested that those placentas which 
had developed at altitude had adapted to hypoxia, demonstrating a blunted oxidative stress 
response during labour, with greater concentrations of taurine and inositol potentially 
indicating a greater antioxidant potential. This occurred alongside a maintenance of 
ATP:ADP ratios and higher PCr concentrations, indicating a preconditioning to energy 
storage (van Patot et al., 2010).    
Anthropometric measures and nutritional intake/absorption  
 Metabolic remodelling processes occurring at the cellular level may be downstream 
of changes to nutritional uptake. It also follows that such changes may be reflected in 
alterations to anthropometry measures. The following refer specifically to responses 
reported in human subjects.   
 Weight loss is a commonly reported consequence of high altitude exposure, 
worsening with increasing degrees of high altitude severity (for example: (Rose et al., 1988, 
Guilland et al., 1985, Boyer et al., 1984). This effect has been attributed to loss of appetite, 
often referred to as ‘high altitude anorexia’, and has prompted investigation into the effects 
of hypoxic exposure on appetite regulating hormones. Levels of circulating plasma acylated 
ghrelin, the one known appetite stimulating hormone, have been shown to fall in response 
to acute hypoxia in healthy male subjects (Wasse et al., 2012, Bailey et al., 2015, Shukla et 
al., 2005). The response of appetite suppressing hormones are less clear, with evidence 
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suggesting higher levels of plasma leptin (Shukla et al., 2005) yet no significant changes to 
peptide YY (Wasse et al., 2012).  
 The effects of high altitude exposure upon nutrient intake appears to extend beyond 
appetite regulation. The degree of body weight loss with altitude exposure has been shown 
to exceed that expected from the reported reduction in energy intake. For instance, the 30-
50% decrease in energy intake reported upon a 40 day simulated ascent of Mt Everest was 
estimated to induce a 1.7kg loss in weight, which was far below the 7.4kg reported (Rose et 
al., 1988). Whilst authors speculated that this loss was largely attributed to detraining, it 
highlights the possibility of additional factors coming into play beyond appetite regulation. 
Indeed, alongside hormone changes are reported changes occurring to intestinal nutrient 
absorption, which has been examined in subjects exposed to 6300m in comparison to sea 
level. Stool sampling revealing decreases in fat intake (sea level vs altitude, 128g/day vs. 
79g/day) were accompanied by a 48.5 % decrease in fat absorption. This occurred 
alongside malabsorption of carbohydrates at the small intestine, as measured through 
decreases in urinary xylose excretion (Boyer et al., 1984).  
 A combination of appetite suppression along with impaired intestinal absorption 
would be expected in turn to alter body composition. However, no clear patterns in body 
composition changes emerge with previous studies, as some demonstrate an initial loss in 
fat mass at lower altitudes followed by lean mass at extreme altitudes (Boyer et al., 1984) 
and some vice versa (Guilland et al., 1985).  
 Alterations to anthropometric measures and nutritional uptake with hypoxic exposure 
remain unclear. The lack of clarity is likely a result of discrepancies in study design, as it is 
highly likely changes to these measures will depend upon duration and severity of hypoxic 
exposure. For instance, neither loss of body weight or changes in body composition are 
universal findings, with no changes being observed in response to moderate altitude 
(<3500m) exposure (Jacobs et al., 2012). Equally, duration of hypoxic exposure is likely a 
determining factor, as are genetic pre-determinants, given that highland natives are reported 
to maintain weight and body composition at 5,400m whilst their Caucasian counterparts 
incurred significant losses in weight and body fat (Boyer et al., 1984).  
Muscle energetics 
It is not clear whether these apparent adjustments in metabolic processes evoked by 
hypoxic exposure translate to an altered economy of exercising muscle. An indication of 
53 
 
energy status of the muscle can be gained through assessment of the creatine kinase 
energy shuttle system. In essence, this system operates to maintain constant ATP levels 
through the transfer of phosphate in the reaction outlined in Equation 1.2.  
 
𝑨𝑻𝑷 + 𝑪𝒓 ↔ 𝑷𝑪𝒓 + 𝑨𝑫𝑷 + 𝑯+ 
Equation 1.2. The creatine kinase shuttle 
Where ATP = adenosine triphosphate, Cr = Creatine, PCr = Phosphocreatine, ADP = 
adenosine diphosphate, H+ = free hydrogen ion.  
 
Examination of this system was performed by Edwards and colleagues both in subjects 
trekking to 5300m and climbers ascending above 7950m. Through the use of 31P-MRS, 
levels of exercise metabolites ADP, Pi and PCr were found to remain at sea level values. 
This was indicative of a retained balance between ATP: ADP production, and so skeletal 
muscle mitochondrial function, was maintained. This occurred despite a reduction in muscle 
cross sectional area (CSA) and aerobic capacity. It suggests that metabolic changes 
occurring in healthy humans at high altitude may preserve in vivo function in the face of 
profound structural changes (Edwards et al., 2010). This conclusion aligns with findings in 
high altitude native populations that demonstrate minimal perturbation to parameters 
associated with phosphorylation potential in the working muscle (discussed previously 
relating to the lactate paradox) (Matheson et al., 1991). However, the manner in which 
muscle function is maintained remains poorly understood. Additionally, both aforementioned 
studies were conducted at sea level, thus meaning the translation to functioning during 
hypoxic exposure is limited.  
Interestingly, the reported atrophy of muscle is usually coupled with preservation of the 
capillary bed, meaning an increase in capillary density is a common occurrence. This would 
increase the O2 delivery to remaining muscle fibres (Hoppeler et al., 2001). In humans, there 
appears to be no preferential loss of fibre type and the significant atrophy tends to coincide 
with preservation of muscle function (Hoppeler et al., 2001, Edwards et al., 2010). Thus, the 
reported atrophy of muscle may be an adaptive response to enhance O2 delivery to the 
working muscle.   
The causes of this hypoxic-induced muscle atrophy are unclear.  Vigano and colleagues 
reported a decrease in mTOR protein levels in human skeletal muscle upon hypobaric 
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hypoxic exposure, which is thus evidence of a decreased stimulus for muscle hypertrophy 
(Viganò et al., 2008). However, this decrease is not a consistent finding, as de Palma and 
colleagues observed no changes in mTOR expression in rat muscle in response to the same 
duration of hypoxic exposure (2 weeks), suggesting it is not controlled by PO2 changes (De 
Palma et al., 2007). It may simply be that the loss in muscle mass is secondary to the 
common reports of a loss in appetite or even activity upon hypoxic exposure (Abdelmalki et 
al., 1996).  
 The maintenance of tissue energetics in the face of a decreased O2 availability, as 
has been reported in skeletal muscle, does not appear to be true for all tissues. Human 
cardiac PCr/ATP levels, for instance, become impaired both in lowlanders (Holloway et al., 
2011, Holloway et al., 2014) and highland native Sherpa populations (Hochachka et al., 
1996). It may suggest that the heart, which has a greater mitochondrial density and 
metabolic rate than skeletal muscle, is incapable of preserving sufficient levels of OXPHOS.  
The apparent maintenance of skeletal muscle energetics also does not appear to 
translate to maintenance of exercise performance in hypoxic conditions.  
Hypoxia and exercise 
The work required to perform exercise requires an input of energy to drive cross 
bridge cycling in skeletal muscle. To maintain a specific steady work rate, ATP must be 
supplied to the working muscle at the same rate at which it is used. As the duration of high 
intensity work rises, so the reliance on OXPHOS for ATP generation is also increased. The 
ability to perform maximal exercise is limited primarily by the ability of the cardiovascular 
system to deliver O2 to the working muscle (Bassett et al., 2000). Maximum oxygen uptake 
(VO2 max), defined as the highest rate at which O2 can be taken up and utilised by the body, 
is thus decreased in hypoxic conditions leading to impairment of exercise tolerance (Bassett 
et al., 2000, Grover et al., 1985). The strain experienced by the cardiovascular system to 
meet O2 requirements is reflected in the cardiac output and heart rate values in response to 
submaximal exercise. At a PB equivalent to 4572m, both measurements exceeded sea level 
values at any submaximal exercise level, a response worsened with prolonged (40 day) 
exposure to lower PB (Wagner, 2000). Whilst it is clear exercise capacity and cardiac output 
are reduced, the mechanisms involved remain to be fully elucidated (Wagner, 2000) and 
likely involves a combination of the complex physiological responses to hypoxia discussed 
above.   
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Despite the restriction in exercise capacity, training in hypoxic conditions has gained 
much interest in the sports science field. Much interest exists around the question of whether 
potential beneficial effects of hypoxia, such as enhanced O2 carrying capacity and  glycolytic 
capacity evoked by HIF signalling, can be elicited without the detrimental effects upon 
muscle wasting and limited training capacity through intermittent hypoxic training (Faiss et 
al., 2013).  
1.2.5 Conclusion 
Hypoxia thus appears to act as a driver of metabolic re-programming, a process that is 
summarized in Figure 1.5. Exposure to hypoxic conditions imposes stresses upon 
mitochondria that result in a decreased oxidative capacity and an increased ROS 
production. Successful adaptation therefore needs to encompass both the restrictions on 
energy production and limit the potential toxicity of ROS. Current evidence suggests that 
despite remaining restrictions upon exercise performance, these requirements can be 
largely met in healthy humans after a period of acclimatisation. This is mediated through the 
following changes: a shift towards anaerobic ATP generation, alterations to TCA cycle and 
ETS activities and changes to oxidative stress markers. In the short term (≤14days) it 
appears that hypoxic-induced decreases in skeletal muscle mitochondrial function, as 
shown through decreases in β-oxidation, TCA function and OXPHOS, are occurring 
alongside maintenance of mitochondrial density. This is followed by a loss of mitochondrial 
density in response to longer term exposures (≥42days) (Horscroft et al., 2014). Evidence 
suggests that skeletal muscle energetics, particularly energy storage capability, can be 
maintained in healthy humans following acclimatisation.   
However, it is clear to see that metabolic remodelling processes induced by hypoxia 
remain controversial. Much is left unanswered and there is a significant lack of consensus 
between studies. Perhaps the most prominent of these discrepancies is the duration and 
degree of hypoxic exposure, both in human and rodent models. Particularly in the case of 
investigations into human physiology, this is further confounded by low subject numbers as 
the majority of high altitude studies are performed on fewer than 20 subjects. In addition, 
many previous studies focus on particular aspects of complex metabolic pathways, including 
the activities of specific enzymes, such as mitochondrial complexes. Although useful, these 
measurements are inaccurate indicators of mitochondrial function, or dysfunction 
(Kuznetsov et al., 2008). A far more rigorous measure is the functional analysis of intact 
mitochondrial O2 consumption through respirometry. Beyond the specificities of 
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mitochondrial function are techniques that encompass a full metabolic profile of a tissue or 
biofluid, which have the potential to present a far greater insight.  
There is a clear need for these issues to be addressed and for more sophisticated 
measures to be included in the continued investigation into mammalian physiology and 
molecular biology in response to hypoxic exposure. Such work has the potential to further 








Figure 1.5. A summary of the metabolic stresses of hypoxia 





1.2.6 Hypoxia in disease:  chronic obstructive pulmonary 
disease (COPD) 
As aforementioned, hypoxia plays a key role in the pathology of numerous disease 
states.  An aspect of this thesis focuses upon hypoxic effects in chronic obstructive 
pulmonary disease (COPD), particularly the exercise limiting component of this disease.   
COPD is a leading cause of morbidity and mortality worldwide, affecting 10-15% of 
the adult population aged ≥40 yrs (Lozano et al., 2013, Buist et al., 2007). The burden of 
COPD is set to increase in the coming decades due to the continued exposure to risk factors 
(predominantly smoking) and aging of the population, as prevalence increases with age 
(Buist et al., 2007). COPD is characterised by persistent and progressive airflow limitation, 
caused by a mixture of small airways disease (obstructive bronchitis) and parenchymal 
destruction (emphysema). This is associated with an enhanced chronic inflammatory 
response to noxious particles in the airways and lung, causing structural changes and 
narrowing of the small airways. Diagnosis and characterisation of COPD has thus far relied 
upon measurement of airflow limitation, assessed by forced expiratory volume in 1 second 
(FEV1) (Pauwels et al., 2012). However, it is now widely recognised that COPD is a 
heterogeneous disease with features that are not captured by FEV1, including muscle 
dysfunction, systemic inflammation and cardiovascular disease (Pauwels et al., 2012).  
Exercise limitation is a common symptom in COPD patients and one that severely 
affects quality of life. Improving exercise tolerance is considered a key goal of effective 
COPD management (Pauwels et al., 2012).  The causes behind the reduction in exercise 
capacity are complex. Initially, it was believed respiratory limitation and dyspnoea were the 
main contributors. However, it has been frequently demonstrated that patients with similar 
values for airflow obstruction have variable exercise capacities. Indeed, peripheral muscle 
fatigue has been defined as a key determinant of exercise capacity, which has been shown 
to precede the sense of breathlessness (Killian et al., 1992b). This muscular limitation is 
likely affected by atrophy and dysfunction of skeletal muscle, with a reported decrease in 
skeletal muscle cross sectional area and shift towards glycolytic type II fibre makeup 
(Swallow et al., 2007, Jobin et al., 1998) with a preferential loss in oxidative type I and IIa 
fibres (Jobin et al., 1998, Gosker et al., 2002).   
A factor likely contributing to exercise limitation is hypoxia. In COPD sufferers, 
increasing perfusion of a poorly ventilated lung leads to a ventilation-perfusion mismatch, 
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resulting in hypoxaemia (Pauwels et al., 2012). Delivery of O2 is further confounded at the 
level of microcirculation, as both capillary number and capillary/fibre ratio are decreased in 
vastus lateralis muscle in COPD patients relative to healthy controls (Jobin et al., 1998). 
Various aspects of COPD pathophysiology are likely linked to hypoxia, including alterations 
in skeletal muscle function. This is reflected in the findings of Koechlin, which demonstrate 
a greater reduction in quadriceps endurance and worsening of muscle oxidative stress at 
rest and post exercise in chronic hypoxemic COPD patients compared to non-hypoxemic 
patients (Koechlin et al., 2005).  
The hypoxic effect is likely driving changes observed in metabolic state. This 
includes a depletion of skeletal muscle energy stores, with positive correlations being shown 
between arterial O2 concentrations (PaO2) and both muscle glycogen and phosphocreatine 
(PCr) concentrations (Jakobsson et al., 1990). Hypoxia may also have a role in inducing the 
shift towards anaerobic means of ATP generation through glycolysis, with increased lactate 
levels found in lower limb muscles (Jakobsson et al., 1990, Shields et al., 2015). This occurs 
alongside a reduction in oxidative capacity, with a loss of oxidative enzymes (Swallow et al., 
2007) and a  decline in mitochondrial oxidative capacity (Rabinovich et al., 2007). 
Interestingly, the hypoxic responses observed in COPD patients appear to differ in 
some aspects compared to healthy subjects. Although healthy subjects exposed to 
hypobaric hypoxia via high altitude also experience significant muscle atrophy, they appear 
to retain muscle function (Edwards et al., 2010) and capillary density (Hoppeler, 2001) 
neither of which are maintained in COPD patients. A number of cellular responses also 
support the idea that COPD sufferers do not respond as healthy humans do to hypoxia. An 
example of this is a blunting of the fundamental HIF-α response. This has been attributed to 
a reduction in levels of the enzyme histone deacetylase (HDAC), specifically to HDAC 7 (To 
et al., 2012, Ito et al., 2005). A lack of HIF-1α induction was demonstrated through a 
suppressed expression of the HIF target gene VEGF, as levels increased to just a quarter 
of that of healthy controls (To et al., 2012).  
Taken together, these findings suggest that tissue O2 delivery, intramuscular O2 
transport and mitochondrial dysfunction may all contribute to exercise limitation in COPD. 
Approaches that reduce the O2 cost of exercise may thus be of therapeutic benefit. 
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1.2.7 Aiding hypoxic acclimation 
Given the common occurrence of hypoxia, both environmentally and clinically, and 
its potential tragic consequences, it would be of considerable benefit to develop 
pharmacological strategies to aid human adaptation/hypoxic survival. Ability to do this could 
potentially benefit subjects suffering from hypoxia as a comorbidity of diseases such as 
COPD, as well as healthy humans that are exposed to hypoxic environments. Little is known 
about how to reduce O2 utilisation at the tissue or cellular level in humans.  
There are several ways to lessen the O2 requirements of a cell. The first is to reduce 
cell work, an approach used by sea turtle hepatocytes (Hochachka et al., 2001). The second 
is to improve the biophysical economy of the cell processes by, for instance, decreasing the 
ATP consumed by an active transporter. The third is to improve mitochondrial efficiency 
through improved the energy coupling. This is measured as the amount of O2 consumed per 
ATP produced, and is termed the P/O ratio. Nitrate have been proposed to decrease the 
O2/ATP at the level of the respiratory chain, as well as having whole body physiological 
effects such as improving exercise performance (discussed below).  A major component of 
this thesis is to examine the potential of dietary nitrate to alleviate hypoxic induced metabolic 
stress.   
 Dietary nitrate supplementation  
Inorganic nitrate (NO3-) can be consumed as part of a normal, healthy diet with high 
levels present in green leafy vegetables and beetroot (Hord et al., 2009). Dietary exposures 
to NO3-  in the general population is estimated to be 52mg/day, with vegetables contributing 
~70% to this (Ysart et al., 1999). Once consumed, NO3- is reduced in a stepwise fashion 
firstly to nitrite (NO2-) and then nitric oxide (NO). NO is a diatomic free radical gas that serves 
as a ubiquitous, multi-functioning signalling molecule. 
 As mammalian cells are not capable of converting NO3-  to NO2-, this process is reliant 
on the nitrate reductase activity of commensal bacteria present within the oral cavity, which 
generate NO2- from NO3-  rich saliva (Spiegelhalder et al., 1976, Duncan et al., 1995). This 
stepwise reduction is potentiated in low O2 tension and low pH conditions (Castello et al., 
2006, Modin et al., 2001). The subsequent reduction of NO2- to NO can occur in a number 
of ways, including: enzymatic reduction by xanthine oxidoreductase requiring hypoxic 
conditions and the presence of NADH (Millar et al., 1998), acidic reduction in areas of low 
pH such as the stomach (Benjamin et al., 1994) and reduction by deoxyhemoglobin (Cosby 
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et al., 2003).  NO2- is thus a major vascular storage pool for NO, existing in far larger 
concentrations than the protein carriers of NO S-Nitrosothiols (Cosby et al., 2003). The NO2- 
pool is a relatively stable source that enables NO to reach distal areas to exert its biological 
effects. Supplementation of inorganic dietary nitrate thus increases plasma NO2-  
concentration, in turn enhancing NO availability (Lundberg et al., 2004).  
In addition, NO can be derived endogenously through the O2 dependent catabolism of 
L-arginine, a reaction catalysed by one of three isoforms of nitric oxide synthase (NOS) 
(Stamler et al., 2001).   The generation of NO via these two mechanisms is summarised in 
Figure 1.6.  
NO is regarded to be the chief mediator of the responses observed with nitrate 
supplementation (Jones, 2014). The following summary of the effects of nitrate 
supplementation are therefore focused upon the signalling responses of NO. In these 
studies, nitrate is either given through consumption of high nitrate containing beetroot juice 
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Figure 1.6. The mechanisms of nitric oxide (NO) production via endogenous or dietary 
pathways 
The following abbreviations are used: NOS = nitric oxide synthase, DeoxyHb = 




Nitric oxide (NO) action 
The signalling responses of NO are complex and are mediated through numerous 
mechanisms, including S-nitrosylation of cysteine redox centres within proteins, which 
involves incorporation of the NO moiety to a sulfur atom.  Motifs for S-nitrosylation have 
been identified on various ion channels, receptors, enzymes, transcription factors and small 
G proteins (Stamler et al., 2001). In addition, NO can interact with haeme-containing 
proteins, such as cytochrome-c oxidase (COX, or complex IV), thus enabling interaction with 
cellular respiration (Stamler et al., 2001).  NO binds with high affinity to the haeme cofactor 
present on the soluble guanylate cyclase (sGC) sensory domain. This binding activates the 
catalytic site, in turn increasing levels of cyclic guanosine monophosphate (cGMP) 
generated from guanosine triphosphate (Underbakke et al., 2014, McDonald et al., 1996). 
sGC is considered the primary cellular receptor of NO. The importance of the 
NO/sGC/cGMP signalling pathway is reflected through responses to defects in this system, 
which have been linked to the following: heart disease, stroke, hypertension, 
neurodegeneration and erectile dysfunction (Bredt, 1999). However, the specific 
mechanisms involved in the downstream responses of this second messenger system, 
along with defects resulting from these pathologies, are less clear.  
Perhaps the best defined downstream signalling pathway of NO derived cGMP is 
that involved with vascular homeostasis. NO is released from endothelial cells (also termed 
endothelial derived relaxing factor) (Palmer et al., 1987) in response to a range of stimuli. 
cGMP-dependent protein kinase G (PKG) is subsequently activated via the sGC mediated 
mechanism. This induces smooth muscle relaxation and so vasodilation likely via changes 
in levels of, and sensitivity to, intracellular calcium (i[Ca2+]), although exact mechanisms 
remain unclear (Taylor et al., 1989, Surks, 2007, Carvajal et al., 2000). The resulting drop 
in blood pressure is a well-defined response to short term nitrate  supplementation (Lansley 
et al., 2011, Vanhatalo et al., 2010, Bailey et al., 2010, Bailey et al., 2009, Hobbs et al., 
2012).    
In rat skeletal muscle, NO derived cGMP signalling has been demonstrated to 
enhance fatty acid oxidation capacity through the master regulator of fatty acid oxidation, 
PPARα (Ashmore et al., 2015b), as outlined in Equation 1.3 
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𝑵𝑶 → 𝒔𝑮𝑪 → ↑ 𝒄𝑮𝑴𝑷 → 𝑷𝑲𝑮 → 𝑷𝑷𝑨𝑹𝜶 
Equation 1.3. Proposed mechanism for dietary nitrate action upon skeletal muscle 
metabolism 
The pathway of action for nitrate dependent enhancement of β-oxidation (Ashmore et al., 
2015b). Where sGC = soluble guanylate cyclase, cGMP= cyclic guanosine monophosphate, 
PKG = protein kinase G and PPARα = peroxisome proliferator activated receptor. 
 
This mechanism demonstrated direct effects upon PPARα expression and 
transcriptional activity, resulting in turn in the upregulation of intra-mitochondrial pathways 
of fatty acid oxidation alongside released inhibition of mitochondrial fatty acid import via the 
carnitine palmitoyl transferase (CPT) system (Ashmore et al., 2015b). These expression 
changes were demonstrated to have functional effects, by enhancing OXPHOS rates in 
response to the addition of the long chain fatty acid palmitoyl carnitine. This is discussed in 
further depth in Chapter 4.  
In mouse cardiac muscle, the PKG second messenger system has been linked to 
endogenous hydrogen sulphide (H2S) production and in turn to cardio protection in ischemic 
conditions (Salloum et al., 2009, Salloum et al., 2015). Upregulation of this system has been 
associated with dietary nitrate consumption, although mechanisms of H2S function remain 
ambiguous (Salloum et al., 2015). 
Whilst questions undoubtedly remain on the specific details of NO signalling 
mechanisms, it is distinctly evident that NO signalling plays a key part in regulating the 
delivery of O2 and nutrients along with mitochondrial O2 consumption, with direct effects 
upon cellular respiration.  
Implications for O2 delivery and utilisation 
NO production, either via endogenous NOS action or NO3--NO2- pathway reduction, 
has been reported to regulate numerous biological effects that influence the transport and 
utilisation of O2 in the tissues as well as production of ROS. Perhaps the best characterised 
of these effects is the previously mentioned mediation of vasodilation and so basal vascular 
tone. Vasodilation increases blood flow, and so O2 delivery, to the tissues. This is particularly 
pertinent in conditions where O2 demand is increased, as occurs in the working muscles 
during exercise, thereby inducing hypoxia-dependent vasodilation. The effects upon tissue 
oxygenation are uncertain and may vary depending on exercise intensity.  
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Interactions between NO and mitochondria  
Beyond vasodilation, NO has been demonstrated to implicate O2 consumption at the 
mitochondria through direct interactions with mitochondrial components. For instance, 
complex I, a major site for ROS production (Lambert et al., 2004), appears to be a key NO 
target. S-nitrosylation of thiols, the functional groups of cysteine residues, leads to inhibition 
of this complex. This response is well documented in rodent models (Shiva et al., 2007, 
Clementi et al., 1998) and is reported to have particular relevance in both hypoxic and 
ischemic conditions, as discussed below.  
Links between NO and the respiratory chain extend to COX/complex IV. In addition to 
its O2 reducing ability, this enzyme appears to have significant links to NO function. NO has 
been shown to compete with O2 for the bimetallic binding site of COX , resulting in inhibition 
of respiration (Brown et al., 1994, Brudvig et al., 1980).  It has been proposed that this 
inhibition of O2 consumption allows for diffusion of O2 deep into the tissue thereby enhancing 
tissue oxygenation and improving the O2 status of fibres situated further away from 
capillaries (Hagen et al., 2003, Thomas et al., 2001, Victor et al., 2009).  
The effects of NO upon COX function are thought to be regulated endogenously through 
mitochondrial NO production, mediated in part through endothelial NOS (eNOS). This 
enzyme is located on the cytoplasmic face of the outer mitochondrial membrane, within close 
proximity to COX (Gao et al., 2004). Deletion of the pentabasic sequence domain that 
anchors eNOS to the mitochondrial outer membrane causes an increase in O2 consumption, 
thus confirming the role of NO as a physiological regulator of COX (Gao et al., 2004). 
Evidence also suggests COX itself is a mediator of mitochondrial NO synthesis in mammals 
independently of eNOS; a process induced in hypoxia that is dependent upon the presence 
of NO2- (Castello et al., 2008, Castello et al., 2006).  
The close relationship between COX and NO is hardly surprising given the evolutionary 
history of COX. It is thought that COX originated within a common ancestor of archaea and 
bacteria from denitrification enzymes at a time prior to oxygenic photosynthesis. The site of 
O2 reduction at the binuclear copper centre of COX is thought to have originated from an 
exchange of genes between the nitric/nitrous oxide reductase and primitive oxidases 
(Castresana et al., 1994, Saraste, 1994).    
Links have also been made between NO and mitochondrial biogenesis. NO production 
by eNOS has been related to an upregulation of key factors involved in mitochondrial 
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biogenesis in calorie restriction, including PGC-1α, nuclear respiratory factor (NRF) 1 and 
mitochondrial transcription factor A (Tfam) (Nisoli et al., 2005). In addition, dietary nitrate 
supplementation has been shown to counteract the hypoxic induced suppression of PGC-
1α in rat skeletal muscle (Ashmore et al., 2015b). However, the link between NO and 
regulation of mitochondrial function is not a consistent finding, as nitrite supplementation 
has been shown to have no effect on mRNA levels of PGC-1α or NRF-2 in rodents (Shiva 
et al., 2007, Nisoli et al., 2005).  
It is therefore clear that NO signalling has implications upon the delivery and usage of 
O2. This thus leads to the question: what are the ramifications of this signalling response 
upon tissue work? Can supplementation of dietary nitrate enhance ability to perform work? 
This has been explored through human exercise studies.  
Effects of nitrate supplementation during exercise  
Investigations into the effects of nitrate supplementation on exercise demonstrate a 
reduced O2 cost of low intensity/submaximal (Larsen et al., 2007, Vanhatalo et al., 2010, 
Bailey et al., 2009, Lansley et al., 2011) and high intensity/maximal exercise alongside an 
improved tolerance to maximal exercise (Bailey et al., 2009, Larsen et al., 2010, Cermak et 
al., 2012). These effects occurred in the absence of a rise in circulating lactate 
concentrations, indicating the fall in O2 requirement was not compromised for through an 
increase in substrate level phosphorylation via glycolysis, and maintenance of exercise work 
performance (Larsen et al., 2007, Bailey et al., 2009, Vanhatalo et al., 2010, Larsen et al., 
2010).  These prior results suggest that efficiency of both mechanical processes and 
oxidative ATP production were improved with nitrate supplementation. Indeed, the ATP 
turnover rate was reported to be lowered with nitrate  supplementation, alongside a fall in 
muscle [PCr] degradation, [Pi] and [ADP], following exercise (Bailey et al., 2010). The 
authors thus linked the observed reduction in O2 cost to a fall in ATP cost of muscle force 
production.  
Effects upon skeletal muscle contraction extend to interactions with contractile 
processes within the muscle that are heavily reliant on ATP hydrolysis. This includes a 
slowing of cross-bridge cycling kinetics, as nitrate supplementation induced a higher force 
generation at the expense of a reduced velocity (Evangelista et al., 2010), and a decreased 
Ca2+ uptake into the sarcoplasmic reticulum due to an NO induced inhibition of sarcoplasmic 
reticulum Ca2+ ATPase (SERCA) activity (Ishii et al., 1998). This SERCA inhibition occurred 
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independently of the cGMP-PKG system, instead being linked to direct interaction with NO 
(Ishii et al., 1998).  
This effect upon the contractile processes in skeletal muscle appears to be most 
prominent in type II, fast twitch fibres (Hernández et al., 2012). Nitrate supplementation has 
been linked to increasing myoplasmic free [Ca2+], which was associated both with an 
increased contractile force and faster rate of force development in mice. This occurred 
alongside a rise in expression of the Ca2+ handling proteins, calsequestrin 1 and 
dihydropyridine receptor, a response that was absent in slow twitch fibres (Hernández et al., 
2012). The beneficial effects of NO signalling upon fast twitch fibres may be aided by the 
lower PO2 present in this fibre type, which is thought to facilitate the reduction of NO3- to NO 
(Ferguson et al., 2015). 
In addition to the mechanics involved in muscle contraction, interplay has also been 
demonstrated between NO and processes directly linked to the generation of muscle fatigue 
specifically the phosphocreatine (PCr) system. Fatigue development during exercise is 
partially linked to the decrease in muscle [PCr] and this decrease is reported to be 
attenuated in subjects undertaking repeated maximal voluntary contractions following nitrate 
rich beetroot juice supplementation (Fulford et al., 2013).  
Despite these seemingly beneficial effects of nitrate supplementation, the ergogenic 
effects are debatable and significant inconsistencies exist between studies. Indeed, some 
studies demonstrate no change in performance with nitrate supplementation in submaximal 
exercise (e.g.(Kelly et al., 2014)) and others a decline in high intensity intermittent exercise 
performance (e.g.(Martin et al., 2014)). There are likely numerous reasons for such 
discrepancies. Firstly, it may relate to exercise duration. The ergogenic effect of nitrate 
supplementation has been reported for short intermittent maximal intensity exercise (Wylie 
et al., 2016, Thompson et al., 2015, Aucouturier et al., 2015), whereby increasing perfusion 
aids oxygenation of type II muscle fibres (Aucouturier et al., 2015, Wylie et al., 2016, 
Ferguson et al., 2015), which are preferentially recruited during high intensity intermittent 
exercise  (Essén, 1978).  In contrast,  minimal evidence exists to support its benefit for longer 
durations (Jones, 2014).   
The discrepancy may also be due to the choice of subject cohort. nitrate  
supplementation has been shown to have the greatest effects in subjects of lower fitness in 
comparison to athletes (Porcelli et al., 2014). Whilst it has also been demonstrated to 
improve the performance of well-trained athletes, it appears to have little effect  in the  elite 
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athlete cohort (Jonvik et al., 2015). The reasoning behind the lack of response in the elite 
cohort is unclear, but may be linked to the higher baseline production of NO via NOS, or 
higher dietary intake as a secondary to greater daily energy intake, alongside a higher 
proportion of type I fibres present in these highly trained subjects (Hultström et al., 2015, 
Jonvik et al., 2015). This signifies that perhaps increasing NO bioavailability is better 
targeted to populations of advanced age, particularly with pathologies, whose baseline NO 
production may be compromised (Hultström et al., 2015).    
A factor that is often overlooked is the potential for inter-individual differences in the 
handling of dietary nitrate within similar subject cohorts. For instance, even within the elite 
athlete cohort, ‘responders’ to nitrate treatment still exist. The source of such differences 
may include variability in nitrate reductase activity within the oral cavity to convert nitrate to 
nitrite as some subjects do not show the characteristic increase in plasma nitrite (Hultström 
et al., 2015).  It may also stem from differences in intrinsic nitrite reductase capabilities of 
mitochondrial aldehyde dehydrogenase (ALDH2). Those subjects exhibiting a common 
polymorphism termed the ALDH2*2 allele demonstrated differences in nitrite handling and 
sGC activity compared to subjects exhibiting the wild type allele following inorganic nitrite 
administration (Ormerod et al., 2017).  
Lastly, the discrepancies may reflect issues in protocols, with the use of inadequate 
dosing levels and time allowed for the increase in plasma nitrite  levels to occur, which takes 
2-3hrs and corresponds to a decrease in blood pressure (Jones, 2014).  Mechanistic studies 
also demonstrate that longer supplementation periods (3-7 days) are required for changes 
to occur in contractile and mitochondrial proteins (Jones, 2014).  
Together, evidence thus suggests there is close relationship between NO regulation 
of O2 delivery and usage and that nitrate supplementation has the potential to aid human 
performance. These processes are summarised in Figure 1.7.  A legitimate question from 
this is what is the role of NO signalling in conditions where O2 supply becomes limited 
through hypoxic exposure, resulting either from high altitude exposure or a disease state? 
Can dietary nitrate supplementation aid human adaptation to these conditions? 
68 
 
Figure 1.7. Reported effects of dietary inorganic nitrate (NO3-) supplementation and proposed mechanisms elicited by nitric 
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The role of NO in hypoxia  
The importance of NO signalling in hypoxia has already been eluded too, with the 
reliance upon low O2 tension for the reduction of NO2- to NO.  The hypoxic induced increase 
in NO production has also been observed at a whole-body level in high altitude studies, with 
biomarkers of NO production, being plasma nitrate and nitrite, increasing in healthy subjects 
with ascent to 5300m along with an increase in a marker of NO activity cGMP. S-nitrosothiol 
production was also increased, suggesting multiple pathways contribute to enhancing NO 
availability  (Levett et al., 2011). Circulating levels of bioactive NO products have been found 
to be greater in high altitude native Tibetan populations compared to lowland natives. This 
was associated with a greater forearm blood flow, and so increased O2 delivery (Erzurum et 
al., 2007).  
Thus, the high levels of circulating NO influence the delivery of O2 and nutrients through 
its vasodilatory effects. Beyond this is the utilisation of O2 in mitochondrial oxidation. Indeed, 
mitochondrial production of NO is reported to be increased in hypoxia (Valdez et al., 2004, 
Schild et al., 2003), with some of this synthesis occurring independently of NOS, for instance 
through COX mediated NO production (Castello et al., 2006).  The potential for NO to 
increase efficiency of O2 usage in this process has inevitably sparked significant interest into 
the effects of NO upon mitochondrial functioning in conditions where O2 supply is 
compromised.  
NO protecting against low O2 conditions  
Evidence suggests that nitrate supplementation improves the ratio of O2 consumed: ATP 
produced (P/O ratio). Such a process may involve a decrease in proton leak meaning a 
larger portion of the mitochondrial inner membrane becomes geared towards ATP synthesis 
rather than uncoupling actions (Larsen et al., 2011, Clerc et al., 2007). This is thus 
suggestive of enhanced respiratory chain efficiency, an effect that is particularly important 
in conditions where O2 availability is limited and which is supported through investigations 
into interactions with specific complexes, particularly complex I.   
Complex I is understood to be the primary site of injury and mitochondrial ROS 
production following ischemia/reperfusion (IR) and so is a key contributor to IR injury 
(Lesnefsky et al., 2001).  Ischemia initially induces low levels of complex I activity. The rapid 
reversal of this upon reperfusion leads to production of hydrogen peroxide and so oxidative 
damage. This damage was attenuated in murine cardiac cells in the presence of NO donors, 
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with  a reduction in protein carbonylation (a marker of oxidative damage), necrotic and 
apoptotic cell death (Chouchani et al., 2013). The s-nitrosation of Cys 39, which is exposed 
on complex I during the low activity condition, was thought to lock complex I in the low active 
state likely by disrupting its interaction with ubiquinone. Reactivation of complex I was 
initiated upon reperfusion through reduction of the S-nitrosothiol by glutathione and 
thioredoxin, but this reactivation is gradual, meaning ROS production became attenuated 
(Chouchani et al., 2013).  
This cardio protective effect has similarly been demonstrated in the rat heart with nitrate  
supplementation during hypoxic conditions (13% O2 for 14 days) (Ashmore et al., 2014). 
Hypoxic induced suppression of complex I supported state 3 respiration (in the presence of 
ADP) was shown to be recovered with nitrate supplementation. This occurred alongside an 
increase in both complex I enzyme activity and protein levels.  In addition, nitrate 
supplementation restored cardiac ATP and ADP levels and alleviated the rise in protein 
carbonyls in response to hypoxic exposure (Ashmore et al., 2014).  
The interaction between nitrate and complex I has also been demonstrated in skeletal 
muscle, as expression of the complex I subunit Ndufs1 was shown to increase in cultured 
myocytes (C2C12) in response to supplementation with nitrate both 50 and 500µM 
(Ashmore et al., 2015b). Effects upon skeletal muscle function have also been demonstrated 
through mitochondrial respirometry, with nitrate supplementation enhancing fatty acid 
OXPHOS in both hypoxic and normoxic conditions and also recovering rat skeletal muscle 
energetics in hypoxia (Ashmore et al., 2015b).   
It may seem logical to assume that recovery of cellular respiratory capacity in hypoxic 
conditions may be solely due to enhanced O2 delivery resulting from NO induced 
vasodilation. However, nitrate dependent enhancement of oxidative capacity occurred in 
normoxic conditions, whereby O2 delivery is plentiful, in addition to hypoxia. Furthermore, 
evidence clearly indicates direct interactions with mitochondrial machinery. It is therefore 
plausible to conclude that nitrate supplementation has direct effects upon metabolic 
regulation.  
Does dietary nitrate supplementation enhance performance in hypoxia?    
Supplementation of nitrate has been attributed to decreasing VO2 at rest and during 
submaximal exercise in hypoxia, an effect associated with an improved tissue oxygenation 
index, which was independent of an increased muscle blood flow (Masschelein et al., 2012). 
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Similar results have been shown when O2 carrying capacity is reduced following blood 
donation, whereby nitrate supplementation recovered decrements in submaximal 
performance in addition to decreasing O2 uptake (McDonagh et al., 2016). This improvement 
in VO2 kinetics has also been demonstrated during high intensity exercise, an effect 
associated with improved hypoxic exercise tolerance (Kelly et al., 2014, Vanhatalo et al., 
2011). These results thus go to support the concept that NO improves efficiency of 
mitochondrial O2 consumption in hypoxia.  
However, the increase in endogenous NO production and activity at high altitude, as 
reported by Levett and colleagues, was not associated with any change in O2 cost of 
exercise or mechanical efficiency. It in fact correlated inversely with microvascular blood 
flow, which was impaired at altitude (Levett et al., 2011). This is in contrast to previous 
findings in response to dietary nitrate supplementation at high altitudes, which was related 
to enhanced flow mediated dilation, indicative of improved endothelial function (Bakker et 
al., 2015).  
In addition to the whole body effects, NO has been shown to play a key role in cellular 
hypoxic signalling. It has been linked to both induction of nuclear hypoxic genes (Castello et 
al., 2006) and HIF-1α signalling, although effects upon the latter are not clear.  Endogenous 
production of NO by COX has been linked to HIF-1α stabilisation in mammalian cells (Ball 
et al., 2012). However, addition of NO along with other respiratory chain inhibitors to HEK293 
cells grown in 1% O2 caused prolyl hydroxylase dependent inhibition of HIF-1α, resulting in 
its impaired accumulation and transcriptional activity (Hagen et al., 2003).  
The literature thus suggests that NO plays an integral part of the hypoxic response. 
However, details on the mechanisms of actions remain unclear.   
Detrimental effects of nitrate supplementation 
The above summary of the effects of nitrate supplementation focus on the potential 
for improving metabolic efficiency. However, an important consideration is the capacity of 
nitrate to cause a harmful effect. Indeed, many of the studies that show beneficial effects do 
so with doses that exceed the recommended daily nitrate intake (Kapil et al., 2014, WHO, 
2003). Interestingly, commercially available beetroot juice also exceeds this limit.  The 
potential detrimental effects include the formation of carcinogenic N-nitrosamines, the onset 
of intolerance and endothelial dysfunction. However, there is currently no evidence that 
nitrate is carcinogenic to humans and has in fact been linked to decreasing risks of many 
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cancers (Kapil et al., 2014).  In fact, the detrimental effects appear to be more closely 
associated with synthetically synthesised inorganic nitrate and exposure to high levels of 
NO2-. This is reflected, for instance, in reported cases of methaemoglobinaemia in children. 
This condition occurs due to interaction of NO2- with haemoglobin in the ferrous state, in turn 
impairing the O2 carrying capacity of haemoglobin. In these cases, onset was associated 
with improper storage of cooked or salted vegetables that accumulated NO2- resulting from 
bacterial contamination. No reports of vegetable induced methaemoglobinaemia have been 
reported in adults (Kapil et al., 2014).  
1.2.8 Conclusion 
 In conclusion, there appears to be two key responses occurring with nitrate 
supplementation and subsequent NO signalling that directly relate to the use and delivery 
of O2:  
1. Vasodilation. This mediation of vascular tone will result in an increased delivery of 
more O2 to the working muscle.  This is observed within 2-3 hours of supplementation 
and corresponds to an increase in plasma nitrite (Jones, 2014).  
2. Actions upon mitochondrial function, resulting in a decrease in VO2, and an 
improvement in energy coupling.  This is associated with changes in mitochondrial 
proteins occurring with longer term supplementation (Jones, 2014).  
At the outset, these two factors may appear contradictory. Why should O2 delivery be 
increased when O2 use is being restricted? However, when considered in the context of 
hypoxic exposure, both factors would likely work together to ensure O2 supply is matched to 
usage. It may also be the case that a decreased VO2 in the mitochondrial population located 
close to the capillary will allow for O2 to reach more distal regions.  
There is still a large degree of controversy in the field of nitrate supplementation, with 
some studies showing supplementation of dietary nitrate has no effect upon function or 
performance. This may be due to poor study design and a lack of consensus between 
studies regarding dosage, duration of supplementation and exercise protocols. It may also 
be the case that nitrate supplementation in a healthy population, whom have an optimal 
production of endogenous NO, has less of an effect in comparison to a patient population, 
where NO production may be compromised. This may be particularly relevant in populations 
where hypoxia is a key factor in disease pathology. Indeed, the potential for nitrate 
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supplementation to act as a therapeutic measure in disease states associated with hypoxia 
remains to be determined.  
Equally, many questions remain regarding mechanisms of nitrate action. The signalling 
mechanisms and specificities of NO action upon mitochondrial function, particularly in the 
context of hypoxia, remain largely unexplored.   
1.3 Summary  
 A sufficient supply of O2 to the tissue is required to maintain oxidative metabolism, 
in doing so preserving ATP production. This is in turn required to fuel energy consuming 
processes within the cell and so is central to the maintenance of order and homeostasis 
within complex organisms. In hypoxia, the lack of O2 causes this fundamental process to be 
compromised and metabolic stress ensues. Metabolic remodelling is therefore required to 
maintain energetic and redox homeostasis. However, it is clear to see that the details of 
hypoxic induced metabolic changes remain ill defined. Furthering our understanding of these 
changes has implications both for healthy humans sojourning to high altitudes and also for 
the plethora of disease states in which hypoxia plays an integral part. By understanding 
mechanisms of healthy hypoxic adaptation, this may provide insight into the processes of 
pathological hypoxia and into developing potential strategies that lessen the impact of 
pathological hypoxia.  
 This thesis encompasses two themes. The first was to investigate the metabolic 
responses of healthy humans to hypobaric hypoxic exposure. The second was to investigate 
the potential of nitrate supplementation to alleviate metabolic stresses of hypoxia and to 
shed light upon the mode of nitrate action. 
1.4 Thesis aims 
The aims of this thesis were as follows:  
1. To examine the metabolic responses of healthy humans to acute, progressive 
hypoxic exposure. This was achieved through employment of metabolomic and 
lipidomic techniques on plasma samples obtained from subjects ascending to 
EBC (5300m).   
2. To examine the effects of chronic hypoxic exposure, along with extreme cold, 
on human physiology and metabolism. A small cohort of subjects was assessed 
before and after a Trans-Antarctic winter expedition, involving prolonged 
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exposure to moderate altitude (≤2500m). Metabolomics assessment of plasma 
was employed alongside anthropometric and exercise physiology measures.  
3. To investigate the potential for dietary nitrate supplementation to ameliorate the 
metabolic stresses of hypoxia in skeletal muscle and the role of PPARα in this 
process. A mouse model of wild type and PPARα-/- was used and the focus of 
analysis was upon skeletal muscle mitochondrial function.   
4. To assess the effects of acute dietary nitrate supplementation upon exercise 
duration and related metabolic changes in a clinical population of COPD 
sufferers. This was examined using a submaximal exercise test alongside 
metabolomic analysis of plasma samples. 













2 Chapter 2 (Study 1): Metabolomic and 
lipidomic profile changes in healthy subjects 
exposed to progressive hypobaric hypoxia upon 
ascent to Everest Base Camp 
2.1 Introduction  
Ascent to high altitudes is associated with changes in a number of environmental 
factors, including: PO2, ambient temperature, relative humidity and solar radiation. It is 
generally accepted that the majority of physiological changes that occur in response to high 
altitude exposure are elicited by a decrease in PO2 (Woolcott et al., 2015), a consequence 
of a fall in PB. This leads to a decreased PIO2 and impaired O2 transfer down the O2 cascade, 
resulting in impaired tissue oxygenation and hypobaric hypoxia.  
As described in the literature review, an inadequate O2 supply to the tissues can 
severely compromise oxidative metabolism and elicit a stress response resulting in 
increased ROS production. Acclimatisation to hypoxic conditions thus requires a robust 
physiological response allied with metabolic remodelling to ensure that ATP demand is met 
in the face of restricted O2 availability.  The remodelling process is complex and currently ill 
defined. Furthering current understanding of this response is of high importance in relation 
to the increasing numbers of lowlanders sojourning to high altitude destinations, as well as 
the growing proportion of the world’s population (currently 7%, ~440million (Woolcott et al., 
2015)) residing above 1500m.  
Given that hypoxia is prevalent amongst a range of diseased populations, 
investigation into hypoxic adaptation is also highly clinically relevant. Indeed, much of the 
work conducted on metabolic adaptations to hypoxic exposure has been in the context of 
cancer, obesity and respiratory disease (Danhier et al., 2017, Hosogai et al., 2007). 
However, the pathways involved in adaptation to hypoxia remain unclear and are particularly 
difficult to study in pathological states, given the plethora of confounding factors and 
complications prevalent in a diseased population (Grocott et al., 2007a). It therefore makes 
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sense to better define the adaptive response in healthy humans before translating this to a 
clinical population. A method of assessing hypoxic exposure in healthy humans is through 
exposure to environmental hypobaric hypoxia, as is experienced at high altitudes.   
The Caudwell Xtreme Everest (CXE) expedition was a large scale field study that 
assessed the healthy human response to  progressive environmental hypoxia during an 
ascent to EBC (Levett et al., 2010, Grocott et al., 2007b). Field studies prior to CXE that 
aimed to investigate hypoxic adaptation tended to use highly selected small groups of 
subjects (n = 12-36) (Cerretelli, 1976, Pugh et al., 1964, West et al., 1983, Johnson et al., 
2005). Studies using larger cohorts of volunteers failed to standardise hypoxic exposure and 
the ascent profiles varied between subjects (Pollard et al., 1996, Pollard et al., 1997, Woods 
et al., 2002). Discrepancies between duration and degree of hypoxic exposure that exist in 
previous studies undoubtedly contribute to the current controversies that exist in the 
literature with regards to metabolic adaptations (Horscroft et al., 2014). CXE was thus the 
first high altitude field study to use a large subject group with strictly controlled ascent profiles 
(Levett et al., 2010, Grocott et al., 2007b).  
 The aspect of CXE described in this chapter is the analysis of metabolomic and 
lipidomic profiles of subjects. These ‘omics’ techniques measure a large number of variables 
of interest within the metabolic, and lipid, systems. They form a fundamental part of the 
system-level understanding of the body and are highly informative techniques for assessing 
responses to a perturbation, such as hypoxic exposure.  Indeed, systems biology and the 
study of humans in extreme environments are argued to be natural symbionts (Edwards et 
al., 2013). Combining these approaches may help to explain the discrepancies and 
paradoxes that have evolved in high altitude physiology studies (e.g. the Lactate paradox, 
in which an apparent blunting of glycolysis occurs upon chronic adaptation to high altitude) 
(Murray, 2009).   
2.2 Aims and objectives 
The aim of this chapter was to examine the effects of acute, progressive hypoxic 
exposure on human metabolism. This was achieved using metabolomic and lipidomic 
analysis of plasma obtained from healthy humans. The objectives of analysis were to answer 
the following questions:  
 What is the normal, healthy human metabolic response to progressive hypoxia?  
 How do individuals vary in their response? 
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This study is the first to investigate metabolic profile changes in a large study cohort 
undertaking a strictly controlled ascent to 5300m. An untargeted approach was employed 
for analysis, meaning no a priori hypothesis was considered. Instead, it presents as a 
hypothesis generating study.  
Given the complexity of the metabolomic and lipidomic techniques, a detailed 
background precedes the study methods section.  
2.3 Metabolomics and Lipidomics Overview 
A large body of work in this thesis assesses potential metabolite changes in response 
to a perturbation, being hypoxia or dietary nitrate supplementation, by use of ‘omics’ 
techniques. This includes metabolomics and lipidomics. A detailed explanation of analytical 
tools and data handling and analysis strategies are discussed below.  
2.3.1 Analytical tools  
 The human metabolome is estimated to comprise many tens of thousands of 
individual metabolites. This includes both those confirmed and predicted, endogenous and 
xenobiotic (Psychogios et al., 2011, Wishart et al., 2012, Thiele et al., 2013). The human 
metabolome database (available at www.hmdb.ca) for instance, contains 41,992 metabolite 
entries.  An example of a similar publicly free database but that is specific for lipids, LIPID 
BANK (http://lipidbank.jp), contains spectral information on 7009 naturally occurring lipid 
structures.  
As already indicated, metabolites have both a highly diverse atomic arrangement 
and an enourmous variation of chemical properties. They range from hydrophilic, polar 
metabolites with a low molecular weight (e.g. amino acids) to hydrophobic, non-polar higher 
molecular weight metabolites (e.g. lipids) (Dunn et al., 2011b). This sets metabolome 
analysis apart from that of the transcriptome or proteome as information within DNA, RNA 
or peptides is encoded in patterns constructed from uniform constituent chemical subunits 
(i.e. polymerised nucleic acids and amino acids). Furthermore, the range of metabolite 
concentrations varies from mmol/L to pmol/L or less. Few good methods exist for 
amplification of metabolite levels as there exists for genomics and transcriptomics in the 
various forms of the polymerase chain reaction. 
The extreme diversity amongst metabolite species makes unbiased detection 
exceptionally challenging. Indeed, detection and quantification of all metabolites in human 
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samples cannot currently be achieved using a singular analytical technique. However, the 
combination of nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry 
(MS) are popular and increasingly used analytical approaches (Psychogios et al., 2011). 
The resulting signals are identified using data libraries, such as the human metabolome 
database (Wishart et al., 2007), or experimentally using analytical chemistry techniques for 
structure elucidation and with metabolite standards where available.  
In this thesis, the method used for metabolomic analysis of human plasma or serum 
was proton (1H)-NMR. In the present chapter, this was used alongside MS, which was 
employed for lipidomic assessment of the non-aqueous phase of plasma extract. The use 
of these spectrometric techniques in this instance was combined with Bayesian statistical 
modelling to confer a highly informative multidisciplinary approach.   
Nuclear magnetic resonance (NMR) spectroscopy 
NMR experiments are typically performed on samples in the liquid state. This 
includes biofluids, such as plasma or serum, as were used in the experiments in this thesis. 
NMR utilises the properties of atomic nuclei with a non-zero spin quantum number. This is 
a quantum property of the nucleus related to angular momentum and charge, and is often 
symbolized as a spinning magnetic field. Examples include 1H, 13C or 31P. These nuclei 
possess a spin angular momentum quantum number ½ and can exist in two energy levels 
– often referred to as spin up or spin down. In the NMR experiments described in this thesis, 
1H-NMR was used.  
In a large population of identical nuclei at equilibrium, the spin and related magnetic 
moments of individual nuclei have equal energy (i.e. they are degenerate), and both are 
randomly arranged. In an NMR experiment, nuclei are exposed to a powerful magnetic field 
which creates a population difference between the spin up and down nuclei as there is a 
slight excess of the lower energy state (this is often the spin down state). The energy 
difference is relatively small, comparable to the thermal energy in the system. Irradiation 
with a pulse radiofrequency wave of the right frequency will convert spins of the lower energy 
state to the higher one until the population difference is cancelled out. The irradiating 
radiofrequency waves are then turned off, allowing the nuclei to relax back to their 
equilibrium potential over a period of time by emitting a characteristic radiofrequency signal. 
This is called a free induction decay, and if the signal is transferred from time to frequency 
using a mathematical approach called a Fourier Transform then a spectrum arises. The area 
of the resonance is directly proportional to the concentration of nuclei that generate it, 
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making NMR innately quantitative.  The chemical environment each nucleus is found within 
modulates the frequency, meaning that output extends beyond the mere ability to separate 
nuclei of different atoms. The spectrum produced by a metabolite will encode precise 
information about the structure, making it a powerful analytical approach. Another important 
advantage is that the sample itself has only to be exposed to a magnetic field and 
radiofrequency pulse, making NMR completely non-destructive enabling re-use of samples 
and avoiding the instrument being impaired by the accumulation of unwanted analyte 
(Rattle, 1995).  
As mentioned, the properties of the chemical environment surrounding the nuclei 
cause a shift in the resulting resonances. This is mediated by a number of factors, including 
the shielding effects of the electron cloud surrounding the nucleus that alters the local field 
at the nucleus. The 1H nuclear resonances will reflect the chemical group to which that 
particular nucleus belongs. Variation in this NMR frequency, or ‘chemical shift’, is small 
(most 1H frequencies only vary within a range of 10 parts per million), but can be measured 
with great accuracy enabling a detailed identification of compounds  (Bothwell et al., 2011, 
Rattle, 1995).    
Chemical shift (δ) is also affected by the properties of surrounding nuclei. The 
energies of nuclei positioned close together interact, a phenomenon denoted spin-spin 
coupling, which causes the δ to be split into sub-peaks. Distinct molecules have a 
characteristic number and pattern of peaks and sub-peaks (Bothwell et al., 2011).  
Analysis of NMR spectra gives precise information regarding chemical structure and 
abundance of the molecules of which the nuclei form a part, thus enabling metabolite 
identification (Rattle, 1995, Bothwell et al., 2011). The quantitative nature, high 
reproducibility and relatively simple sample preparation make NMR a highly desirable 
technique. It is also non-selective, as the sensitivity is independent of the hydrophobicity or 
acidity of the compounds being analysed (Dunn et al., 2011b). One large downside to the 
approach is its relatively poor sensitivity, which arises because the nuclear transitions that 
are measured in the NMR experiment are very close to the thermal energy of the system, 
meaning population differences between the low and high energy states are very small 
(Dunn et al., 2011b). Only those metabolites in high abundance (100nmol/l to 1µlmol/l or 
higher) can be detected, with usually less than 100 metabolites detectable per sample in a 
typical liquid-state metabolomics experiment (Dunn et al., 2005, Bothwell et al., 2011). 
Further, 1D spectroscopy (typically used for metabolomics experiments and the method 
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adopted in this thesis) results in spectral crowding whereby alterations in low abundance 
metabolites may be obscured by those species in higher abundance and with similar 
chemical shifts, which in turn limits biomarker discovery. An additional limitation is the lack 
of sensitivity towards compounds that form part of plasma lipoprotein complexes and 
aggregates. This includes resonances from abundant plasma lipids such as cholesterol, 
cholesterol esters and phosphatidylcholine. These present in relatively immobile micellular 
structures with partially constrained molecular motions (Nicholson et al., 1983, Nicholson et 
al., 1989). In the present chapter, the 1H-NMR analysis was reserved for the aqueous phase 
of plasma. 
NMR experiments are typically performed on samples in the liquid state. This 
includes biofluids, such as plasma or serum, as was used in the experiments in this thesis. 
Sample preparation is relatively minimal and requires addition of a small amount of 
deuterated solvent (e.g. deuterium oxide (D2O)) to provide a frequency lock signal required 
to control for magnetic field drift. A δ  reference compound may also be added (Dunn et al., 
2011a). For the 1H-NMR experiments presented in this thesis, a Carr-Purcell-Meiboom-Gill 
(CPMG) pulse sequence was applied in each experiment. Essentially, this approach 
enhances the sharp features in the spectrum by suppressing the broad features (Nicholson 
et al., 1989). In doing so, it enables better visualisation of low molecular weight metabolites. 
The extracted lipid fraction of plasma was assessed using MS.  
Mass spectrometry (MS) 
The other major technique currently applied for metabolite detection, which is used 
in the lipidomics section of the Everest project described here, is MS. This operates by the 
formation of positively or negatively charged species (ions) from analytes of interest (in this 
case metabolites). Ions, including molecular, fragment and adducts, are then separated 
according to their mass-to-charge ratio (m/z). Separation and detection are performed under 
high vacuum pressures to reduce the number of ion-ion or ion-molecule collisions, which 
can influence mass resolution, accuracy and instrument sensitivity. In metabolomics or 
lipidomics experiments, the vast majority of ions carry a single charge (i.e. z = 1), meaning 
that m/z usually = m.   
Structural similarities within lipid classes (e.g. the eight broad classes outlined in the 
LIPID MAPS classification system (www.lipidmaps.org) (Fahy et al., 2009)) allow the 
measurement and (at least partial) classification of a large number of lipid species in a single 
MS run. However, the increased structural complexity and size of many lipids, including 
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differing isomers and fatty acid constituents, makes completely unambiguous identification 
particularly challenging and presents the most significant current analytical and experimental 
obstacle for investigators (Wishart, 2011). Positive identification of a metabolite requires 
several parameters including accurate mass, fragmentation pattern, isotope abundance 
pattern and retention time, to match with that of a purified metabolite under identical 
conditions. This definitive identification is not plausible for large numbers of metabolites. It 
is therefore broadly accepted for metabolites to be ‘putatively annotated’, a term defined by 
the Metabolomics Standards Initiative (Sumner et al., 2007). This method of identification 
uses a single measured parameter, such as accurate mass, and matches this to a metabolite 
present in a library or database. Although less time-consuming than definitive identification, 
the confidence in correct identification is lower (Dunn et al., 2011a), hence ‘key’ compounds 
still need to be annotated more rigorously. Indeed, some claim that unless metabolites are 
identified by two orthogonal techniques the assignment should still be labelled as tentative 
(Sumner et al., 2007).  An option is use of targeted or semi-targeted experiments, the latter 
being used in the present chapter of this thesis as discussed below, which involved the 
addition of internal standards to the sample.  
MS based metabolomics has been successfully applied as a biomarker tool in both 
epidemiology and stratified medicine (Sreekumar et al., 2009, Nicholson et al., 2008). By 
their very nature, these studies are large scale designs, thus requiring multiple MS batch 
runs. This, in turn, substantially increases experimental variation arising from the MS 
measurements. Of high interest in the metabolomics field, therefore, is the development of 
highly reproducible and robust MS measurements. Strength of experimental design is thus 
imperative to achieving such results. Good practice has been shown to involve the use of 
three sample types: biological, pooled quality controls (QC’s) and blanks (Kirwan et al., 
2014).  
MS can be performed with or without a precedent chromatography separation step, 
and with it exist multiple advantages and disadvantages. The dominant MS platform for 
some years was gas-chromatography-MS, however technological improvements led to 
widespread adoption of liquid chromatography-MS as the tool of choice. This includes those 
technologies with enhanced sensitivity and separation resolution such as ultra-performance 
liquid chromatography (Dunn et al., 2011b). Chromatographic separation of molecular 
species within a sample prior to infusion into the MS simplifies the resultant spectra and 
improves the ionisation of individual analytes.   
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The application of a prior chromatography step is, however, vastly time consuming 
in comparison to direct infusion MS (DIMS) techniques, which enable rapid, high throughput 
analysis. In comparison to LC-MS, whereby metabolites are broken up into fragments, the 
metabolites detected in DIMS are whole. Whilst DIMS has been demonstrated to present 
comparable classification and prediction capabilities to LC-MS (Lin et al., 2010), it benefits 
from rapid analysis time consuming ~5% of the time required for analysis of LC-MS data 
(Lin et al., 2010). DIMS also demonstrates high technical reproducibility and requires 
minimal sample biomass (Kirwan et al., 2014). However, the absence of chromatography 
does come with some disadvantages, including ion suppression and co-elution of 
metabolites into the MS. In addition, the spectra produced from DIMS are more complex, 
yielding only m/z alongside intensity values. This means that without the addition of internal 
standards, identification of metabolites is limited to putative annotations at best (Sumner et 
al., 2007) .  
The advantages outlined for the DIMS method make this the optimal choice for 
analysis of the lipidomics data presented in the current chapter. Here, a high resolution DIMS 
approach was adopted (DIHRMS). Given the sample number, multiple batches were run, 
with each batch containing the biological sample, quality control, blanks and internal 
standards. This thus ensured reproducibility between sample runs and enabled accurate 
metabolite identification.   
2.3.2 Experimental design 
 Targeted or non-targeted? 
Design of metabolomics experiments can either take a targeted or non-targeted 
approach. Both have their advantages and disadvantages and can be highly effective and 
complementary when used in conjunction.  
 Untargeted metabolomics, or metabolic profiling, attempts to measure all the 
analytes in a sample, including chemical unknowns. In this approach, the study begins with 
limited biological knowledge. Whilst there may be a general hypothesis available (e.g. there 
is a metabolic difference between two conditions), there is no specific a priori hypothesis 
stating which metabolites are related to the (patho-) physiological change. It aims to produce 
data on an extensive range of metabolites present in multiple metabolite classes or 
pathways that are dispersed across the metabolic network. The metabolome coverage is 
therefore intended to be unbiased and as comprehensive as possible. This method is not 
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quantitative and metabolite identification is a challenge. In order to reduce the resulting data 
sets into more manageable entities, dimension-reduction techniques such as principal 
components analysis (PCA) or multidimensional scalings (a method for visualising the level 
of similarity of individual cases of a dataset) can be employed. The results of such 
experiments can be inductive or hypothesis-generating and can provide insight into novel 
changes occurring to the metabolome as a result of the perturbed state (Roberts et al., 2013, 
Dunn et al., 2011b). The examination of metabolic profiles in this manner has led to 
numerous advances in biological understanding, including the role of sarcosine in prostate 
cancer progression (Sreekumar et al., 2009).  
Targeted metabolomics involves the detection of a specific number of metabolites 
(typically in the order of tens to hundreds) that are related in function or class. This method 
is used in hypothesis testing or deduction studies whereby the metabolites (or at least, 
pathways) of interest are known (Dunn et al., 2011a).   
A major development effort is required to establish a successful targeted technique. 
Absolute quantitative metabolite concentrations are determined with high specificity and 
accuracy by using the addition of internal standards. These are typically isotopically-labelled 
versions of the endogenous metabolites, usually containing 13C or 2H isotopes (Dunn et al., 
2011b). As only those targeted metabolites are detected, this does mean that the number 
of discovery opportunities is reduced. However, one hybrid option is to use semi-
quantitative/targeted methods where a number of ‘class specific’ standards are spiked into 
samples. This relies on the assumption that similar classes of compounds give comparable 
signals. 
In Chapter 2 of this thesis, an untargeted profiling approach was adopted for the 
assessment of the aqueous phase of plasma using 1H-NMR. A semi-targeted approach, with 
the addition of deuterated standards, was used for the assessment of the plasma lipid 
fraction using DIHRMS. The untargeted profiling approach was also applied to serum 
analysis in Chapter 3 of this thesis. In Chapter 5 of this thesis, a small scale targeted 
approach was employed.   
2.3.3 Data processing  
A single NMR or MS spectrum represents a vast amount of data. This is both in terms 
of data points per sample (typically 32k or 64 k for NMR (Dunn et al., 2011a)) and also the 
number of samples, and so resulting spectra, acquired to obtain meaningful results. Several 
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pre-processing steps are therefore required to transform the raw spectroscopic data in such 
a way that subsequent analysis is easier, more robust and accurate. Various advancements 
in these procedures strive to prevent loss of data and to eliminate unwanted variation. Given 
the difference in the output from the NMR and MS techniques, the intermediary pre-
processing steps can differ for each method, as is the case for this thesis, although some 
overlap exists between the two.   
NMR data pre-processing 
 NMR spectra produced from analysis of a complex set of biofluids can be influenced 
by variances including the following: incorrect phasing, varying baselines, varying biofluid 
concentrations and shifting peak locations. Pre-processing steps are thus required to ensure 
these variances do not interfere with subsequent data analysis. In this thesis, a variety of 
pre-processing methods were employed within each study, depending upon the study 
design and the quality of the spectra produced.  For each study, specific detail on the pre-
processing steps are outlined in the respective methods sections, but an overview and 
background of these processes is outlined as follows.  
Accounting for the effects of shifting peaks  
A biofluid matrix is highly complex. Variances can exist in the relative concentrations of 
specific ions, salts and metabolites as well as the overall dilution of samples. These 
parameters can influence the chemical shifts of peaks, affecting different peaks by varying 
extents, even if they belong to the same metabolite (Dieterle et al., 2006).  Given that peak 
shifts are not desired for most applications, steps are usually taken to handle these 
variations.  
A simple approach for this is alignment of peaks to a reference compound. In chapter 2 
and 3, the compound 3-trimethylsilyl-1-propanesulfonic acid sodium salt (DSS) was added 
to the NMR buffer and was used to reference spectra (δ =0). Alternatively, the endogenous 
compound formate (δ = 8.44 ppm) can be used, as was the case in Chapter 5 (Kriat et al., 
1992). This can be performed manually, using either Topsin (Chapters 2 and 5) or ACD labs 
(Chapter 3). However, human error can become problematic with the manual approach in 
large data sets, as was the case for Chapter 2,  therefore further refinement was performed 
in Matlab using the icoshift program (Savorani et al., 2010). This algorithm enables fast 
alignment of all spectra simultaneously and at full resolution.    
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 It is at this stage that phasing can be corrected (using either Topsin or ACD labs) and 
the over dominating water peak removed (De Meyer et al., 2008).  
1. Normalisation 
The pre-processing method of normalisation scales spectra to the same overall virtual 
concentration. This method takes into account variances such as differences in sample 
dilution, the range of which will depend upon the water intake of the subject. Dilution will 
influence all metabolite concentrations, meaning intensities of all peaks within a spectrum 
will be altered by the same factor. In addition, metabolomic fluxes may only affect select 
metabolites and so select peaks of the corresponding spectrum. Such specific changes are 
usually of interest, therefore normalisation is adopted to compensate for differences in 
overall concentration whilst avoiding obscuring specific metabolite changes. The end goal 
is for effective normalisation between spectra to ensure large peaks do not dominate 
subsequent analysis.  
An approach that encompasses both changes in overall dilution and those of specific 
metabolites is probabilistic quotient (PQ) normalisation (Dieterle et al., 2006). This method 
assumes that changes in the concentration of single analytes only influence specific regions 
of the spectrum whereas changes in the overall concentration influence the spectrum in its 
entirety. It is an advancement upon the standard normalisation approach that uses integrals 
(De Meyer et al., 2010). This assumes integrals of a spectra are mainly a function of the 
overall sample concentration and so normalises the individual intensities of a specific 
spectrum by dividing them all by the summed intensity of that spectrum. Spectra are 
therefore scaled to the same total integral. PQ normalisation usually begins with spectra 
following integral normalisation and generates a reference spectrum from this, typically a 
median spectrum (De Meyer et al., 2010).  The distribution of the quotients, derived from 
amplitudes of the spectrum, are then normalised with those of the reference spectrum. This 
approach has been demonstrated to be far more robust than integral normalisation (Dieterle 
et al., 2006).  
2. Spectral binning 
Statistical analysis of the complex data set produced can be aided by data reduction. 
This requires a reduction in the number of variables and so spectral resolution through 
binning methods, which can be employed either before or after the normalisation step.  
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Standard or equidistant binning involves division of the spectra into equally sized bins, 
usually between 0.02-0.04ppm (De Meyer et al., 2010). These discrete regions are then 
integrated and a list of integral values is produced for each spectrum, essentially reducing 
the spectrum to a bar chart. This reduces the resolution of the data and can lead to a loss 
of information, as for instance smaller peaks within a bin can be obscured, whereas other 
bins may only contain noise. In addition, peaks at the edge of bins may be scattered over 
several bins, leading to the presence of artefacts, the distribution of which may change 
between spectra depending upon variations in peak locations (De Meyer et al., 2008). This 
has been addressed through the development of more advanced binning algorithms such 
as adaptive intelligent binning. This is a non-equidistant approach that focuses upon better 
peak definition. It recursively identifies the edges of existing bins and avoids the use of 
arbitrary parameters or reference spectra (De Meyer et al., 2008).  However, both methods 
remain in common usage, depending on the specifics of the data at hand. 
3. Scaling 
In principle, the integral values across an NMR spectrum are proportional to both the 
concentration and the number of resonances present. The variation in intensity within an 
NMR spectrum is therefore directly proportional to changes in concentration and proton 
density. However, in the absence of scaling, the largest resonances would in turn have the 
greatest influence upon subsequent data analysis, thus obscuring variations of interest in 
regions of low intensity. Whilst PQ normalisation addresses this issue between spectra, 
scaling is required to bring down the effects of the larger peaks within a spectrum. 
Appropriate scaling thus ensures the relative importance of each variable within the dataset 
is suitable.  
A standard method of scaling to the unit variance uses the reciprocal of the standard 
deviation as the scaling weight, and so does not address this problem as it results in all 
variables having equal potential to influence the model (Keun et al., 2003).  Instead, an 
effective method of ‘bringing down’ the larger peaks whilst ensuring they aren’t lost into the 
noise of the data set is Pareto Scaling. This is an intermediary between the extremes of no 
scaling and unit variance and uses the scaling weight of 1
√𝜎
⁄  , where 𝜎 = standard deviation 
(Keun et al., 2003).  
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4. Controlling for bias.  
Medium to large scale metabolomics experiments are constrained by the fact that it is 
not possible to run samples in one batch. This brings into light the issue of instrument 
reproducibility. In the case of NMR spectroscopy, this is not normally an issue as the sample 
does not physically interact with the operating parts of the instrument, so changes in the 
sensitivity from instrument contamination are normally not observed (Dunn et al., 2011b). 
Instead, this feature is usually reserved for LC-MS experiments.  
Despite this, a batch effect was observed in the NMR data set produced from Chapter 
2, as is discussed further in the results section of this chapter. Briefly, PCA clearly revealed 
separation of two groups that was entirely unrelated to experimental differences. In order to 
correct for this, a method was applied that has been shown previously to normalise the batch 
effects observed in LC-MS metabolomics data collection termed Eigen MS (Karpievitch et 
al., 2014, Karpievitch et al., 2012). This singular value decomposition based method applies 
the following steps, as described by Karpievitch and colleagues (Karpievitch et al., 2014):  
 ANOVA is used to capture and preserve the variation due to treatment effects 
of the study. This is done by using the R function lm(), which estimates the 
treatment effects. The residuals (loosely meaning an error in the result) 
function () also accesses a matrix of residuals.  
 Singular value decomposition is then applied to the matrix of residuals to find 
any systemic trends that can be attributable to bias.  
 The number of bias trends is subsequently determined by a permutation (or 
randomisation) test.  
 The effects of bias are then removed from the data. In the present study, a 
conservative approach to bias trend removal was adopted and only the most 
obvious bias trend removed.   
MS data pre-processing 
Controlling for Bias 
In the case of mass spectrometry, where the sample inevitably interacts directly with the 
instrument, changes in the measured analyte response over time are inevitable (Dunn et al., 




To assist controlling for this effect and to provide robust quality assurance for the 
chemical features detected, Quality Control (QC) samples can be periodically analysed 
throughout an analytical experiment. During the data pre-processing steps (see below), data 
conditioning algorithms can be applied using the QC sample responses as a bias to assess 
the quality of the data. This includes removal of peaks with poor repeatability, correction of 
any signal attenuation and integration of batch data  (Dunn et al., 2011b).  
For the MS experiments performed in Chapter 2 of this thesis, QC samples obtained 
from pooled samples were used alongside internal standard blank samples to correct for 
batch effects.  
Following signal correction and batch integration using QC’s, further quality assurance 
is required for each detected peak (Dunn et al., 2011b). For the MS experiments presented 
in Chapter 2, only peaks with deviations within + 5ppm of the target mass defined by the 
internal standard with an intensity threshold >1000 were retained. Lipid molecules with 
>10% missing values were removed.  
  
2.3.4 Statistical analysis 
The output of any -omics experiment is production of a vast data set. In the instance 
of metabolomics, levels of thousands of metabolites can be measured in hundreds of 
samples. Such high dimensionality in a data set makes it difficult to visualise samples and 
to undergo simple exploration.  
In addition, there are a number of technical features that can present challenges with 
data analysis. For instance, MS spectral data are known to be noisy and inherently contain 
various sources of uncertainty (Katajamaa et al., 2007). Whilst NMR is generally regarded 
as being highly quantitative and reproducible, there are a number of potential sources of 
experimental error akin to MS, including sample preparation, peak identification and 
summarisation (Katajamaa et al., 2007). A high level of noise in the data set can result in an 
excessive false discovery rate and can mask small, discrete metabolite changes  
(Broadhurst et al., 2006, Saccenti et al., 2014). Necessary precaution thus needs to be taken 
when considering analysis strategies.  
Along with these potential problems are features of metabolomics data sets that can 
aid with data analysis and interpretation. For instance, metabolomic data are known to be 
highly collinear, meaning multiple things tend to change together or along the same line 
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(Suvitaival et al., 2014a). This property arises from the concurrent involvement of 
compounds in biological processes and lends itself to multivariate statistical methods that 
are able to distinguish patterns within a data set. The differing statistical approaches to 
analysis of such data sets and the benefits and hindrances of these are discussed below.  
Univariate statistics 
Univariate analysis involves measurement of 1 variable at a time and includes, for 
instance, t tests.  In the context of metabolomics data sets, this would result in significance 
testing for tens of hundreds of metabolites.  The very nature of univariate testing is that the 
more tests that are performed (so the more metabolites tested) the higher the chance of 
claiming a difference that is actually false (type I error). In other words, a null hypothesis of 
there being no difference between groups that is actually true is rejected. It is common 
practice to allow a 5% or one in 20 chance that a type I error is made. The criteria for defining 
a significant difference between two population means is therefore set at 5%, which is a 
parameter referred to as α of 0.05.   
Correction is therefore required for multiple testing to prevent against the increasing 
probability of having false positives, or a type I error (Saccenti et al., 2014).   However, these 
corrections (such as Bonferroni tests) are highly conservative and can incur the risk of 
introducing false negatives, or type II errors, whereby the null hypothesis is actually false 
yet the test fails to reject it (Saccenti et al., 2014). It follows that the probability of making a 
type II error is known as β. The power of a test, being the probability that a significant 
difference is found, is 1-β. 
Alongside the number of tests, a p value is also affected by sample size. For a fixed 
α (so 0.05), the relationship between the number of samples measured and the difference 
in population means is critical. In turn, this means that the likelihood of distinguishing a 
significant difference is a function of sample size, so will increase with increasing sample 
number (Broadhurst et al., 2006).  In addition, the dependence of the p value upon only one 
hypothesis is that a huge effect observed in a small trial can result in the same p value as a 
minute and uninteresting effect in a large trial. This therefore presents as an inadequate 
measure of the strength of evidence (Broadhurst et al., 2006, Cornfield, 1966).  
Therefore, despite its common use, the p value does have significant limitations that 
in turn bring into question the degree of its usefulness. Caution must thus be taken when 
interpreting p values and particularly when employing such testing methods to a 
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metabolomics data set and should be restricted to examination of a few select metabolites, 
if at all.  
Multivariate statistics 
Adoption of multivariate methods enables for all variables to be used simultaneously, 
essentially acting as a pattern recognition process. Aside from the mean, such methods 
make use of co-variances or correlations that reflect the extent of the relationships among 
variables. This approach therefore contrasts to univariate methods that focus solely upon 
the mean and variance of a single variable (Saccenti et al., 2014). Using all variables 
together avoids loss of information and finds underlying trends in the data set. 
One such multivariate method that is used routinely as a first step in the analysis of 
metabolomics data is principal components analysis (PCA). In essence, this approach 
attempts to find a small set of variables that explain the pattern of the original data set 
(Nicholson et al., 2008). This is achieved by  reducing the dimensionality of the data and 
modelling underlying trends, or ‘latent variables’, whilst retaining most of the variation within 
the data set (Ringnér, 2008).  This is accomplished by identifying directions, termed principal 
components, along which the variation in the data set is maximal.   
A principal component (PC) is thus a weighted linear combination of each of the 
original variables. The original data matrix becomes compressed into a smaller number of 
latent variables, typically three to four PCs. Within these few components, each sample is 
represented by relatively few numbers instead of values for thousands of variables. The 
weight given to each variable within a PC describes how influential that variable is in relation 
to others. The first PC is the direction along which samples show the largest variation. The 
projection of each sample onto this first PC reduces the dimensionality from a two-
dimensional to a singular dimension data set. Information that is not captured in the first PC 
forms the residuals through which the second PC is calculated. This second component is 
thus the direction uncorrelated to the first component along which the samples show the 
largest variation. The lack of correlation between PCs means they may represent different 
aspects of the dataset.    
The output of PCA is a plot of samples. This makes it possible to visualise the data 
set and assess similarities and differences between samples. It may result in grouping of 
the samples, separating possible regularities or trends in the data set from noise, and also 
enables determination of outliers.   
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PCA is therefore designed to identify directions with the largest variation. As it is 
unsupervised, it does not separate classes of samples. It also does not capture repeated 
measures in a data set. In addition, it does not distinguish experimental artefacts that result 
from the high throughput technologies used in omics analysis, meaning dominant PCs may 
in fact correlate with these artefacts (Ringnér, 2008). This latter point was dealt with later in 
the present chapter, whereby the initial PCA plots of the NMR data revealed separation of 
samples based on experimental artefacts, which were subsequently corrected for using 
EigenMS. PCA results therefore critically depend upon the aforementioned data pre-
processing steps (Ringnér, 2008).  
Statistical Inference 
 Statistical inference is a process of drawing conclusions about populations or 
scientific truths from the underlying distribution of the data. These inferred properties include 
testing hypothesis and deriving estimates. The population is assumed to be sampled from 
a larger population, which sets it aside from the uni/multivariate descriptive statistics already 
described that are solely concerned with the properties of the observed data set.  
 Many models of inference exist and include broad theories such as Bayesian 
statistics.  
Bayesian statistics 
Obtaining data from an experiment, but not knowing either the mean (θ) or variance 
(σ2), requires for inferences to be made about the values of θ and σ2 based upon the data 
observations (y). In a Bayesian approach, a prior distribution (p) is introduced into the model. 
This either expresses a state of knowledge or ignorance about θ or σ2 before the data were 
obtained. From here, it becomes possible to calculate the probability distribution of θ and 
σ2, given the data y, using the following equation: 𝑝(𝑦ǀ θ, σ2) (Box et al., 2011). Inferences 
can be made about the parameters derived from this distribution. This concept is the basis 




𝒑(𝜽ǀ𝒚) =cp (y ǀ 𝜽) 𝒑(𝜽) 
Equation 2.1. The basis of Bayes theorem 
Where: 
p(θ) = what is known about θ without knowledge of the data, aka the prior distribution 
of θ. 
𝑝(𝜃ǀ𝑦) = what is known about θ given the knowledge of the data, aka the posterior 
distribution. This can also be called the likelihood function and may be regarded as 
a function of y but not of θ. It contains all relevant information about the sample and 
is the function through which the data y modifies prior knowledge of θ.  
c = normalising constant to ensure the 𝑝(𝜃ǀ𝑦) integrates or sums to one.  
  
This theorem tells us that the posterior distribution is proportional to the product of 
prior distribution multiplied by the likelihood for θ given y (Box et al., 2011). In other words, 
Bayes theorem describes the probability of an event based upon prior knowledge of 
conditions that may be related to that event. Through the use of Bayes theorem, subjective 
degrees of belief obey the rules of probability. It allows sufficient flexibility to react to the 
complexity of biological systems that is free from technical limitation. As this system of 
inference can be readily applied to any probability model, it allows for greater emphasis to 
be placed upon scientific interest and less to mathematical convenience (Box et al., 2011).  
Importantly, the Bayesian approach focuses upon distributions as opposed to single 
numbers.  
The general framework of Bayesian statistics thus codifies how to proceed in a 
rational way with analysis and inference of data taken from high dimensional biological 
systems where only a minute subset of relevant variables are measured (Baldi et al., 2001).  
A complete Bayesian treatment is highly computationally demanding, therefore shortcuts 
can be developed that strike a balance between rigor and computational efficiency (Baldi et 
al., 2001).  
The use of Bayesian statistics for analysis of multi-dimensional data sets is not a 
new concept and indeed has been employed previously to -omics data to great effect. This 
includes the use of Bayesian integration to define functionally related genes and metabolites 
identified using transcriptomics and metabolomics respectively (Bradley et al., 2009). Here, 
the transcript-metabolite correlations were evaluated in light of the experimental context in 
which they occurred, as well as the class of metabolite involved. In this way, Bayesian 
integration was able to effectively predict known enzymatic and genetic regulatory 
94 
 
relationships, including those central to the glycolytic-gluconeogenic switch (Bradley et al., 
2009).  
 Bayesian approaches have proven particularly useful in the assessment of 
metabolomics data obtained from MS analysis. For instance, application of  a Bayesian 
alignment model to LC-MS data was demonstrated to integrate relevant information required 
to significantly improve the performance of the retention time alignment (Tsai et al., 2013). 
Bayesian approaches have also been adopted in the integration of spectral peaks in MS 
analysis originating from the same compound (Suvitaival et al., 2014a, Suvitaival et al., 
2014b).  
Posterior/Non-informative prior 
As already stated, the formulation of models from Bayesian statistics requires prior 
distributions (or knowledge) for any known parameters. This prior distribution is supposed 
to represent what is known and unknown about the parameters before the data is available. 
Such a distribution thus represents either the degree of prior knowledge or relative ignorance 
(Box et al., 2011).  This concept has faced controversy, with some viewing the use of prior 
knowledge in the analysis as interfering with the process of scientific inference by bringing 
a degree of prejudice. In other words, it is usually preferred to let the data ‘speak for 
themselves’ rather than distorting ‘what the data are trying to say’. However, this is can be 
dealt with through a combination of careful model choice and the use of appropriate ‘non-
informative’ prior distributions, which aim to obtain inference that is appropriate for an 
unprejudiced observer (Box et al., 2011). Essentially, this means that the prior is developed 
as the model progresses, ending with the construction of a posterior prior, or distribution. 
This approach was adopted in the analysis presented in the present chapter and it results 
in the construction of a fluid and sophisticated model.  
Hierarchical modelling 
In the experiment described in Chapter 2, the data are naturally hierarchical: there 
are multiple measurements of each metabolite in each subject, while we seek the trends in 
these metabolites across the entire study population. For this reason, we adopted a 
hierarchical approach to statistical modelling. This was achieved by fitting linear models to 
each binned 1H-NMR region or lipid variable at the subject level and further fitting 
distributions to the parameters from these models. By adopting a Bayesian hierarchical 
method, we were able to build fully connected hierarchical models where the distributions of 
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the parameters (at the ‘highest’ level of the model) constrained the values of the parameters 
for an individual subject, a phenomenon known as ‘shrinkage’ (Kruschke et al., 2015, 
Kruschke, 2010). In other words, this allowed layers of the hierarchical model to 
communicate, in doing so ensuring the observations are treated in context of the data set 
as a whole as opposed to in isolation.  
However, as alluded to above, Bayesian statistics are computationally expensive. 
Simple frequentist hierarchical models were therefore fitted initially to select variables of 
interest for further modelling. Mean slopes residing around 0 indicate little change with 
altitude, and so were considered uninteresting and were discarded. Selected were those 
mean slopes that were > ±1.96 SDs from the mean. Finally, Bayesian inference is somewhat 
different to frequentist approaches (e.g. there are no p-values). Hence we adopted the 
criterion that metabolites should not include 0 in the high-density (95%) interval of the 
posterior distribution of z-transformed slopes. Together, this means that two levels of filtering 
were employed to ensure that only those slopes undergoing large degrees of change were 
considered.  
2.3.5 Reporting of methods 
 Effective communication of methodology, analytical approaches and methods of 
identification is key to avoiding misinterpretation of results in metabolomics studies. 
Attempts have been made to build a general consensus upon reporting strategies (Sumner 
et al., 2007). This is recognised to be an ongoing process within a field that is continuously 
developing and the need to reassess reporting standards for metabolite identification has 
been recognised (Creek et al., 2014, Salek et al., 2013). However, the guidelines for 
chemical analysis and metadata remain highly applicable and are an essential means of 
determining whether the distribution of claimed biomarkers in fact results from confounding 
factors (Sumner et al., 2007, Broadhurst et al., 2006). This includes detail regarding the 
experimental design, subjects, treatment, collection, sampled preparation and NMR/MS 
spectral acquisition. The methodology reported in this thesis therefore encompasses each 
of these factors.    
2.4  Study Methods  
The study design, risk management plan and individual protocols for Caudwell 
Xtreme Everest (CXE) were approved by the University College London (UCL) Research 
Ethics Committee (in accordance with the declaration of Helsinki). The study was designed 
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and conducted by the UCL Centre for Altitude Space and Environment Medicine (CASE).  
Both verbal and written informed consent was obtained from all subjects.  
2.4.1 Study Participants 
Subjects were members of the public and were recruited by word of mouth and via 
public advertising. Subjects, males and females aged over 18 with no upper age limit, were 
required to pass two separate health screening stages (Levett et al., 2010). Exclusion criteria 
were as follows:  
 Diabetes mellitus: defined as the need to control blood glucose levels through diet, 
oral hypoglycaemics or insulin therapy 
 Significant respiratory disease: defined as a disease that could deteriorate at altitude, 
rendering the subject at risk during the trek to EBC. For instance, severe chronic 
obstructive airways was an exclusion criteria whereas mild asthma was not.    
 Significant cardiovascular disease: defined as disease that could deteriorate at 
altitude, rendering the subject at risk during the trek. For instance, ischemic heart 
disease with angina and symptomatic heart failure were excluded whereas controlled 
hypertension was not.    
 Females were required to not be pregnant.  
From this screening process, 198 healthy volunteers were selected to participate in the 
study.  
2.4.2 Study design 
Ascent profiles and logistical details have been reported previously (Levett et al., 
2010). Baseline measurements were performed in London (LDN) in a laboratory at UCL (75 
meters above sea level) between January 4th and February 26th 2007. Field studies were 
performed between 31st March and 6th June 2007 at laboratories set up at the following 
locations (altitudes expressed as meters, m): Kathmandu (KTM, 1,300m), Namche (NAM, 
3,500m), Pheriche (PHE, 4,250m) and Everest Base Camp (EBC, 5,300m). Data collection, 
including plasma sample collection, was performed at each of these time points.  
Trekkers were split into 13 smaller groups (16 subjects max in each) and two groups 
left the UK each week for the duration of the expedition. The ascent rate was chosen in order 
to minimise the incidence of high altitude illness during the trek and so maximise the number 
of participants able to participate in laboratory tests at EBC (Hackett et al., 1976). All subjects 
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underwent an identical ascent profile, arriving at EBC on day 11 (Figure 2.1). To maintain 
an identical pattern of hypoxic exposure, subjects were restricted to ascending no higher 
than 300 vertical meters above the laboratory altitude on rest days. Details on PB, PiO2 and 
















































LDN 75 24.1 (1) 754 (10) 148.0 100.5 19.7 
KTM 1300 26.1 (1.5) 650 (3) 126.2 86.7 16.8 
NAM 3500 19.6 (2.6) 505 (3) 95.4 67.3 12.8 
PHE 4250 13.1 (1.7) 461 (2) 86.7 61.5 11.6 
EBC 5300 21.5 (5.6) 404 (3) 74.7 53.8 9.9 
Notes: Altitudes derived from map values to the nearest 50m; Barometric pressure (PB) and 
temperatures are mean (SD) values recorded in the field laboratory during testing. PiO2 = 
inspired partial pressure of O2, derived from PB (Levett et al., 2010).  
Figure 2.1. A depiction of the ascent and descent profiles of trekker subjects 
participating in the Caudwell Xtreme Everest study. 
Abbreviations are as follows: LDN = London, KTM = Kathmandu, NAM = Namche, PHE = 




2.4.3 Plasma sample Analysis 
Blood sampling 
 All blood samples were taken in a rested, fasting state from the antecubital vein and 
collected in 10ml BD ethylenediamine-tetra-acetic acid (EDTA) blood tubes (Southern 
Syringe Services LTD). Plasma was separated from blood cells by centrifugation of whole 
blood at 800G for 15 mins and immediately frozen in 1 ml aliquots in liquid nitrogen. Samples 
remained in liquid nitrogen for the duration of the expedition (including carriage back to 
Kathmandu) and were transported back to the UK on dry ice, where they were stored at -
80°C in a commercial cryostorage facility until transport to King’s College London on dry ice. 
Here, they were maintained at -80°C until analysis.   
Plasma preparation 
 Plasma samples were defrosted at room temperature. A chloroform: methanol 
extraction was used to separate the plasma sample into aqueous and lipid fractions. A 1:1:1 
extraction was performed (Beckonert et al., 2007), with 500µl of methanol (Hypergrade for 
LC-MS, Merck) and 500µl of chloroform (HiPerSolv Chromanorm for HPLC, VWR 
international), both ice cold, being added to 500µl of plasma in a 1.5ml Eppendorf. This was 
vortexed for 2 mins and then left in the freezer (-20°C) to stand for 30 mins. They were 
subsequently centrifuged for 3 mins at 9100G (Force 1624 Microcentrifuge) to separate the 
sample into the upper (methanol, and so aqueous, fraction) and lower phases (chloroform, 
and so lipid, fraction), as depicted in Figure 2.2. 700µl of the upper phase was pipetted into 
an Eppendorf ready for further preparation before NMR analysis. ~200µl of the lower phase 
was pipetted off into an Eppendorf and frozen at -80°C ready for mass spectrometry 
analysis. Key stages of sample preparation and data processing are presented in Figure 




 Figure 2.2. Outline of the preparation and analysis of plasma sample fractions, 
separated by methanol: chloroform extraction. 
This includes the preparation of the upper aqueous fraction for 1H-Nuclear Magnetic 
Resonance (NMR) spectroscopy and the lower lipid fraction for direct infusion high 
resolution mass spectrometry (DIHR), where samples were infused in the Exactive Orbitrap 
using a Triversa Nanomate. Data processing steps followed, after which hierarchical 

















Data alignment and ‘clean up’: 
E.g. Pareto Scaling  
Data visualisation: 
PCA  






Peak picking and 






Upper phase/methanol fraction preparation 
The upper fraction was dried down at 30°C for 4 hours using a vacuum centrifuge 
(Eppendorf Concentrator 5301) and then re-suspended in 600µl of the following solution: 
double distilled H2O containing 5% D2O for NMR (Acros organics, CAS: 7789-20-0) and 1 
mM DSS (Aldrich, 178837-5G). D2O was required for the magnetic lock and DSS was used 
as a reference compound. The resulting solution was transferred to 5mm NMR tubes within 
a 96 tube rack.  
1H-NMR spectral acquisition 
1H-NMR spectra of plasma samples were obtained using a Bruker Avance III 700 
MHz spectrometer (Bruker Biospin, Karlsruhe, Germany) at the operating 1H frequency 
700.2 MHz with a temperature of 298K. A Carr-Purcell-Meiboom-Gill (CPMG) pulse 
sequence (Bruker experiment: cpmgpr1d) was applied to better visualise low molecular 
weight metabolites. A spin relaxation delay of 76msec was used and a total of 32 scans 
acquired. An exponential window function was applied with a line broadening of 0.3Hz prior 
to Fourier transformation.  
All samples were analysed on a subject by subject basis, meaning plasma taken 
from the same subject at all 5 time points was defrosted and treated at the same time and 
run within the same NMR experiment. This was to ensure any daily differences in 
experimental procedure were removed from analysis when data between time points were 




Data processing  
Resulting spectra processed using Topsin (Bruker). Spectra were converted from 
time to frequency domain using serial processing. The phase was adjusted so all peaks 
within the spectra were positive. Spectra were aligned so that the DSS peak was at 0. This 
was initially performed manually, yet some spectra remained improperly aligned, therefore 
further refinement was performed in Matlab using the icoshift program (Savorani et al., 
2010).  
The spectra were then split into two regions using Matlab. The aromatic region (δ 6-
10ppm; including resonances from polyphenols, compounds with single aromatic rings and 
carboxylic acids e.g. formic acid) was found to be particularly noisy, therefore was excluded 
from analysis. The second region, the aliphatic region, was taken forward for analysis 
following removal of the water peak. This region was normalised via PQ normalisation using 
R software. At this stage, spectra were not binned so remained at a full resolution.  To ensure 
subsequent analysis was not dominated by the larger peaks, Pareto scaling was employed. 
An average spectra resulting from these normalisation steps is presented in Figure 2.3.  
In order to visualise the spread of the data, PCA was performed on this spectral 
region. Plotted below is PC1 vs. PC2 (Figure 2.4). This plot revealed a clear separation of 
the data from region 1 into two distinct groups captured by PC1. As this data was coloured 
based on location, the spread into two groups is not due to variation dependent on the 
experiment i.e. a change with location (so altitude). Instead, it was likely due to sample 
processing differences, such as slight alterations in gain between NMR batch runs.  
Further investigations were thus carried out to determine what factor was causing 
the change and this was subsequently excluded. The method employed for this was 
EigenMS (Karpievitch et al., 2014).  Three bias trends were found to capture most of the 
variance in the data, the first of which was easily identified visually as it captured 77% of the 
variance (Figure 2.5). This essentially corresponds to the variance captured by PC1. This 







Coloured based on altitude location, demonstrating the separation of groups based on a 
methodological artefact as oppose to experimental intervention. A clear batch effect is 
captured by PC1.  
Figure 2.3. Aliphatic spectral region, overlaid. 
An average of all spectra at all time points following alignment, PQ normalisation and 
scaling.  
 
Figure 2.4. Principal component (PC) analysis scores plot 





































Figure 2.5. Identification of bias trend and correction using Eigen MS.  
Bias trend 1 was found to capture 77% of the variance within the data (left panel), which was 
normalised using Eigen MS (right panel). Each dot is representative of a spectrum, plotted 
in time order. Units are arbitrary and correspond to the variance captured by the trend.  
Figure 2.6. PCA scores plot following Eigen MS processing. 
Coloured according to altitude location.  
 














The above plot (Figure 2.6) depicts the data set colour coded based on altitude 
location.  At this stage, both Dr Edwards and I remained blinded to which altitude was 
represented by each colour to ensure no preconceptions or bias were introduced to the 
subsequent analyses. Although discrete, a separation can be observed between groups in 
this figure. As this data set was treated using EigenMS, we can be confident that this 
separation is not due to technical processing differences, but due to the differences in 
experimental intervention, being altitude.  
Spectral binning 
 Following EigenMS, the full resolution spectra were binned at a ratio of 10:1, 
meaning each bin consisted of 10 data points. This ratio was found to sufficiently reduce the 
size of the data set, whilst retaining maximal information.  
Influence of EDTA and DSS on 1H-NMR spectra 
 As mentioned, the tubes used to collect blood contained the anticoagulant EDTA. 
Both free EDTA and that which complexes with endogenous compounds including Ca2+, 
magnesium (Mg) and Zinc (Zn), are known to produce sharp 1H-NMR resonances that can 
mask metabolite peaks of interest and so can severely inhibit recovery of information from 
the resulting spectra (Barton et al., 2010). Whilst it is clear that a number of metabolites give 
rise to peaks obscured by EDTA, these also have other resonances that allow their 
identification and quantification meaning relevant biochemical information can still be 
recovered (Barton et al., 2010).  
 Another potential interference with the resulting spectra are resonances derived from 
DSS. The methyl peak from DSS gives rise to the reference peak at δ 0 ppm. In addition, 
peaks arise from methylenes 1,2, and 3 at 2.91, 1.76 and 0.63 ppm, respectively  (Gottlieb 
et al., 1997).  
 The presence of EDTA and DSS derived spectral peaks were apparent upon the 
resulting spectra and also appeared in subsequent analysis steps. However, given that 
metabolites within these regions present additional peaks, this was not seen as a major 




Lower phase/lipid fraction 
 The lower chloroform/lipid fraction was examined using DIHRMS. In preparation for 
this, samples were randomised and QC’s prepared to run alongside samples. Where 
possible, samples were kept on dry ice and were transferred to the -80°C freezer in periods 
between protocol stages. All solvents were of LC-MS or HPLC grade (Sigma Aldrich, 
Gillingham, UK).  
Randomisation 
Randomisation was required to prevent against possible ‘batch effects’ occurring 
between multiple DIHRMS runs. Sample randomisation was generated using MATLAB and 
was based upon subject BMI and sex as well as the altitude/location of the sample collection. 
Quality Controls (QC’s) 
These were required across a range of dilutions to define the linear range of the 
instrument, ensuring lipid species detected within the very low range could be excluded. 
QC’s were prepared by pooling 20µl of each CXE sample and diluting to a range of 
concentrations with the addition of chloroform as follows: 
 QC 100: 1ml pooled sample 
 QC 50: 500µl pooled sample, 500µl chloroform 
 QC 25: 250µL pooled, 750µl chloroform  
In addition, QC samples were obtained from pooled human plasma samples used as a 
standard QC for MS experiments in the laboratory of Prof Griffin. These were diluted using 
the same ratios as above, but using PBS as opposed to chloroform.  
Both sets of QC’s were run with each plate alongside PBS and chloroform, which thus 
acted as blanks. Together, QC’s and blanks were utilised to correct for batch effects in the 
data processing stages outlined below.  
Plate loading  
30µl of CXE sample, QC’s and  blanks were loaded onto a glass coated 96 well plate, 
with the loading of CXE samples following the randomised order defined previously.  To the 
96 well plate, 150µl of internal standard (IS) mix and 750µl methyl tert-butyl ether (MTBE) 
were added, with MTBE ensuring full extraction of lipids.  The IS mix contained the following 




sphingosylphosporylcholine, undecanoic acid, and trilaurin. The internal standards were 
used to correct for variations in m/z across the dataset acquired. 
The first chloroform ‘blank’ sample for each plate was retained as such through the 
addition of 150µl chloroform instead of IS mix. The plate was subsequently shaken for 30s. 
Using a VIAFLO 96/384 electronic pipette (Integra), 25µl of the resulting sample mixture was 
transferred to a glass coated 384 well plate and 90µl Mass spectrometry (MS) mix [7.5 mM 
NH4Ac IPA:MeOH (2:1)] added. The plates were then sealed using Corning aluminium 
micro-plate sealing tape (Sigma Aldrich Company, UK) and kept at -80°C until required for 
DIHRMS analysis.  
Direct infusion high resolution mass spectrometry (DIHRMS) 
The method used was akin to that presented previously (Koulman et al., 2014).  
Samples were infused into an Exactive Orbitrap (ThermoScientific, Hemel Hampstead, UK) 
using a Triversa Nanomate (Advion, Ithaca, US). Each well of the 364 well foil-sealed plate 
was pierced using the Nanomate infusion manual prior to analysis. Following this, a fresh 
tip was used to take up and aspirate 5µl of sample, followed by a 1.5µl air gap. The tip was 
pressed against a fresh nozzle and the sample dispensed using 0.2 psi nitrogen pressure. 
Ionization was achieved with a voltage of 1.2 kV, resulting in the production of both positive 
and negative ions, with an acquisition time of 72s and a mass acquisition window from 200 
to 2000 m/z. Data acquisition by the Exactive in the positive mode began 20s following 
aspiration. After 72s, the Nanomate and Exactive switched to negative mode with a 
decrease in voltage to -1.5 kV. The spray was maintained for another 66 s, after which 
analysis stopped. The tip was discarded prior to analysis of the subsequent sample. 
Throughout analysis, the plate was maintained at 15°C. Samples were run in row order.  
An example spectrum produced from this analysis, with both negative and positive 











Figure 2.7. An example spectrum produced from direct infusion high resolution 
mass spectrometry.  
This spectrum was produced from analysis of the lipid fraction of a plasma sample 
(subject J16, Pheriche) in negative and positive modes using direct infusion high 




 Initial processing of resulting MS data was performed using R studio. Raw data files 
were converted to .mzXML file format using MS convert (ProteoWizard). Any raw file formats 
below ~10,000 kb were discounted as this was indicative of a failed run, for instance due to 
problems with the direct spray. These samples were subsequently re-run. 
 The next stage was ‘peak picking’ of the data set, which essentially involved automatic 
assignment of each ion detected using an algorithm. To do this, an R script was run using 
the following programmes downloaded from http://www.bioconductor.org/:  data.table, 
xcms, mzR and Rcpp. Using a script developed by Prof Griffins’ laboratory, the data were 
processed in both positive and negative modes to produce .csv files containing m/z and m/z 
deviation information. During this process, only peaks with deviations within +5 ppm of target 
mass and with intensity >1000 were retained and those with >10% missing spectral values 
removed. Also added to the R working directory, and essential for peak assignment, was a 
lipid library. This was based upon masses taken from the LIPID MAPS directory, from which 
appropriate masses were calculated for each potential lipid. Isobaric species have been 
identified and this library currently contains 3400 ions in positive mode and 1600 ions in 
negative mode. It was at this stage that QC and IS standard samples were used to correct 
for a batch effect.  
Finally, each individual lipid peak was displayed in the .csv file as a ratio of what was 
detected. Lipids were identified based upon accurate mass in relation to the IS mix, thus 
enabling a semi-quantitave/targeted approach. From here, it was possible to proceed to 
statistical analysis.  
2.4.4 Data modelling using Bayesian statistical methods 
 The overarching question in this study was as follows: which metabolites respond to 
changes in altitude? In light of this, we hoped to capture the consistent movement of 
metabolites in a specific direction with increasing altitude. Due to the nature of the study 
design, measurements of each metabolite were reported for each subject across 5 locations 
(with some exceptions in cases where sample collection was missed or spectra quality 
insufficient). The analytical approach aimed to capture the overall metabolite trend across 




Metabolite trends across time points can be captured in the most basic sense utilising 
a linear model, whereby it becomes possible to assess whether the regression line for all 
subjects is above 0, thus, metabolites undergoing obvious changes can be visualised. 
Regression lines can be fitted for each subject and an average calculated. This thus 
presents two levels of hierarchy:  
1. Slope derived from linear regression 
2. Distribution of the data set, derived from the mean and SD values.  
In this simple hierarchical model, no communication exists between these two 
entities, so the individually fitted regression lines are fixed and the average is calculated 
separately. By use of Bayesian hierarchical modelling, it becomes possible for both the 
individual and average regression lines to be influenced by one another. In doing so, this 
method of analysis captures the fact that both individual and average linear regressions 
should be changing together. This is thus the method adopted in the present study.  
The first level of this model is the individually fitted regression, which were then used 
to inform the second level, being analysis of the average slope. This approach models at 
the level of the individual subject and this is then built on for an overall analysis of the group 
as a whole. Thus, both the individual and group regression can be assessed simultaneously 
and the individual regression lines are constrained by the average regression lines. This is 
in contrast to classical methods such as analysis of variance (ANOVA), whereby changes 
at each time-point are assessed through multiple comparisons of the entire dataset and the 
relationship between metabolite changes occurring within the same subject is ignored. 
Essentially, these classical approaches do not capture the 2 layers of analysis that it is 
possible to combine in the Bayesian model, being: the individual response and the group 
response.  
The Bayesian approach enabled a highly sophisticated, fluid model to be built. 
Communication existed between the two layers of analysis, being the individual and group 
responses, enabling the full structure of the data to be captured.  The first step in applying 
this model was to identify which spectral peaks and corresponding metabolites are 
undergoing changes distinct enough to warrant further investigation. Exclusion criteria for 
this were derived from an r2 plot for all regression lines. R2 was used because all values 
dealt with are positive (squaring of a negative number = positive). All signals from r2 that 
were of a greater frequency than 0.1 (i.e. not residing around 0), so those appearing at the 
tail end of the adjusted R2 vs. Frequency plot, represent spectral regions (from 1H-NMR) or 
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identified metabolites (from DIHRMS) undergoing a large change. These were then taken 
forward for Bayesian hierarchical modelling.    
Of crucial importance when interpreting the output of this modelling approach is the 
slope of the resulting credible regression lines. The slope is essentially the relationship of 
how one metabolites is transmitted across time points. This is representative of the effect 
size, therefore depicts metabolite changes per km change in altitude. It has numerous 
advantages over more traditional methods of significance testing as it places emphasis upon 
the size of the difference rather than confounding this measure with sample size as 
significance does (Broadhurst et al., 2006). This thus avoids a scenario where a large 
sample size, as is the case in this study, presents hugely significant changes in a small, and 
likely uninteresting, difference. 
Identified metabolites are presented with corresponding identification codes from 
either the human metabolome database (HMDB), or in the case of certain lipids where 
HMDB identification was not available, chemical entities of biological interest (CHEBI) are 
included.  
2.4.5 Calculation of absolute changes  
From the Bayesian modelling output, the direction of metabolite change with 
progressive altitude exposure can be clearly observed.  However, it is difficult to gauge from 
this output the degree of change and to compare this between observations. This was 
approached through the following assessments.   
For the aqueous phase metabolites, the binned 1H-NMR spectral regions 
corresponding to an identified metabolite that underwent the largest slope change from the 
Bayesian model output were assessed. The change in spectral intensity between LDN and 
EBC was calculated and from this the median % change derived. Given that this was a 
measure of spectral intensity, no absolute value such as concentration/ml plasma could be 
given for the change, instead arbitrary units were employed. The LDN and EBC values were 
also corrected to the LDN value, to give a normalised ratio of change. The same approaches 
were employed for assessment of the degree of change in lipid abundance, although this 
only included those definitively identified lipids.  
The median value was chosen as in most instances, data within a variable (so 
comparison between individuals within a spectral region or lipid) did not follow a Gaussian 
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distribution, as assessed using the D’Agostino-Pearson (omnibus K2) normality test, 
therefore would likely skew the mean.   
This absolute measure of change with ascent is presented alongside the relative 
measure, derived from the median of the slope (AU/km). In addition, this absolute change 
was normalised to the LDN value and plotted as LDN: EBC ratio to enable visualization of 
the changes.  
2.4.6 Physiological variables 
 Physiological measurements were conducted shortly after waking, prior to any oral 
intake in the morning of the same day that blood samples were obtained. This includes 
arterial O2 saturation and body weight.   
Arterial O2 saturation (SpO2) 
 An estimation of arterial O2 saturation (SpO2) was measured from the right index 
finger using a pulse oximeter (Onyx 9500, Nonin, USA) following 10 minutes of rest. 
Measurements were taken by independent individuals, meaning the subject was blind to the 
oximeter to prevent feedback alterations to respiratory rate, thus SpO2.  
Statistical analysis 
 The LDN and EBC values for SpO2 and body weight data were abnormally 
distributed, as assessed using the D’Agostino-Pearson (omnibus K2) normality test. 
Therefore, a Wilcoxon matched-pairs signed rank test was employed for analysis. This was 
performed and graphs constructed in Graphpad Prism 7. By focusing upon the differences 
between LDN and EBC, it provided insight into the extreme nature of the EBC environment 
in comparison to LDN.   
Correlation/Linear regression Analysis 
 To assess whether a relationship exists between changes to metabolic/lipid profile 
and those of physiological variables (SpO2, body weight), correlation analysis was 
performed. The Δ abundance of metabolites/lipids from LDN to EBC that were identified as 
undergoing large changes with ascent were plotted against the Δ SpO2 or body weight from 
LDN to EBC. For the aqueous fraction metabolites, this specifically refers to the Δ of spectral 
region intensity undergoing the greatest change, and for lipids, the definitively identified lipid 
variables (as outlined in section 2.4.5). Data that followed a Gaussian distribution, as 
assessed using a D’Agostino-Pearson (omnibus K2) normality test, were tested using a 
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Pearson Correlation Coefficient to distinguish whether a relationship existed between these 
parameters. For data that did not follow a Gaussian distribution, a non-parametric Spearman 
rank correlation (two tailed) was applied to distinguish whether a relationship existed 
between these parameters. If a significant relationship was identified, linear regression 
analysis was subsequently performed to find the best line that predicts Y from X.  
2.5  Results 
2.5.1 Subject details  
198 subjects (125 male, 73 female, 44 + 14 years of age, BMI 25.07 + 3.16 kg/m2) 
participated in the expedition to EBC. Details on the subject recruitment process have been 
outlined previously by Levett and colleagues (Levett et al., 2010). All subjects arrived at 
KTM, 197 at NAM, 195 at PHE and 190 (96%) at EBC. Those not reaching the specific 
altitudes suffered either acute mountain sickness or non-altitude related medical conditions 
(Levett et al., 2010).  
SpO2 and body weight changes with ascent  
 The degree of hypoxic exposure experienced at this extreme altitude was reflected 
through progressive decreases in arterial O2 saturations (SpO2) with ascent (Figure 2.8A). 
A 20.4 % decrease (median, n=187, p<0.0001) from 98% observed at LDN to 73% at EBC 
(Figure 2.8C).  
 Body weight similarly underwent a progressive decrease (Figure 2.8B), with 
differences from LDN to EBC presenting an average (median) weight loss of 3.7% (3 kg) 





Figure 2.8. Changes in physiological variables with ascent to EBC. 
This includes recording of resting arterial O2 saturation (SpO2) (A) and body weight (kg) (B) 
across all altitudes. Differences in SpO2 (C) and body weight (D) between LDN and EBC, 
presented as minimum to maximum box and whisker plots, with the middle line representing 
the median and the box the interquartile range (25th to 75th percentiles), tested using a 






























































































2.5.2 Plasma metabolomics/lipidomic analysis  
 As a result of subjects failing to arrive at the laboratory or insufficient amounts of 
plasma being obtained for subsequent analysis, samples were not analysed for all 198 
subjects at every altitude location. A total of 965 samples were obtained for 
metabolomics/lipidomics analysis, with exact numbers at each altitude specified in Table 
2.2. The goal of this analysis was to examine which metabolites responded to changes in 
altitude and to detect an overall trend across the 5 altitude locations. 
 
Table 2.2. Total plasma sample number analysed using metabolomics and lipidomics 
from each laboratory location. 





NMR and MS  
LDN  197 197 
KTM 198 198 
NAM 195 195 
PHE 193 193 
EBC 192 182 
Plasma aqueous fraction analysis 
 The focus for Bayesian analysis was upon the big changes with altitude ascent.  
These were identified as the binned regions of the 1H-NMR spectrum undergoing the largest 
degree of change and so residing at the tail ends of the distribution curve, situated ± 1.96SD 
away from the mean.  A total of 50 bins were found to fit this criteria.  
The spectral regions identified as undergoing the largest degree of change were 
correlated through a heatmap displayed in Figure 2.9.  From this, it is clear to see that the 
spectral regions undergoing the largest changes display the strongest correlation with 
regions corresponding to the same metabolite, thus confirming that metabolite identification 
of ‘big changers’ was accurate. Here, the presence of peaks related to EDTA and DSS 
become clearly apparent. The changes in these particular spectral regions are likely 
indicative of alterations to plasma concentration with increasing altitude.   
To derive changes with altitude, these binned spectral regions were taken forward 
for hierarchical Bayesian analysis. The results from the Bayesian model represent 
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alterations in the abundance of circulating levels of the metabolites relating to these specific 
spectral regions. These changes are visible through the slope, or simple regression, which 
depicts the effect size, therefore how much that particular metabolite changes per unit 
change with altitude. If the slope is positive, this indicates an increase in the respective 
metabolite, if negative, it is indicative of a decrease. The slope is expressed as arbitrary 
units per km change in altitude.  
Aqueous metabolite changes   
 Changes in aqueous metabolites are summarised in Table 2.3 and include 
alterations in the substrate and product of glycolysis as glucose (D-Glucose HMDB00122) 
decreased and lactate (L-lactic acid, HMDB00190) increased with ascent to EBC. A 
progressive decrease was observed in the isomer of the essential branched chain amino 
acid leucine, isoleucine (L-isoleucine HMDB00172). The spectral peaks corresponding to 
these metabolites that underwent the largest degree of change were identified as 1.31ppm 
for lactate (27.4% increase), 3.35ppm for glucose (52.4% decrease) and 0.92 ppm for 
isoleucine (60.5% decrease). An example of the Bayesian hierarchical model output is 
displayed in Figure 2.10 below, whereby the responses of the individual are presented 
alongside the overall group response. Both relative and absolute changes for each of these 
peaks is presented in Table 2.3. The differences in peak intensity from LDN to EBC, 





























           
 
 
Figure 2.9. Heatmap correlation plot of spectral regions identified as undergoing large 
changes with increasing altitude.  
Spectral regions are identified as parts per million (ppm) and metabolites corresponding to 
these regions are labelled. Those regions belonging to the same metabolite are shown to 
be strongly positively correlated, as represented by the dark blue, large dots. Orange regions 







A. Lactate (1.3ppm)  
B. Isoleucine (0.92ppm) 
Figure 2.10. Spectral regions and related metabolites presenting a significant trend 
with increasing altitude, identified using Bayesian hierarchical modelling. 
A Lactate. B.  Isoleucine. On the left hand side of each graph set is presented a select 
example of individual responses of the group (expressed as a ‘Unit’) at each altitude. The 
multiple blue lines are credible regression lines, representing the top (or most likely) 
underlying distribution. The most likely distribution from the individual response was then 
taken to inform the distribution of the group.  The individual response is therefore constrained 
by the average response of the group, which is presented on the right hand side as ‘All Units’. 
Here, the changes in each individual across each altitude are presented. Y axes metabolite 
units are arbitrary units, derived from the spectral intensity changing per km altitude. 
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Note: Displayed is the metabolite peak (ppm) undergoing the largest degree of change, with 
intensities at LDN and EBC, the median % change between these two locations and the 
slope.    
  



















Isoleucine 0.92 0.012 0.0049 -60.5 
 
-0.00142 Decreasing 
Glucose 3.35 0.016 0.0081 -52.4 
 
-0.0014 Decreasing 







Figure 2.11. Alterations in aqueous metabolite intensities from LDN to EBC 
1H-NMR spectral regions (and corresponding metabolites) undergoing the largest degree of 
change with ascent to EBC, identified using Hierarchical Bayesian statistics. Values are 
corrected to LDN, and so are expressed as a ratio of LDN: EBC, with a value of 1 indicative 
of no change. Presented as minimum to maximum box and whisker plots, with the middle 



















































Plasma lipid fraction analysis  
 Negative ion mode revealed 1012 observations from 322 variables (including QC’s 
and blanks) and positive mode 1012 observations of 238 variables. To identify variables, 
being lipids, to be taken forward for subsequent data analysis, a median of observations 
derived from each subject in positive and negative modes were calculated.  From the 
negative mode, 6 metabolites were identified with mean slopes greater than 1.96 SD away 
from the mean, and 11 metabolites from positive mode. These were taken forward for 
Bayesian modelling.   
 Two examples of the lipidomic Bayesian modelling output are presented in Figure 
2.12. All lipid species identified as undergoing large increases with ascent are outlined in 
Table 2.4 and those undergoing large decreases outline in Table 2.5. The largest lipid 
increase was identified as triglyceride (TG) 52:3, with a median increase from LDN to EBC 
of 53.9%. The largest decrease in a definitively identified lipid was that of TG 48:1, with a 
median decrease of 43.1%. Alterations in abundance of identified lipids is expressed as 



















SM_34:1  B. 
Figure 2.12. Example of hierarchical Bayesian analysis of plasma lipids undergoing 
significant changes with progressive altitude exposure, identified through DIHRMS. 
A. Phosphocholine (PC) 46 carbons: 2 double bonds (46:2), identified in negative ion 
mode. B. Sphingomyelin (SM) 34:1, identified in positive mode.  An example of individual 
responses of the group (expressed as a ‘Unit’) at each altitude. This individual response is 
constrained by the average response of the group, which is presented on the right hand 
side as ‘All Units’. Here, the changes in each individual across each altitude are presented. 




















Table 2.4. Lipids identified as undergoing increases with progressive altitude 
exposure 
Note: Displayed are the variables undergoing the largest degree of change, with intensities 
at LDN and EBC, the median % change between these two locations and the slope. 
Variables are listed in descending order of median % change from LDN to EBC.  Text in 





























































































Positive 104.0 110.0 4.1 1.584 
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Note: Displayed are the variables undergoing the largest degree of change, with intensities 
at LDN and EBC, the median % change between these two locations and the slope. 
Variables are listed in descending order of median % change from LDN to EBC.  Text in 





















































































Figure 2.13. Alterations in lipid abundance from LDN to EBC.  
Lipids (assessed using DIHRMS) undergoing the largest degree of change with ascent to 
EBC, identified using Hierarchical Bayesian statistics. Values are corrected to LDN, and so 
are expressed as a ratio of LDN: EBC, with a value of 1 indicative of no change. Presented 
as minimum to maximum box and whisker plots, with the middle line representing the median 




































































Triglyceride (TG) and free fatty acid changes  
 The abundance of triglycerides (TGs) with carbon chain: double bond ratios of 52:3 
(CHEBI: 84661) and 52:4 (CHEBI: 84660) increased with ascent to EBC. Decreases with 
ascent were observed in TGs containing palmitate and oleate (50:1 (CHEBI: 84665), and 
48:1 (CHEBI: 85726)). This occurred alongside increases in the most abundant fatty acids 
within adipose tissue, being the saturated palmitic acid (16:0) (HMDB00220) as well as 
unsaturated linoleic (18:2) (HMDB00673) and oleic (18:1) (HMDB00207) acids.   
Phosphatidylcholine (PC)  
Phosphatidylcholines (PC) 46:2 (CHEBI: 72430) decreased with ascent. In addition 
to their role as a key component of plasma membranes, PC’s are the primary phospholipid 
required for lipoprotein synthesis (Eisenberg, 1984). 
Sphingomyelin (SM)  
Increases were observed in an essential cell membrane component, particularly 
within the membranous myelin sheath surrounding nerve cell axons, sphingomyelin (SM) 
34:2 (CHEBI:64587).  
Multiple lipid identifications  
A number of variables identified as undergoing large degrees of change possessed 
an m/z value that corresponded to multiple possible lipids. These are presented in non-bold 
text in both Table 2.4 and Table 2.5.  
Amongst these changes are alterations to numerous PC’s alongside 
phosphoethanolamines (PE’s) and phosphatidic acids (PA’s); increases in lyso-
phosphatidylcholine (LPC) 18:0 (HMDB10382) alongside lyso-phosphoethanolamine (LPE) 
19:0; and lastly increases in phosphatidylserine (PS) 36:2 (CHEBI:72066) alongside 
phosphatidylglycerol (PG) 36:4. Alterations in abundance of these lipids is of importance, 
given the degree of relative and absolute changes. Further investigation to establish a 
definitive identification is therefore warranted.     
2.5.3 Correlation analysis 
To assess whether a relationship existed between altitude dependent changes in 
metabolites/lipids from LDN to EBC and the specific physiological variables presented here, 
correlation plots were constructed. 
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Plots of changes in aqueous metabolites against body weight Figure 2.14 revealed 
a significant correlation between changes in glucose and body weight (p=0.007), with 
decreases in body weight being associated with decreases in plasma glucose (Figure 
2.14B). Linear regression analysis demonstrated a low p value (<0.05) coupled to a low r2, 
thus indicating that although a significant degree of variance can be explained by the 
relationship between these variables, much remains unexplained. No significance was 
observed for either lactate or isoleucine. Equally, no significant correlations were observed 
between the changes in these aqueous metabolites and SpO2 (Figure 2.15).  
Plots of the change in fatty acid vs. body weight from LDN to EBC revealed a 
significant correlation between the unsaturated oleic (18:1) (p=0.0127) and linoleic (18:2) 
(p=0.0062) FA’s and body weight from LDN to EBC, with loss of body weight at altitude 
being associated with increasing levels of unsaturated FA’s oleic and linoleic acids (Figure 
2.16B,C). Linear regression analysis again demonstrated a low p value (<0.05) coupled to 
a low r2. No correlation was found between these unsaturated FA’s and SpO2 (Figure 2.17)  
Equally, no correlation existed between changes in unsaturated FA’s (Figure 2.16, Figure 








Figure 2.14.Correlation of Δ aqueous metabolites vs. Δ body weight. 
A, Lactate, B, Glucose, C, Isoleucine. These metabolites are those identified as undergoing 
large changes with progressive altitude exposure. Δ calculated as EBC-LDN. Correlation 
analysis performed using Pearson rank correlation coefficient as data was non-normally 
distributed. Significant (p˂0.01) correlations were analysed further using linear regression.  
 
  















r2 = 0.102 p<0.0001
Y=84.02*X-1.959
B.












Figure 2.15. Correlation of Δ aqueous metabolites vs. Δ body weight. 
A, Lactate, B, Glucose, C, Isoleucine. These metabolites are those identified as 
undergoing large changes with progressive altitude exposure. Δ calculated as EBC-LDN. 
Correlation analysis performed using Pearson rank correlation coefficient as data was 
non-normally distributed. Significant (p˂0.01) correlations were analysed further using 






























Figure 2.16. Correlation of Δ fatty acids (FA) vs. Δ body weight. 
 A, B: Saturated FA’s C, D: Unsaturated FA, shown as carbon: double bond ratio. These 
FA’s are those identified as undergoing large changes with progressive altitude exposure. 
Δ calculated as EBC-LDN. Correlation analysis performed using Pearson rank correlation 
coefficient. Significant (p˂0.01) correlations analysed further using linear regression. 
 
 
   
 





























Figure 2.17. Correlation of Δ fatty acids (FA) vs. Δ SpO2 
A, B: Saturated FA’s C, D: Unsaturated FA, shown as carbon: double bond ratio. These 
FA’s are those identified as undergoing large changes with progressive altitude exposure. 
Δ calculated as EBC-LDN. Correlation analysis performed using Spearman’s rank 
correlation coefficient for normally distributed data or Pearson rank correlation coefficient on 
































Figure 2.18. Correlation of Δ triglycerides (TG) vs. Δ body weight. 
The TG’s selected for this analysis were those identified as undergoing large changes with 
progressive altitude exposure, shown as carbon chain: double bond ratio.  Δ calculated as 
EBC-LDN. Correlation analysis performed using Spearman’s rank correlation coefficient for 






































Figure 2.19. Correlation of Δ triglycerides (TG) vs. Δ SpO2. 
The TG’s selected for this analysis were those identified as undergoing large changes with 
progressive altitude exposure, shown as carbon chain: double bond ratio.  Δ calculated as 
EBC-LDN. Correlation analysis performed using Spearman’s rank correlation coefficient for 
normally distributed data or Pearson Correlation coefficient on non-normally distributed data. 
 
  




































Figure 2.20. Correlation of Δ lipid vs. ΔSpO2 or body weight. 
A, B: Phosphatidic choline (PC), C, D: Phosphatidylserine (PS). These lipids were identified 
as undergoing large changes with progressive altitude exposure, shown as carbon chain: 
double bond ratio. Δ calculated as EBC-LDN. Correlation analysis performed using 
Spearman’s rank correlation coefficient for normally distributed data or Pearson rank 
correlation coefficient on non-normally distributed data. Significant (p˂0.01) correlations 





































Hypoxia, either in response to environmental exposure or pathological states, 
induces metabolic stress and remodelling processes, the details of which are not well 
defined. In the first study of this thesis, metabolic adaptation to progressive hypoxia was 
examined using metabolomic and lipidomic analysis of the aqueous and lipid fractions of 
plasma, respectively, collected from 198 human subjects upon a strictly controlled ascent to 
EBC (5300m). The severity of hypoxic exposure could be observed through the ~20% 
decrease in SpO2. This significant perturbation to the system was also reflected through 
decreasing body weight, which fell by ~3.7%, an effect that is in line with previous high 
altitude studies (Boyer et al., 1984, Guilland et al., 1985). Further investigation into 
downstream metabolic alterations was therefore warranted.  
The aims of metabolomics and lipidomic assessment were twofold: 1) to identify 
commonalities in the healthy human response to progressive hypobaric hypoxia, 2) to 
distinguish how individuals vary in their response. To capture the altitude vs. metabolite 
relationship across these two layers in both metabolomics and lipidomics data sets, a 
hierarchical Bayesian model was employed.   
In addition to the effects of altitude, subjects experienced a number of other 
perturbations upon their ascent to EBC that could potentially be reflected in their metabolic 
profiles. This includes the effects of the flight, both to KTM from LDN and from KTM to Lukla 
to begin their trek, as well potential dietary changes. A vital part of the analysis was therefore 
to distinguish the effects of increasing altitude from other perturbations to the system. The 
approach for identification of circulating metabolites undergoing the greatest perturbations 
with increasing altitude was to focus upon those located at the tail ends of the distribution 
curve (≤1.96 SD away from the mean). The Bayesian hierarchical modelling method was 
then adopted to assess the overall trend in metabolites. If an altitude effect was present, 
then this trend should be distinctive across all 5 locations.  
An overview of the largest metabolite changes identified in both plasma fractions and 
possible consequences of these alterations are presented in  Figure 2.21. 
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Figure 2.21. A summary of plasma metabolite changes and possible effects these 
changes indicate with ascent to Everest Base Camp.  
Derived from analysis of both lipid and aqueous phases, and the insight this provides into 
metabolic adaptation. Aqueous fraction changes: decrease in glucose, increase in lactate, 
indicative of increasing glycolysis; decrease in isoleucine. Lipid fraction changes:  a decrease 
in triglycerides TGs containing palmitate and oleate along with increases in these free fatty acids 
(FA). This change is indicative of adipose tissue mobilisation and impaired de novo lipogenesis 
(DNL). Decreases in phosphatidylcholines (PCs), perhaps indicative of changes to lipoprotein 
protein synthesis.  
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2.6.1 Aqueous metabolite changes 
Specific changes in aqueous metabolites were indicative of increasing reliance upon 
anaerobic glycolysis, with a decrease in the substrate glucose occurring alongside an 
increase in the product lactate. A shift towards glycolytic metabolism is a key theme in 
numerous prior high altitude studies.  For instance, a HIF-1α mediated increase in glucose 
transporters (GLUT-1 and GLUT-4) to the plasma membrane (Xia et al., 1997, Semenza, 
1999) and upregulation of lactate dehydrogenase (Firth et al., 1995, Green et al., 1989) have 
been demonstrated in response to hypoxic exposure in both human and animal studies. This 
is alongside reports of a shunting of pyruvate away from entry to the TCA cycle and towards 
lactate formation, as shown through HIF-1α dependent inhibition of PDH through induction 
of PDK1, a response essential for hypoxic adaptation in mouse embryo fibroblasts (Kim et 
al., 2006). Indeed, the increase in lactate is supported by prior studies related to the CXE 
expedition, where the use of colorimetric enzyme assay kits demonstrated progressive 
increases in plasma lactate upon ascent, peaking at EBC (Siervo et al., 2014). 
However, much discordance exists in relation to the lactate response, culminating in 
the ‘lactate paradox’ (Hochachka et al., 2002).  This phenomenon presents as a lower lactate 
production under O2 limiting conditions. It is a response reported post exercise (West, 1986) 
that may be explained through tighter coupling between ATP demand and supply 
(Hochachka et al., 2002).  It has been recognised to occur in hypoxic-acclimatised 
individuals and highland native populations, becoming particularly prominent following 
exercise (Hochachka et al., 2002, Matheson et al., 1991). On this presumption, the present 
results would suggest that subjects remained unacclimatised following the 11 day ascent. 
Proteomic analysis of muscle biopsies acquired from subjects (CXE lab staff) exposed to 
5300m for 6 days following the same ascent prolife as the subjects in the present study, 
revealed a decline in the abundance of enzymes required for glycolytic metabolism (Levett 
et al., 2015). This thus indicates that a longer stay at altitude may be required for 
acclimatisation to occur in lowland native subjects.   
A seemingly novel response outlined in the aqueous plasma fraction was a decrease 
in isoleucine. This has not been highlighted in previous environmental hypoxia studies and 
is, to the author’s knowledge, a novel finding. The consequences of this are not clear.  
Isoleucine is an essential branched chain amino acid (BCAA), therefore cannot be 
endogenously synthesised, but rather needs to be provided by the diet. The fact that this 
change may be related to a dietary shift therefore cannot be ruled out. However, if the 
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decrease was due to a reduction in protein consumption, this would likely be reflected in 
changes to other BCAA’s, being leucine and valine and this was not the case. The specificity 
of the change thus indicates the fall in isoleucine levels is due to increased utilisation as 
opposed to a decreased supply, either from dietary sources or protein turnover. 
Prior studies examining responses to very acute hypoxia (5-18hrs) in rats (9.5% O2) 
(Muratsubaki et al., 2011) and HeLa cells (1% O2) (Troy et al., 2005) have been associated 
with increasing isoleucine levels. The disparity with the results of chapter 2 may be reflective 
of the differences in duration and severity of hypoxic exposure.  
It may seem logical to associate the apparent increasing isoleucine utilisation 
observed in the present study with rising energy demand. An instance whereby rising energy 
demand is not met is fatigue. This is in turn associated with impaired mitochondrial function, 
as demonstrated through falling ATP production (Kume et al., 2015). In rats, fatigue has 
been associated with mobilisation of BCAA metabolites leading to an increased plasma 
isoleucine level, detected via metabolic profiling and related to proteolysis of skeletal muscle 
in rats (Kume et al., 2015). In this scenario, O2 supply is ample, meaning the metabolic 
stresses are not akin to what is experienced in hypoxia. It suggests the BCAA metabolic 
pathway response is complex and may differ depending upon the specific form of metabolic 
stress and levels of O2 availability. 
There are a number of possible functional consequences of decreasing plasma 
isoleucine content. This includes structural effects within skeletal muscle.  An optimal ratio 
of BCAA’s (leucine:isoleucine:valine) has been shown to be crucial in development of 
intramuscular fat (Duan et al., 2016a) and protein synthesis, for instance through 
upregulation of mTOR signalling (Duan et al., 2016b). These results, whereby isoleucine is 
decreasing independently of leucine or valine thus suggests a disruption of this ratio, which 
may have downstream implications both for fat and protein metabolism.  In relation to this, 
mTOR is downregulated in hypoxia (Wullschleger et al.) and levels decreased in response 
to 7-9 days exposure to 4559m in human vastus lateralis (Viganò et al., 2008). Again, 
associations between changes in muscle protein synthesis and decreasing plasma 
isoleucine are speculative, requiring further investigation.  
Interestingly, lower BCAA levels have been associated with improving metabolic 
health. Dietary restriction of BCAA intake has been shown to improve glucose tolerance in 
both mice and humans (Fontana et al., 2016). In rats, a 45% restriction in dietary BCAA’s 
have been associated with relieving mitochondrial metabolic overload in skeletal muscle 
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through preventing the accumulation of short and medium chain acyl CoA’s to facilitate the 
complete oxidation of fatty acids, thus improving efficiency of skeletal muscle β-oxidation 
(White et al., 2016). This effect was accompanied by improvements in skeletal muscle insulin 
sensitivity (White et al., 2016).  It may be the case, therefore, that lower isoleucine levels 
observed in the present study result from a favourable adjustment to improve skeletal 
muscle metabolism, particularly gluco-insular signalling. The aforementioned decreases in 
plasma glucose would go to support this assumption.  
2.6.2 Lipid changes 
Assessment of changes in plasma lipid metabolites revealed a significant degree of 
insight into lipid homeostasis during progressive hypoxic exposure. Increases were 
observed in the most abundant saturated and unsaturated fatty acids, being palmitic acid in 
the first instance and linoleic and oleic acids in the second. The change in the unsaturated 
fatty acids from LDN to EBC demonstrated a negative correlation with the change in body 
weight, thus indicating a potential link between these two factors. However, whether the 
increase in circulating unsaturated fatty acids may be a result or cause of decreasing body 
weight remains to be determined.   
This change in circulating fatty acids occurred alongside decreasing levels of the 
main constituent of body fat, TGs, specifically those containing palmitate and oleate (48:1, 
50:1). It is expected that, to retain a balance in circulating TG levels, specific decreases will 
be accompanied by compensatory increases, as is reported here in TGs 52:3 and 52:4.   
TGs containing 48-50 carbons are typically associated with de novo lipogenesis 
(DNL), a process by which excess carbohydrates are converted to fatty acids and 
subsequently to TGs for storage (Ameer et al., 2014).  Decreases in TGs 48:1 and 50:1 with 
ascent to EBC are therefore indicative of a suppressed DNL, an affect reported previously 
to be mediated via HIF-1α signalling (Menendez et al., 2007, Suzuki et al., 2014).  
Alongside impaired DNL, the results are indicative of increased fat store mobilisation, 
a process known to be induced via sympathetic nervous system changes, with 
catecholamine release initiating a cAMP dependent phosphorylation of hormone sensitive 
lipase. This in turn stimulates TG mobilisation (Kraemer et al., 2002). Insulin acts 
antagonistically to impair this signalling system, thus inhibiting TG breakdown.   
Alterations in both adrenaline/noradrenaline and insulin have been reported in 
previous investigations of the CXE expedition team. This included CXE investigators (n=24), 
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whom  underwent an identical ascent profile to EBC as that described in the present study, 
yet remained at EBC for 8 weeks (Siervo et al., 2014). An initial increase in adrenaline and 
noradrenaline was observed upon ascent to NAM. Theoretically, this sympathetic nervous 
system activity could induce the fat store mobilisation response observed in the present 
study.  
This initial sympathetic nervous system response observed by Siervo and colleagues 
was followed by a decrease in adrenaline/noradrenaline and a sharp increase in insulin and 
C-peptide in response to longer term residence at EBC or above (Siervo et al., 2014). This 
was thus indicative of an onset of insulin resistance. Increasing circulating levels of free fatty 
acids (notably palmitic, oleic and linoleic acids) have been shown to induce insulin 
resistance in several models (Shen et al., 2016, Shi et al., 2006, Benoit et al., 2009), 
including those of obesity through a mechanism reliant upon c-Jun amino terminal kinases 
(JNKs) (Hirosumi et al., 2002). It is therefore entirely possible that the increased mobilisation 
of fat stores reported here, with the resulting increase in circulating fatty acids, is a causative 
factor for the spike in insulin concentrations observed in response to longer term exposure 
(Siervo et al., 2014). This may thus suggest that any favourable adjustments in gluco-insular 
signalling indicated through decreasing isoleucine levels is a short time effect that is followed 
by the onset of insulin resistance in the long term. However, this conclusion is somewhat 
speculative and further investigations are required before a firm conclusion can be drawn 
from possible associations between increasing circulating fatty acids and insulin resistance.  
An additional factor that could lead to the build-up of circulating fatty acid levels is 
impaired β-oxidation capacity. This response is commonly reported amongst high altitude 
studies (Horscroft et al., 2014). Previous proteomic examination undertaken on CXE 
expedition subjects revealed decreasing OXPHOS enzyme abundance, which may imply 
OXPHOS capacity is impaired and so fatty acid metabolism is in turn suppressed (Levett et 
al., 2015).  
Beyond alterations to fat storage and synthesis, lipidomics analysis also revealed 
changes in key membrane components. This includes the decreases in PC 46:2. PC’s are 
key constituents in the construction of lipoproteins, in particular very low density lipoprotein 
(VLDL) (Eisenberg, 1984), which is required for lipid transportation from the liver to cells. 
This observation thus goes to suggest progressive hypoxic exposure may affect lipid 
transport via VLDL. Disruption to the lipoprotein transport system in hypoxia has been 
reported previously with regards to the mobilisation of FA’s from VLDL via lipoprotein lipase 
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(LPL). LPL activity was inhibited in adipose tissue and pre-adipocytes exposed to chronic 
intermittent (Drager et al., 2012) and acute hypoxia (Mahat et al., 2016b), respectively. 
Further investigation into the lipoprotein transport system in response to hypoxic exposure 
is thus warranted.  
Changes were also observed in the key membrane component, SM. The role of this 
lipid in hypoxic conditions has not undergone sufficient investigation. However, given the 
crucial role it plays in membrane of neural tissue, it may be that rising levels are indicative 
of disruption to membrane composition. This could result from a stress response, both from 
hypoxia and also the resulting increase in circulating free fatty acids. In particular, saturated 
fatty acids including palmitic acid have been associated with toxicity, demonstrated through 
increasing inflammation, generation of ROS and increasing apoptosis (Kennedy et al., 2009, 
Miao et al., 2015).  
There were numerous instances whereby multiple lipid identifications were present. 
Further investigation to firmly derive exact details may, for instance, involve adoption of a 
prior chromatography separation step to produce and separate lipid fragments (Dunn et al., 
2011a).  
2.6.3 Correlation analysis 
Correlation analysis revealed a positive correlation with changes in glucose and body 
weight, yet a negative correlation with changes in unsaturated fatty acids. However, whether 
the body weight change is a cause of the metabolite alterations or vice versa remains to be 
determined.  
Interestingly, despite the large changes in SpO2 between LDN to EBC (~20% 
average decrease), this was not found to correlate with any identified metabolite. This may 
highlight the importance of other factors aside from the delivery of O2 to tissues that 
influences metabolic acclimatisation to hypoxic exposure. This concept has been recognised 
in the context of VO2 max, whereby normalisation of arterial O2 content occurs alongside 
continued impairment to exercise capacity (Calbet et al., 2003).  
2.7 Conclusion 
 In this study, systemic metabolic responses to progressive high altitude exposure 
were assessed utilising metabolomics and lipidomic profiling of human plasma. Alterations 
identified in the aqueous fraction included the novel finding of decreasing isoleucine with 
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ascent, alongside lactate and glucose changes that were indicative of the well-documented 
increased reliance upon anaerobic metabolism. Fluctuations in the lipid profile with ascent 
were suggestive of increased mobilisation of lipid stores and suppressed DNL. This occurred 
alongside changes to lipids that are essential membrane components, particularly those 
involved in the lipoprotein transport system. This study has therefore highlighted potential 
metabolic biomarkers for progressive hypoxic exposure in healthy humans. Further 
investigation is required to validate these biomarkers with targeted studies and to assess 





3 Chapter 3 (Study 2): Antarctica winter 
expedition pilot study: physiological and 
metabolic responses to prolonged hypoxia and 
extreme cold. 
3.1  Introduction 
Hypoxic exposure, both in healthy humans sojourning to altitudes and resulting from 
disease states, can be experienced at varying severities and longevities. As already 
highlighted, much of the discrepancy between previous high altitude studies results from 
differences in duration and severity of hypoxic exposure (Horscroft et al., 2014).  Unravelling 
the controversy surrounding metabolic remodelling processes therefore needs to 
encompass this variability. In particular, the responses to chronic hypoxic exposure is a 
highly understudied area. Indeed, the very definition of ‘chronic exposure’ is unclear and 
varies between studies. Some have defined it as ≥42 days (Horscroft et al., 2014), some ≥ 
3 months (Woolcott et al., 2015) and others as little as 2 weeks (Siebenmann et al., 2016).   
Despite this discrepancy, evidence suggests metabolic responses to chronic hypoxia 
may differ from those apparent in acute exposure. For instance, reports of decreasing lactate 
accumulation in response to exercise in chronic compared to short term exposure (the 
lactate paradox) suggests further shifts in metabolic remodeling processes (Hochachka et 
al., 2002). This is alongside alterations to the mitochondrial network, with exposure to ≥42 
days being associated with decreasing mitochondrial density in skeletal muscle (Horscroft 
et al., 2014). Interestingly, this trait is present in adapted high altitude native Tibetan 
populations, whom display a lower skeletal muscle mitochondrial density in comparison to 
lowlanders (Kayser et al., 1996). Examination of native highland populations at a genetic 
level reveals the presence of polymorphisms in genes specifically related to metabolic 
function (Simonson et al., 2012, Simonson, 2015).  
Further investigation into chronic exposure is therefore warranted. In the current 
study, a small cohort of subjects were examined pre and post an attempted winter crossing 
of Antarctica, which included prolonged exposure to high altitude with 24 weeks at 2,500m. 
Inevitably, this occurred alongside intermittent exposure to the extreme cold temperatures 
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of the Antarctic winter that far exceeded the degree of cold exposure experienced by 
subjects in Chapter 2.  
It is generally considered that the decreased PIO2 experienced at altitude is the main 
cause of the observed physiological effects (Woolcott et al., 2015). However, high altitude 
exposure usually coincides with cold ambient temperatures and the interaction between 
hypoxia and cold are often overlooked. This is especially pertinent when considering the 
metabolic effects of cold exposure. 
  Acclimatisation to extreme cold undoubtedly relies heavily upon behavioural 
adaptations such as the wearing of warm clothing, but this can be accompanied by 
significant physiological changes that in turn influence substrate utilisation, specifically 
increasing reliance upon carbohydrate and fat oxidation (Vallerand et al., 1989).  
A fall in body temperature to the lower extreme of thermoneutrality (lower critical 
temperature) initiates metabolic energy transformation, or thermogenesis (Stocks et al., 
2004). In the short term this includes shivering thermogenesis. Despite its reliance upon 
muscular contraction, substrate utilisation during shivering is not akin to utilisation evoked 
by exercise as shivering induces larger increases in plasma free fatty acids, β-
hydroxybutyrate and insulin compared to exercise (Tipton et al., 1997). This is alongside 
reports of increasing utilisation of skeletal muscle glycogen stores (Jacobs et al., 1985).  
With longer term acclimation to cold, there is also a heavy reliance upon metabolic 
processes for non-shivering thermogenesis. Of particular relevance are those changes 
taking place in mitochondria located within adipose tissue. Uncoupling of oxidative 
phosphorylation here is thought to play an essential role in cold-induced shivering 
thermogenesis, a response believed to be regulated by the cold-sensing receptor TRPM8 
expressed in both white and brown adipose tissue (Frontini et al., 2010, Rossato et al., 
2014).   
Long term alterations to metabolic processes can also be observed through 
measurements of basal metabolic rate (BMR) in populations indigenous to extreme cold 
environments. A strong correlation between BMR and climate has been observed (Roberts, 
1952).  The BMR of indigenous Siberian populations, for example, was found to be 5% 
higher than values predicted based on body mass. These elevations appeared to be 
attributable to environmental stress rather than high dietary protein consumption, as was 
previously believed (Leonard et al., 2005).  
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The combination of cold exposure and hypoxia appears to modify responses to both 
conditions. Whilst cold exposure is reported to increase rate of pulmonary O2 consumption 
(VO2) at rest (Vallerand et al., 1989), this was attenuated at altitude (3,350m and 4,360m), 
a response reported to be sustained over a 6 week period, only being recovered upon 
descent (Blatteis et al., 1976). Reliance upon shivering thermogenesis has been reported to 
increase in hypoxia, both in response to acute (90 mins) cold exposure at  12% O2 and a 
longer term (6 week) exposure to both 3,350 and 4,360m (Robinson et al., 1990, Blatteis et 
al., 1976). Interestingly, the latter study concluded that the combination of suppressed VO2 
alongside increased shivering was indicative of suppression of non-shivering thermogenesis 
during this prolonged period (Blatteis et al., 1976).  
Together, the current literature presents two key points that have been overlooked 
in high altitude research to date: 1. A lack of understanding regarding the physiological and 
metabolic responses of healthy humans to chronic hypoxic exposure  2. The combination of 
hypoxia and cold upon these adaptive responses. Both of these factors are explored in this 
present thesis chapter.  
In this pilot study, a small group (n=5, age 28-54 years) of Trans-Antarctic winter 
trekkers were assessed pre and post a 40-week expedition, during which 24 weeks were 
spent above 2,500m. This study is a continuation of the theme explored in Chapter 2, 
however, the duration of hypoxic exposure, whilst of moderate altitude, far surpasses that 
of Chapter 2. In addition, given the extreme nature of the Antarctic winter with temperatures 
on the high plateau regularly falling below -60˚C (British Antarctic Survey 
https://www.bas.ac.uk/about/antarctica/geography/weather/temperatures/), the degree of 
cold exposure is way beyond that experienced by subjects in Chapter 2. This pilot study is 
therefore a unique investigation into, arguably, the most extreme environment on earth.  
3.2 Aims and objectives 
This applied field study aimed to explore physiological responses of healthy humans 
exposed to the Antarctic winter for a prolonged period. This encompassed chronic hypoxia 
and intermittent exposure to extreme cold. The objectives were to gain a broad 
understanding of physiological changes occurring in response to one of the world’s most 
hostile environments. For the purpose of this thesis, there is a particular focus upon 
metabolic changes and physiological parameters related to these. For this, serum 
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metabolomics analysis was undertaken alongside anthropometric and functional 
physiological measurements to provide a broad characterisation of the response.  
This pilot study is the first to provide an in-depth examination of human physiology to 
prolonged exposure to this extreme environment and so presents as a hypothesis 
generating study. Whilst changes were expected to occur post expedition compared to pre, 
the details of expected changes were uncertain.  
3.3 Methods  
3.3.1 Expedition overview and aims 
 This expedition was the first ever attempted crossing of the Antarctic in the winter 
months. The 5 male subjects (aged 28-54 yrs, BMI pre-expedition 26.36 + 3.87 kg/m2) were 
assessed in the UK prior to and following their 40 week stay in Antarctica, with the attempted 
winter crossing lasting 33 weeks, including 24 weeks above 2,500m. Due to issues that 
severely impaired subject safety, the crossing was halted on week 8. Given difficulties in 
evacuation procedures in the winter months, subjects were subsequently forced to set up 
winter camp. Living cabins/cabooses were taken along with the expedition on caterpillar 
trucks. Once winter camp was established, subjects spent the majority of their time residing 
within the cabins, only being exposed to the outside elements intermittently.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
Subjects recorded food diaries and body weight data throughout the expedition. An 
array of measurements were also taken at King’s College London pre and post expedition 
that included: assessment of metabolic profile, body composition, exercise and lung function 
testing.  
3.3.2 Ethical approval  
Prior to participation, written informed consent was obtained from all subjects. All 
procedures were approved by the National Health Service Wandsworth Research Ethics 
Committee (reference number: 12/LO/0457) and conformed to the Declaration of Helsinki.  
3.3.3 Study design  
Pre-testing was conducted at King’s College London on 12th December 2012, after 
which subjects spent a 40-week period in Antarctica, beginning on January 22nd. The 
attempted winter crossing expedition, outlined in Figure 3.1, began with departure from 
Crown Bay on 21st March and lasted 33 weeks. During this time, subjects spent weeks 5-29 
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above 2500m and reached the highest altitude of 2,824m on week 8. The crossing was 
halted on the 9th May and winter camp established on 30th May (week 11) at 2,752m. 
Subjects remained here until week 28, after which subjects began their descent. The final 
point near Belgian Princess Elizabeth Station (1,367m) was reached on week 32, being 1st 
November 2013. Subjects remained here until 23rd November, at which point they flew 




Figure 3.1. A diagrammatic representation of altitude exposure during the attempted 
Antarctic winter crossing expedition 
The 33 week attempted crossing was measured from the point at which subjects departed 





3.4.4 Measurements taken during the expedition 
Dietary intake and activity 
 Water intake (ml/day) and food intake were recorded, the latter as total energy intake 
(kcal/day), broken down to: protein, fat and carbohydrate (g/day). These values were 
obtained through weighed food diaries, taken across a 7-day period at 17 points within the 
attempted crossing time (33 weeks). Body weights were also recorded at these same 
periods using digital balance scales (model details not available) following an overnight fast 
and voiding of urine.   
 Outside activity data were obtained from diary records taken across a 7 day period 
at 8 time points within the attempted crossing time. A subjective scale was used to estimate 
duration of light and heavy work undertaken during these periods. Light work was roughly 
defined as walking or general camp maintenance and heavy work as, for instance, shoveling 
snow. Given the degree of subjectivity and lack of accuracy, this measure was merely used 
as a broad estimation and general overview of subject activity levels.   
 Both food and activity data are presented as an average over the 7 day periods to 
present intake or activity on a ‘typical’ day.   
3.3.4 Measurements taken at King’s College London 
Serum samples 
Serum samples were taken from fasted subjects at rest (in the morning, prior to the 
exercise protocol) pre and post expedition. They were obtained by venesection in serum 
separating tubes and immediately spun for 10 minutes at 520g at 4◦C.  The resulting 
supernatant was pipetted into 2ml polypropylene cryotubes, and immediately frozen at -
80◦C.   
1H-NMR serum metabolomics 
For analysis, serum samples were defrosted at room temperature and centrifuged at 
16,000g for 10 minutes. The supernatant was aliquoted, leaving the pellet, and the spin 
repeated. A 300 µl aliquot of the resulting supernatant was then mixed with 300 µl of NMR 
buffer (250 µl DSS plus phosphate buffered saline (PBS) at a concentration of 5 mM added 
to 50 µl 99.9% D2O). The final solution contained 8 % D2O for the magnetic lock. The 
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resulting mixture was transferred to 5mm NMR tubes within a 96-tube rack ready for spectral 
acquisition. 
NMR spectral acquisition  
The same methodology was adopted as used in Chapter 2 (2.4.3). Given the small 
number of samples, all were run in the same experiment.   
NMR data processing 
Data were Fourier transformed using an exponential window function with a line 
broadening of 0.3Hz in the frequency domain. Spectra were converted from time to 
frequency domain using serial processing and subsequently phase corrected and aligned, 
with chemical shifts being manually referenced to DSS (at δ = 0 ppm), in ACD labs (ACD 
Labs Software.Ink), before being imported into Matlab (Mathworks, Natick, MA) at full 
resolution. Following this, spectra were normalised using probabilistic-quotient 
normalisation (Dieterle et al., 2006) and binned using adaptive intelligent binning (De Meyer 
et al., 2008), both in Matlab.  
NMR Data Analysis 
Given the hypothesis generating nature of this study, an untargeted approach was 
adopted to assesssubjects’ metabolic profiles, with changes being identified initially through 
principal components analysis. Principal component 2 (PC2) was shown to capture 30% of 
variance in the metabolic profiling data. Within this, the peak integrals of glucose and the 
shoulder of the fatty acid CH2 resonance underwent a significant decrease post expedition, 
as tested using a paired Sample T test (see 3.3.10). Identification of the metabolites 
associated with the peaks undergoing significant changes was undertaken using Chenomx 
software (Chenomx NMR Suite 7.1). 
3.3.5 Cardio pulmonary exercise testing  
Maximal oxygen uptake (V̇O2max) was determined using a continuous exercise test 
on a cycle ergometer (Lode Coriva, Lode, Groningen, Netherlands).  Breath-by-breath 
measurements of O2 and CO2 concentrations as well as volume of expired air were recorded 
continually throughout the test (Oxycon Pro; CareFusion, Basingstoke, U.K.).  Subjects 
wore a face mask to which the volume and gas sensors were attached. The O2 and 
CO2 analysers were calibrated with known gases in accordance with the manufacturers’ 
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guidelines.  A 3 L syringe was used to calibrate the volume sensor before testing 
commenced.  
Subjects initially cycled at a work rate of 50 W for 3 mins after which the power output 
continually increased until the subject could no longer continue despite verbal 
encouragement.  The rate of increase of power output (1 – 2W every 3 – 5 s) was estimated 
for each subject such that maximal effort would be reached within 10 – 12 min.  The subjects 
cycled at constant self-selected rate typically between 75 – 80 rpm.  Heart rate was 
continually monitored throughout the test using a 12 lead ECG.  VO2max was determined as 
the greatest O2 uptake recorded over a 20s period at the end of the test. To ensure a valid 
V̇O2max was attained subjects had to meet at least two of these criteria: 1) achievement of 
maximum heart rate greater than age predicted maximum (220 - Age), 2) a respiratory 
exchange ratio of >1.15 and 3) a plateau in VO2 indicated by an increase in VO2 of no more 
than 100ml/min in the final two 20 s periods of the test.  Ventilatory threshold (VT) was 
determined using a combination of the v-slope method (the point where a clear steeper 
increase in V̇CO2 compared to V̇O2 occurs) and the ventilatory equivalent method (the point 
where V̇E/V̇O2 rises without a concomitant rise in V̇E/V̇CO2).  VT was assessed by 2 
independent investigators with any differences between the two resolved by a third 
investigator when necessary (Gaskill et al., 2001).  
Respiratory exchange ratio 
Calculated from breath by breath measurements of CO2 and O2 concentrations taken 
during the maximal O2 uptake (VO2 max) test. To capture changes in RER across each 
percentile of the VO2 max test, the area under the curve was assessed for each subject for 
the full exercise duration.  
3.3.6 Body composition 
Subject height and mass were determined using a stadiometer and calibrated 
balance beam scales, respectively. Bone mineral density (BMD) of the whole body, hip and 
lumbar spine was assessed by dual-energy X-ray absorptiometry (DXA) using a Hologic 
Discovery A scanner (Hologic, Bedford, MA).  Fat mass and fat free mass were also 
determined from DXA scans. 
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3.3.7 Resting Cardiovascular Function 
Upon arrival at the laboratory resting cardiovascular function was assessed using a 
Finometer Pro (Finapres Medical Systems, Amsterdam, Netherlands) with a finger cuff 
attached to the middle finger of the right arm.  Systolic (SBP), diastolic (DBP) and mean 
arterial pressure (MAP) were recorded once every minute for 5 min at the end of a period of 
15 min of quiet supine resting, as was resting heart rate. Average values of each variable 
were calculated. 
3.3.8 Lung Function 
 The greatest peak expiratory flow (PEF), forced vital capacity (FVC), forced 
expiratory volume in 1s (FEV1) and FEV1/FVC% were recorded using an Oxycon Pro 
(CareFusion, Basingstoke, U.K.) calibrated prior to use.  Subjects were instructed to inhale 
rapidly to total lung capacity and then without pausing exhale as forcefully as possible until 
no more air can be expired.  Subjects were seated and required to maintain an upright 
posture during all manoeuvres which were performed in accordance with the ATS/ERS 
Guidelines (Miller et al., 2005).   
3.3.9 Maximal voluntary muscle strength 
Maximal voluntary strength (MVC) was assessed in the knee extensors of the 
dominant limb.  Subjects were seated upright with their arms folded in a custom-built 
dynamometer with their knee in 90º of flexion.  Their lower leg (~3cm proximal to the ankle) 
was strapped in a padded steel brace attached by a rigid bar to a strain gauge.  Signals from 
the strain gauge were recorded on Spike 2 software via an analogue-to-digital converter 
(Cambridge Electronic Design (CED) 1401, U.K.) at a sampling rate of 2 kHz.  Percutaneous 
stimulating electrodes (8 x 12 cm) were strapped around the distal and proximal segments 
of the quadriceps and attached to a constant current stimulator delivering square wave 
stimulation (pulse width 0.2 ms at 400 V; Digitimer Stimulator DS7, Digitimer Ltd., U.K.). 
Waist and shoulder straps were used to minimise any hip or upper body movement. The 
distance from the centre of rotation of the knee joint to the steel brace was measured to 
allow torque to be calculated.   
The testing procedure began with determination of the maximal twitch response.  
Current was increased in a stepwise manner until no further increase in torque was 
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observed.  After a brief rest subjects performed 6 MVCs.  Subjects were asked to generate 
maximal force as quickly as possible and hold the contraction for 3-4 s.  Strong verbal 
encouragement and visual feedback from a monitor placed in front of the subject were given. 
At least 1 min of rest was given between each contraction.  During three of the maximal 
effort contractions a maximal electrical impulse was delivered to the muscle. The greatest 
MVC was used for analysis.   
3.3.10 Statistical analysis  
The low subject numbers in this study mean that the emphasis of data interpretation 
is in the observed trends. However, statistical tests were still performed in order to gauge 
the degree of change. As this data set contains insufficient numbers for normality testing, a 
Gaussian distribution was assumed and differences in physiological variables pre to post 
expedition were identified using a paired Student T test. To display the trends of the data, 
the individual responses are presented. Correlations between Δ metabolite change and Δ 
AUC RER were examined using a Pearson correlation coefficient. Statistical analysis and 
generation of graphs was conducted in Graphpad Prism.  
3.4  Results 
3.4.1 Food intake, activity and body weight data recorded 
during the expedition 
Dietary intake was recorded throughout the winter expedition through food diaries 
kept by each subject. This analysis revealed details of nutrient intake on a daily basis, 
detailed in Figure 3.2A. Total protein intake was 108.67 + 18.17 g/day (+ SD), carbohydrate 
intake 350 + 101 g/day and fat intake 122 + 25 g/day. Total energy intake was an average 
(mean) of 2871.8 + 543.1 kcal/day (Figure 3.2B). Water intake was kept relatively constant 
(2,167.0 + 649.6 ml/day) from weeks 1-20 (Figure 3.2C). Following this, from weeks 22-33, 
water intake increased as did the inter-individual differences, reflected by the increasing SD 
(3,294.2 + 934.0 ml/day). 
Exposure to the outside varied throughout the expedition and also significantly 
between subjects. Total time spent outside averaged 153 + 94 mins/day (Figure 3.3A). This 
was divided into a broad estimation of light and heavy work (Figure 3.3B), which averaged 
128 + 80 mins/day and 44 + 48 mins/day respectively. A drop in average activity levels can 
be observed following week 11, which coincides with the point at which winter camp was 
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established. This then increased once descent from winter camp was underway (week 28). 
Light work was also performed inside and was sustained at 60mins/day for each subject 
throughout the duration of the expedition.  
Body weight data obtained during the expedition revealed an average decrease of 
2.56 +2.15 kg from week 1 to week 32 Figure 3.4. Statistically, this difference was close to 







































































Figure 3.2. Nutrient (A), energy (B) and water (C) intake expressed as daily values 
throughout the winter expedition duration. 
Nutrient intake is broken down into protein, fat and carbohydrate (CHO) intake. Data 
were collected each day over the 7 day period on the expedition week specified and is 





Figure 3.3. Work performed outside throughout the winter expedition duration 
Depicted as total work performed (A) and as an estimate of the division between heavy and 
light work (B). Data were collected each day over the 7 day period on the expedition week 






































































3.4.2 Pre: post expedition measurements 
Metabolic profile changes 
The spectra produced from 1H-NMR metabolomics analysis of serum pre and post 
expedition were overlaid, as shown in Figure 3.5.  Multivariate statistics revealed a reduction 
in principal component 2 (PC2) post expedition, which captured 30% of variance in the 
metabolic profiling data (Figure 3.6). The separation of variables by PC2 is demonstrated 
in Figure 3.7. Within PC2, peaks corresponding to glucose and a fatty acid CH2 resonance 
underwent significant decreases by 35.9 (+ 22.9) % and 39.6 (+ 20.6) % respectively 
(p>0.05) (Figure 3.8, detailed in Table 3.1). Unfortunately, it was not possible to identify the 
subtype of fatty acid from which this resonance was derived.  
Anthropometric and functional physiological measurements 
The anthropometric and physiological measurements taken pre and post expedition 
and are summarised in Table 3.2. No significant change in body weight was observed post 
expedition in comparison to pre (Figure 3.9A). Equally, no significant change was observed 
in BMI pre to post expedition (26.4 + 3.9 vs. 26.0 + 3.5 kg/m2). However, changes were 
observed in body composition post expedition, with an increase in % lean and decrease in 
% fat tissue by 2.1(+ 0.8) % (p<0.05), displayed as average values (Figure 3.9B) and 
individual values (Figure 3.9B.C). This change was also reflected in the decrease in body 
fat by 11 (+ 5) % (p˂0.05) (Figure 3.9E). In addition, a 1.8 (+ 0.9) % decrease (p<0.05) was 
observed in spine BMD (Figure 3.9F).  
Lung function measurements revealed no significant change in either FEV1 (L) or 
FVC (L).  However, FVC numerically increased in all subjects post expedition, a change that 
was close to significant (p=0.06) and that is reflected in the decrease in the FEV1/FVC% by 
5.8 (+ 3.3) % post expedition (p<0.05) (Figure 3.9G).  
Regarding cardiovascular measures, no significant changes were observed in 







Figure 3.5. An average 1H-NMR spectra taken from all subjects. 
Pre expedition (black) overlaid with post expedition (red). Highlighted are the peaks 





































Figure 3.7. Scores plot of principal components 1 and 2.  
Green corresponds to pre expedition and red post.  
















































Changes in CH2 fatty acid resonance peak





















Changes in glucose peak integral
pre to post expedition
Variable Mean Pre (+SD) Mean Pre (+SD) Difference (+SD) P value 
Fatty acid CH2(n) 
peak 
0.05 (0.013) 0.028 (0.010) -0.018 (0.013) 0.038* 
Glucose peak 0.045 (0.012) 0.029 (0.009) -0.016 (0.016) 0.033* 
Note: Respective metabolites were identified within principal component 2 following 1H-
NMR spectral analysis. 
Figure 3.8. Peak integrals undergoing significant decreases within principal 
component 2. 




Table 3.2. Summary of changes in anthropometric variables, resting lung function and 
















Note: BMD- bone mineral density; FVC - forced vital capacity; FEV1-forced expiratory 
volume in 1 second, bpm- beats per minute, sBP – systolic blood pressure, dBP- diastolic 
blood pressure, MAP – mean arterial blood pressure.  n=4-5, values presented as mean + 
standard deviation, *denotes significance, p<0.05.  
  
Variable Mean Pre (+SD) Mean Post (+SD) Difference P value 
% Lean tissue  79.3 (3.7) 81.4 (3.0) 2.1 (0.8) 0.015* 
% Fat tissue 20.7 (3.7) 18.6 (3.0) -2.1 (0.8) 0.015* 
Body fat (kg) 16.0 (4.7) 14.0 (3.7) -2.0 (1.1) 0.034* 
Body weight (kg) 77.9 (9.58) 76.9 (9.3) -1.02 (2.5) 0.41 
Spine BMD g/cm2 1.2 (0.05) 1.13 (0.04) -0.02 (0.01) 0.035* 
FVC (L) 6.38 (1.29) 7.11 (1.88) 0.72 (0.62) 0.060 
FEV1 4.29 (0.65) 4.34 (0.71) 0.05 (0.22) 0.661 
FEV1/FVC% 68.2 (9.7) 62.4 (8.4) -5.8 (3.3) 0.016* 
Heart rate (bpm) 60 (6) 63 (7) 3 (7) 0.39 
sBP 123 (6) 121 (5) -2 (8) 0.61 
dBP 72 (8) 75 (9) 2 (6) 0.37 



































































































































































Figure 3.9. Anthropometric and physiological measurements taken pre and post 
expedition. 
Individual body weight (kg) B. % lean and fat tissue, presented as mean values (+ SD) C. 
Individual subject values for % fat and D. lean tissue, E. body fat, F. spine BMD (bone mineral 




Exercise data  
 Physiological measures related to exercise are displayed in Table 3.3. Examination 
of maximal muscle strength in the dominant leg revealed an increase in all subjects bar one 
post expedition (Figure 3.10). The trend towards an increase was reflected in the p value 
that was close to significance (p=0.06). 
An 11.6 (+1.9) % increase (p>0.001) was observed in VO2 max corrected to lean 
mass post expedition vs. pre (Figure 3.11A). Similarly, numerical increases in VO2 max 
corrected to total weight were observed in all bar 1 subject post expedition, however, this 
difference was not significant (Figure 3.11B). No difference was observed in maximal heart 
rate during exercise.  
A significant increase was observed in RER. This was recorded at each percentile 
of the VO2 max test and the area under the curve (AUC) for each subject was calculated. A 
7.8 (+ 3.6) % increase (p>0.01) in AUC for RER was observed post expedition compared to 
pre (p<0.01). The average (mean) response of the group is depicted in Figure 3.11C, with 
individual differences displayed in Figure 3.11D.  
To examine whether a relationship existed between the identified changes in serum 
metabolites and the AUC for RER, these variables were correlated. No significant 
relationship was observed between Δ glucose peak integral (Figure 3.12A) or Δ fatty acid 
peak integral vs. Δ AUC RER (Figure 3.12B). However, the relationship displayed in Figure 
3.12B appears to be indicative of a possible linear association between Δ fatty acid and Δ 
AUC RER, in spite of the high r2 and p value (r2 = 0.62, p=0.11). This would therefore be 




   
Table 3.3. Summary of changes in exercise parameters pre and post expedition. 
 
 
Figure 3.10. Maximal voluntary contraction pre and post expedition 























Variable Mean Pre (+SD) Mean Post 
(+SD) 
Difference (+SD) P value 
VO2 max (L/min) 3.2 (0.6) 3.5 (0.4) 0.2 (0.3) 0.163 
VO2 max (ml/kg/min) 42.1(4.9) 45.5 (3.8) 3.38 (5.3) 0.187 
VO2 max (ml/kg lean 
tissue) 
50.4 (5.1) 56.1 (5.0) 5.8 (0.6) 0.0003*** 
Max heart rate (bpm) 191.6 (5.6) 189.6 (5.1) -2.0 (6.8) 0.546 
AUC RER 8.85 (0.30) 9.54 (0.26) 0.68 (0.31) 0.007** 
MVC (Nm) 204.5 (16.7) 226.5 (33.9) 22.0 (27.7) 0.062 
Note: VO2 – pulmonary oxygen uptake; bpm-beats per minute; bpm-beats per minute RER- 
respiratory exchange ratio; AUC- area under the curve, MVC – maximal voluntary 
contraction; Nm- Newton meters. n=4-5, values presented as mean + standard deviation, 






Figure 3.11. Maximal rate of oxygen consumption (VO2 max) and respiratory 
exchange ratio (RER) 
As measured through an incremental exercise test, pre and post expedition, presented as 
individual values. A. VO2 max corrected to % lean mass B. VO2 max corrected to total 
weight. C. Average RER (+ SD) presented at each 10th percentile of a VO2 max test, D. Area 
under the curve (AUC) for RER both pre and post expedition values, presented for each 









































































































Figure 3.12. Correlation plots for Δ glucose (A) and fatty acid peak integrals (B) (pre: 
post expedition) vs. respiratory exchange ratio area under the curve (RER AUC). 








































The Antarctic winter is amongst the most extreme environments on earth and 
presents significant physiological challenges. Upon the Antarctic plateau, high altitudes (and 
so hypobaric hypoxia) are combined with monthly mean temperatures falling below -60°C. 
This pilot study aimed to investigate the effects of prolonged exposure to this environment 
upon an array of physiological parameters. Measurements obtained from subjects pre and 
post expedition revealed metabolic profile changes occurring alongside alterations to body 
composition, exercise capacity (corrected to lean mass) and lung function. 
Assessment of serum metabolic profile and RER during incremental exercise pre 
and post expedition revealed evidence indicative of metabolic remodelling and possible 
shifts in substrate utilisation.  Specifically, metabolomics analysis of serum demonstrated 
decreases in the peak integrals for glucose and a fatty acid CH2 resonance. Alongside this 
is the increase in RER, which is thus suggestive of a shift towards carbohydrate oxidation 
during exercise.  
The exact causes or consequences of these shifts are unclear. Given that dietary 
intake remained relatively constant throughout the expedition, this suggests that such shifts 
are provoked by environmental factors as opposed to dietary changes. However, this 
interpretation is limited as both dietary data and activity data are lacking from the time of 
pre-expedition, meaning there is no baseline measurement for either. The assumption is 
therefore made that these subjects sustained similar nutrient take and level of activity prior 
to the expedition as during. 
 The observed changes may instead be indicative of hypoxic and/or cold adaptation. 
Alterations in carbohydrate and fat metabolism have been identified as having a key role 
both in response to hypoxic (Horscroft et al., 2014) and cold exposure (Vallerand et al., 
1989, Stocks et al., 2004). Indeed, results from the previous chapter go to support this, with 
significant shifts being identified in plasma glucose as well as various lipids in response to 
short term progressive hypoxic exposure. Given the nature of high altitude environments, 
this is inextricably linked to a drop in ambient temperatures. Together with the present study, 
these results therefore suggest changes in carbohydrate and fat metabolism play a key role 
in shaping the response to a combination of hypoxic and cold exposure.  
 Specifically relating to cold exposure, increasing RER has been reported in 
response to acute cold exposure (Vallerand et al., 1989), although this finding is not 
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consistent (Timmons et al., 1985). Similar disparity is also apparent in hypoxic studies, likely 
due to differences in duration and severity of hypoxic exposure (McClelland et al., 1998).  
No prior studies appear to have examined exercise RER measurements in response to such 
chronic exposure as is presented here. 
This shift in metabolic signature may also be reflected through the observed changes 
in anthropometric measures. This revealed a decrease in % and kg of body fat and an 
increase in % lean tissue. As dietary intake remained constant, with proportions of fat, 
carbohydrates and protein as well as overall intake remaining within recommended daily 
levels (Trumbo et al., 2002), it again suggests such alterations resulted from environmental 
exposure as opposed to dietary changes. The loss of fat tissue may be indicative of 
alterations to lipid storage capacity. Indeed, results from Chapter 2 indicate that the 
processes of de novo lipogenesis may be impaired with progressive hypoxic and cold 
exposure. This concept would align well with the shifts away from fat towards carbohydrate 
utilisation, as indicated by the RER results of the present study. However, neither the causes 
nor consequences of these changes in body composition are clear. 
Previous high altitude studies reveal mixed results regarding body composition 
changes, with some reporting an initial loss of fat mass followed by lean and others vice 
versa (Guilland et al., 1985, Boyer et al., 1984, Rose et al., 1988). Interestingly, these prior 
studies tend to observe that changes in body composition are accompanied by a loss of 
body weight, the degree of which increases with increasing altitude severity (Rose et al., 
1988, Boyer et al., 1984, Guilland et al., 1985).  For instance, Caucasian subjects exposed 
to 5400m demonstrated a 1.5-1.9kg loss in body weight, which increased to 3.4-4kg at 
7100m (Boyer et al., 1984, Guilland et al., 1985). However, weight loss at altitude is not 
reported across all studies, with subjects being exposed to 3,454m for 28 days reporting no 
change in either body weight or fat mass (Jacobs et al., 2012). This therefore indicates that 
maintaining body weight becomes an issue at more extreme altitudes (above ~3500m) and 
may result from the commonly reported loss of appetite (Vats et al., 2004). The lack of weight 
change in the subjects of this present study, both during the expedition and measured pre 
and post, may therefore be due to the altitude exposure being at the lower end of the 
spectrum (2500m). The consistent nutrient intake reported by the present subjects suggests 
loss of appetite was not experienced. The lack of body weight change may also be reflective 
of the prolonged nature of the study, with body weight stabilising over the duration of the 
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expedition as subjects acclimatised, a trend indicated through body weight changes 
recorded throughout the expedition.   
At a functional level, the apparent shift in metabolic signature and body composition 
were accompanied by significant improvements in VO2 max corrected to % lean tissue. 
Although not significant, trends were also observed for increasing MVC and FVC in most 
subjects post expedition, the latter contributing to the significant increase in FEV1/FVC. 
Together, these changes may indicate a possible training effect. This may be a 
consequence of increasing physical exertion, however it is not possible to derive such a 
conclusion in the absence of baseline activity levels and accurate measures of exercise 
severity. Equally, such measures could reflect potential benefits of hypoxic adaptation upon 
O2 delivery, for instance resulting from increasing erythropoiesis and angiogenesis 
(Rodriguez et al., 1999, Shweiki et al., 1992). However, further investigation is required 
before a firm conclusion can be derived.   
Given previous reports of the effects of extreme environmental exposure upon lung 
function, it may perhaps appear surprising that FVC tended towards an increase.  Cold 
exposure is known to have a detrimental impact upon lung function (Cotes et al., 2009). In 
addition, prior altitude studies demonstrated a decrease in resting FVC levels, accompanied 
by no change in FEV1 (Welsh et al., 1993, Ziaee et al., 2008). In the instance of the study 
conducted by Welsh and colleagues, this measure was taken at extreme altitudes (8,848m) 
and was linked to an increase in chest fluid due to an increase in both pulmonary blood 
volume and interstitial edema fluid (Welsh et al., 1993). The translation to the current study 
is therefore limited given the moderate height of altitude and the fact that spirometry 
measures were conducted at sea level, meaning altitude induced obstruction is not relevant. 
Another anthropometric measurement noted to undergo a change that is somewhat 
set aside from metabolic or performance measures was spine BMD. This underwent a 
significant decrease post expedition. Although this decrease was slight, such minor changes 
have been related to increasing fracture risk, so are of high importance (Nguyen et al., 1993).   
Whilst the causes are not clear, there are numerous possibilities, including effects of hypoxia 
upon the regulation of bone density (Arnett et al., 2003, Utting et al., 2006) including HIF-1α 
regulation of osteoclast (Knowles, 2015). Other factors known to impact BMD include 
decreases in activity levels (Mazzeo et al., 1998, Vuori, 2001), which is not the case here 
given that subjects maintained a certain degree of activity throughout and in fact displayed 
an improvement in exercise parameters upon their return. A more plausible possibility is the 
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effect of dietary changes, particularly changes in Ca2+ (Kelly et al., 1990), vitamin C 
(Aghajanian et al., 2015) and D (Bischoff-Ferrari et al., 2004). Whilst energy intake was 
reported to remain constant throughout, details on Ca2+, vitamin C and D intake were not 
recorded, meaning no conclusion can be drawn.  
Another factor that may have altered BMD is the altered day-night cycle, with 
darkness prevailing in the Antarctic winter months. As most humans depend upon sunlight 
exposure to satisfy their vitamin D requirements (Holick, 2004), it is highly likely that the 
subjects of this study, with their prolonged lack of sunlight exposure, suffered from 
insufficient vitamin D levels. This would in turn likely be detrimental to maintenance of BMD.   
3.5.1 Study limitations 
 This study presents a highly unique and novel exploration of the effects of an 
inhabitable environment upon human physiology. It employs a comprehensive 
characterisation of physiological changes. However, given that the main aim of the 
expedition was to cross Antarctica as opposed to conducting a robust scientific experiment, 
there are numerous limitations in the study design that in turn impact the ability to deduce 
meaningful conclusions from the data set.  
 Firstly, the small subject numbers severely limits statistical power, meaning that one 
outlier in a data set can have a profound effect upon the degree of significance. This was 
demonstrated in measures of VO2 max corrected to total body weight and also MVC, 
whereby the response of 1 subject in the opposite direction to the rest of the group likely 
impacted the statistical outcome.  
 Secondly, the means by which physiological measures were taken markedly impacts 
interpretation. The majority of measures were taken in London pre and post expedition. 
Measures that are prone to rapid fluxes, including metabolic profile and to a lesser extent 
body composition and lung function, are thus unlikely to fully reflect the impact of the 
Antarctic winter environment. This is less of a concern for measures of MVC and perhaps 
also exercise performance, given that previous studies demonstrating maintenance of 
muscle energetics in response to altitude exposure were conducted a week after the 
subjects returned to the UK (Edwards et al., 2010).   
 The present study is therefore a considerable contrast to that presented in Chapter 
2, where measures (including blood samples) were taken at altitude upon a large cohort 
undergoing a strictly controlled ascent profile.   
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3.6  Conclusion 
This pilot study is the first to provide an in-depth examination of human physiology 
and metabolism in response to prolonged exposure to high altitude in the coldest 
environment on Earth. It has highlighted key areas of interest for future investigations into 
chronic hypoxic and extreme cold exposure. This includes a change in metabolic signature, 
involving alterations to both glucose and fatty acid homeostasis with a shift towards 
increased reliance on carbohydrate metabolism during exercise and a reduction in body fat. 
This was accompanied by an improvement in VO2 max corrected to % lean mass. In 





4 Chapter 4 (Study 3): PPARα 
independent effects of dietary nitrate 
supplementation on skeletal muscle 
mitochondrial function in hypoxia.  
4.1  Introduction 
All oxidative tissues are dependent upon a continuous supply of O2 to maintain 
energetic and redox homeostasis. As already discussed, an inadequate supply of O2, as 
occurs in response to hypoxic exposure thus requires remodelling of metabolic processes 
to ensure the demand for ATP is met. Skeletal muscle is particularly interesting in this 
respect given its high capacity for respiration and for altering metabolic rates. The latter can 
be adjusted in response to exertion or other features such as mitochondrial density or 
substrate preference (Murray, 2009, Kiens et al., 2011).  
As aforementioned, the metabolic remodelling of skeletal muscle in response to 
hypoxic exposure remains a debatable topic. To summarise, studies examining the effects 
of environmental hypoxia in humans and rodents have demonstrated impairment of skeletal 
muscle mitochondrial function, with an attenuation of oxidative processes including β-
oxidation (Viganò et al., 2008, Levett et al., 2012, Roberts et al., 1996, Abdelmalki et al., 
1996, Morash et al., 2013, Galbès et al., 2008), TCA cycle activity (Viganò et al., 2008, 
Green et al., 1989, Abdelmalki et al., 1996, De Palma et al., 2007, Pastoris et al., 1995, 
Magalhaes et al., 2005) and oxidative phosphorylation (Viganò et al., 2008, Levett et al., 
2012, McClelland et al., 2002, De Palma et al., 2007, Pastoris et al., 1995, Jacobs et al., 
2013, Magalhaes et al., 2005, Gamboa et al., 2010)  (see 1.2.4 for details). The effects upon 
glycolytic processes are less clear, with some studies demonstrating an increase in 
glycolytic biomarkers such as lactate dehydrogenase activity, (Green et al., 2000) and some 
a decrease (Green et al., 1992, Viganò et al., 2008, Green et al., 1989, Levett et al., 2012). 
This thus throws into doubt the proposal that the downregulation of oxidative processes 
including fatty acid oxidation is attenuated for by a compensatory shift towards glycolysis, 
as has been shown in the heart, for instance (Essop, 2007, Cole et al., 2016). 
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 Downregulation of oxidative processes appears to be occurring alongside 
maintenance of mitochondrial density in the short term (<14 days). This is altered in 
response to medium (<42 days) or long term (42d) exposure, where a significant loss of 
mitochondrial density has been observed (Horscroft et al., 2014). It has therefore been 
suggested that hypoxia-induced remodelling of mitochondrial pathways precedes a loss of 
mitochondrial density (Horscroft et al., 2014).  
Developing a means of attenuating the metabolic stress of hypoxia upon 
mitochondrial functioning would be highly beneficial for aiding human adaptation/survival, 
either in response to environmental exposure or pathological states. For this, as outlined in 
section 1.2.7, the potential of dietary nitrate supplementation was investigated.  Specifically 
in this chapter, the focus is upon the effects of nitrate supplementation upon mitochondrial 
function and potential signalling mechanisms.  
Although the potential for dietary nitrate to alleviate hypoxic induced metabolic stress 
has been recognised, the signalling mechanisms of nitrate action in hypoxia remain unclear. 
A mechanism outlined previously in skeletal muscle was reliant upon a master regulator of 
fatty acid oxidation PPARα. Nitrate supplementation was demonstrated to enhance fatty 
acid oxidation capacity (palmitoyl carnitine stimulated respiration) in rat skeletal muscle 
through PPARα  (Ashmore et al., 2015b). Expression levels of PPARα were shown to 
increase dose dependently with nitrate supplementation, a response coupled with a rise in 
PPARα-DNA binding activity and downstream effectors including carnitine palmitoyl 
transferase 1 (CPT1) (Ashmore et al., 2015b). This mechanism was mediated through NO 
activation of the sGC-PKG-cGMP secondary messenger signalling system, with inhibition of 
sGC and the cGMP downstream effector PKG shown to abolish gene expression changes  
(Ashmore et al., 2015b).  
This response is particularly interesting when considering the importance of PPARα 
signalling upon metabolic control, as discussed in section 1.2.4. A consensus on the role of 
PPARα in hypoxia is far from being reached. In particular, the role of PPARα in hypoxic 
skeletal muscle is yet to be sufficiently investigated. Equally, the effects of nitrate 





4.2 Aims and objectives 
The aims of this study were to investigate potential for dietary nitrate 
supplementation to preserve skeletal (soleus) muscle mitochondrial function in hypoxia and 
the involvement of PPARα in this process. For this, a mouse model of PPARα genetic 
ablation (PPARα-/-) was used. Assessment of mitochondrial function in permeabilised mouse 
skeletal muscle fibres was performed following four weeks of severe hypoxic (10% O2) 
exposure with dietary nitrate supplementation. Alongside this was analysis of numerous 
proteins related to skeletal muscle metabolic function.  Analysis focused on investigating the 
following objectives: 
1. Does nitrate supplementation protect skeletal muscle mitochondria function and 
aid hypoxic acclimatisation?  
2. Is PPARα required for this effect? 
An overview of study interventions is outlined in Figure 4.1.  
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4.3  Hypothesis  
Dietary nitrate - supplementation would preserve skeletal muscle mitochondrial 
function in hypoxic conditions and that this process would be reliant upon PPARα.  
Figure 4.1. Diagrammatic summary of study interventions. 
The examination of the interaction between hypoxia, dietary nitrate (NO3-) and PPARα on 







4.4  Methodology background 
Analysis of mitochondrial function is central to the assessment of intracellular energy 
metabolism (Kuznetsov et al., 2008). Below is given a description of the analysis of 
mitochondrial function performed in this study.  This was assessed in situ within selectively 
permeabilised skeletal muscle fibres using a substrate/inhibitor titration to examine select 
mitochondrial pathways/complexes.  The fundamental principles of this polarographic O2 
sensing technique are outlined below and precede the detailed methodology of this study. 
4.4.1 Respirometry 
Cellular respiration is an exergonic reaction during which substrates are oxidised and 
the electron acceptor O2 is consumed in exchange with the environment (detailed in section 
1.2.1). In this study, the consumption of O2 for mitochondrial respiration was measured in 
the soleus using respirometry. The soleus was chosen for a number of reasons. Whilst 
mouse skeletal muscle has a predominating fast twitch fibre type, the soleus does have a 
relatively higher type 1 fibre make up, in turn leading to a high mitochondrial content (Lin et 
al., 2002). Additionally, the effects of nitrate supplementation were demonstrated previously 
in this muscle in rats (Ashmore et al., 2015a) and the assays performed here were shown 
to work effectively in mouse soleus using Clark type O2 electrodes (Morash et al., 2013).  
  Respirometry experiments were performed using a Clark-type electrode 
(Strathkelvin Instruments, UK), which consists of a probe whose tip is exposed to a cathode 
and anode. The electrodes are put into electrolyte (10mM KCl). Upon polarisation of the 
anode and cathode, O2 reacts with water at the cathode and chloride reacts with silver at 
the anode simultaneously, as follows:  
𝑶𝟐 + 𝟐𝑯𝟐𝟎 + 𝟒𝒆
− → 𝟒𝑶𝑯− 
Equation 4.1. Reaction at the cathode 
𝟒𝑨𝒈 + 𝟒‐𝑪𝒍− → 𝟒𝑨𝒈𝑪𝒍 + 𝟒𝒆− 
Equation 4.2. Reaction at the anode 
  
               The result of these reactions is a current flow. For each O2 molecule reduced, 4 e- 
of current will flow through the circuit. This current varies linearly with O2 concentration. The 
system is calibrated with atmospheric O2 (distilled water added to the chamber and allowed 
to equilibrate with atmospheric O2) and in the presence of an O2 scavenger (sodium 
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dithionite). Thus, the detected current is converted to an estimation of O2 concentration 
within experimental range. As the electrodes are located under an O2 permeable membrane, 
this ensures other species do not interfere with the reactions.  
Experiments were performed within two water-jacketed chambers in duplicate to 
control for any differences in electrode performance. Respiratory medium was put into the 
chambers and the biological sample added to this. The chambers were subsequently 
capped, meaning the area for gaseous exchange is minimised as the liquid phase meets 
the gaseous phase within the capillary tube (Figure 4.2). Metabolic substrates and inhibitors 
were added to the chamber in saturating concentrations via the capillary tube, where they 
subsequently titrate with the medium. The temperature of the chambers was regulated at 
37°C via a water bath, via the water-jacketing system, as temperature is known to have a 
large effect on mass corrected respirometry rates of biological samples (Hughes, 1965).  
The cathode consumes O2 at a rate determined by O2 in the chamber medium, which 
is in turn derived from O2 flux into the sample. Thus, negative changes in O2 concentration 
are an indication of O2 consumption by the tissue and are measured as O2 flux (JO2). The 
majority of this consumption is mitochondrial and so falling levels can be attributed to 
mitochondrial respiration. The electrical current, therefore O2 concentration is measured 
over time and a steady state time derivative of O2 concentration is determined for each 














Figure 4.2. The respirometry experimental set up. 
Experiments were run simultaneously in the two water-jacketed chambers, with water being 
heated via the water bath. Fibre bundles were added to the chambers using non-magnetic 
forceps, to avoid displacing the magnetic stirrer within the chamber. Substrates/inhibitors 
were added to the chambers using Hamilton syringes (green for substrates, red for 




4.4.2 Sample preparation  
 There are few options for the preparation of biological samples for respirometry. The 
most physiologically relevant of these methods is the use of intact tissue. This, however, 
has its limitations in that the main mitochondrial effectors are unable to penetrate the cell 
membrane (Kuznetsov et al., 2008). The presence of endogenous ATP means that, in the 
absence of a suitable inhibitor such as oligomycin, ATP synthase is constitutively active. 
These issues can be avoided by the use of either isolated mitochondria or cell 
permeabilisation. The latter was used in this study due to ease and speed of sample 
preparation.  
Selective cell membrane permeabilisation was achieved using the detergent 
saponin. This chemical permeabilisation agent has a hydrophobic steroid core, causing a 











cholesterol per phospholipid in comparison to the mitochondrial outer and inner membranes 
(0.5 mol vs. 0.07 and 0.01 mol respectively), saponin selectively attacks the plasma 
membrane, leaving the mitochondrial membranes intact (Kuznetsov et al., 2008). The pores 
created in the plasma membrane allow for the cytosol and all its solutes, including 
metabolites and cytosolic enzymes such as lactate dehydrogenase, to be washed out. The 
composition of the intracellular space becomes equilibrated with incubation medium, 
meaning functionally intact mitochondria of these permeabilised preparations respond 
quickly to changes in concentrations of substrates and inhibitors added to the medium 
(Kuznetsov et al., 2008).   
4.4.3 Metabolic substrate/inhibitor assays  
The metabolic substrates or inhibitors, added in series, enable the respiratory 
capacity of different components of the mitochondria to be assessed, including: β-oxidation, 
TCA cycle and electron transfer chain. In each assay, O2 consumption/flux (JO2) was 
measured in the following states:   
1. Leak state respiration (LEAK) – JO2 was first measured in the presence of 
substrates, but in the absence of adenylates (so no ADP). In this state, protons 
and electrons are extracted from respiratory substrates during their passage 
through the TCA cycle and/or β-oxidation. These are accepted by the redox 
cofactors nicotinamide adenine dinucleotide (NAD) and flavin adenine 
dinucleotide (FAD) and subsequently donated to the electron transfer 
chain/system (ETS). Transport of electrons along this chain of complexes 
generates the energy required to pump protons into the intermembrane space. 
This results in the generation of a proton motive force (ΔµH+) across the inner 
mitochondrial membrane, driving protons back into the mitochondrial matrix. 
Passage of protons back across the inner mitochondrial membrane in this state 
cannot occur via ATP synthase due to the absence of ATP. It therefore occurs 
either by proton leak across the membrane itself or proton slip via uncouplers or 
the mitochondrial complexes. The resulting dissipation of ΔµH+ will drive a low 
level of flux through the ETS, leading to consumption of the electron acceptor O2 
at complex IV. Thus, ΔµH+ in the LEAK state is not used to drive ATP synthesis. 
The resulting JO2 is due to non-phosphorylating electron transfer, so is indicative 
of maximal ΔµH+ dissipation in the absence of ATP synthesis and is limited by 
proton leak. This measure may reflect inherent physiological inefficiencies that 
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are associated with oxidative phosphorylation. However, non-phosphorylating 
respiration is also thought to have an imperative function in maintaining low ROS 
production (Nicholls et al., 2013) as well as regulating lipids as fuel substrates 
(Samec et al., 1998, Rousset et al., 2004) .  
2. Oxidative phosphorylation capacity, (OXPHOS) – ADP was then added 
in saturating concentrations, enabling the activity of ATP synthase. Passage of 
protons via ATP synthase is a path of lower resistance for protons to re-enter the 
matrix, causing an increased dissipation of ΔµH+ and so in turn a greater JO2. In 
this state, JO2 is limited by either electron donation to the ETS or the OXPHOS 
capacity of ATP synthase. In this study, ADP was added to differing substrate 
combinations in assay 1 and 2 to assess the control of various pathways over 
OXPHOS.     
Assay 1 
 The aim of this assay was to assess the oxidative metabolism of the principle substrates of 
mitochondrial oxidation: fats and carbohydrates, specifically, long chain fatty acid palmitoyl 
carnitine and pyruvate respectively.  
1. Malate: This was added at the start of both assays. Malate is an anion that cannot 
permeate the lipid bilayer of membranes, therefore is transported into the 
mitochondria via di or tri-carboxylate carriers or 2-oxoglutarate exchanger. In the 
matrix, it is converted to oxaloacetate (OAA) and fumarate by the action of malate 
dehydrogenase and fumarase respectively. In the absence of acetyl CoA, OAA 
cannot be converted to citrate, therefore accumulates and inhibits succinate 
dehydrogenase. No further TCA cycle activity can occur and high respiratory 
capacities are not sustainable.  
2. Palmitoyl carnitine: Palmitoyl carnitine enters the mitochondrial matrix via carnitine-
acylcarntine translocase. Once in the matrix, it is broken down to acetyl CoA via β-
oxidation.  In this process, protons and electrons will be accepted by NAD+ to form 
NADH and FAD to form FADH2. NADH will donate its electrons to complex I and 
FADH2 to electron transfer flavoprotein (ETF), which lies down stream of complex II. 
JO2 here is limited by the flux of electrons from β-oxidation, so is a measure of 
capacity for β-oxidation, which was investigated in both LEAK (Figure 4.3A) and 
OXPHOS (Figure 4.3B) states in this study. Dietary nitrate were shown previously 
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to enhance the oxidation capacity for this long chain fatty acid in normoxia, a process 
reliant upon PPARα mediated mechanisms  (Ashmore et al., 2015b).   
3. ADP addition 
4. Pyruvate: The end product of glycolysis pyruvate, a monocarboxylic acid, passes 
into the mitochondrial matrix by the pyruvate carrier in exchange for OH-. Here, it is 
converted to acetyl CoA by pyruvate dehydrogenase. Electrons and protons 
released from this process will be accepted by NAD+ forming NADH, which will pass 
to complex I. In the presence of OAA, derived from the previous addition of malate, 
acetyl CoA is then converted to citrate. JO2 at this stage will be limited by electron 
supply, which is controlled by the activity of TCA cycle enzymes (Figure 4.3C). It is 
thought that JO2 recorded following the addition of pyruvate reflects the capacity of 
TCA cycle flux. However, electron flux will also be influenced in some way by the 
previous addition of palmitoyl carnitine due to convergence of electron flow at 







Figure 4.3. Respirometry assay 1. 
A. Addition of malate and palmitoyl carnitine in the absence 
of ADP, so without the production of ATP. O2 consumption 
therefore reflects leak of protons back across the inner 
mitochondrial membrane.  B. Addition of ADP, thus 
meaning O2 consumption results from oxidative 
phosphorylation. C. Addition of pyruvate, with the ADP 




Assay 2  
The aim of this substrate/inhibitor assay was to assess the function of mitochondrial 
complexes I and II.  
1. Malate: See above 
2. Glutamate: Glutamate is transported into the mitochondrial matrix via the 
glutamate-aspartate carrier. Here, it enters directly into the TCA cycle by 
combining with OAA to form α-ketoglutarate. NADH formed from this process will 
donate its electrons to complex I. Oxoglutarate/α-ketoglutarate is subsequently 
dehydrogenised leading to further NADH production, which will also feed into 
complex I. Complex II function will be inhibited by the production of fumarate from 
malate through product inhibition.  JO2 is thus limited by electron flux through 
complex I, so is indicative of complex I capacity. This was measured both in the 
LEAK (Figure 4.4A) and OXHOS (Figure 4.4B) states in this study.  
3. ADP addition 
4. Rotenone: Rotenone interferes with the flow of electrons by preventing the 
transfer of electrons from complex I to ubiquinone.  
5. Succinate: The addition of saturating concentrations of succinate will drive the 
succinate fumarate reaction forward, leading to maximal electron donation at 
succinate dehydrogenase/complex II. JO2 in this state is limited by complex II 






Figure 4.4. Respirometry assay 2. 
A. Addition of malate and glutamate in the absence of 
ADP, so without the production of ATP. Proton flux 
predominantly passes through complex I. O2 consumption 
therefore reflects leak of protons back across the inner 
mitochondrial membrane. B. Addition of ADP, thus 
meaning O2 consumption results from oxidative 
phosphorylation. C. Addition of the complex I inhibitor 
rotenone followed by complex II substrate succinate. In the 




Membrane integrity check 
At the end of each assay of this study, mitochondrial membrane integrity was 
assessed following the addition of cytochrome c (Cyt c). Cyt c is a loosely bound peripheral 
protein of the mitochondrial inner membrane that shuttles electrons from complex III to 
complex IV. If the inner membrane remains intact, the addition of exogenous cytochrome c 
will not affect respiration. In the instance of inner membrane damage, however, endogenous 
cytochrome c is released from the intermembrane space, inhibiting electron transfer to 
complex IV, thereby inhibiting respiration. The addition of exogenous cytochrome c will thus 
stimulate respiratory rate and restore maximal ADP stimulated respiration. This thus acts as 
a control measure as any tissue that consumed O2 following cytochrome c addition at a rate 
that exceeds 15% of the rate derived from addition of the previous substrate was discounted. 
This thus ensured any fibres damaged in the preparation were removed from analysis.  
Ratios  
From the respirometry data derived from the assays described above, it is possible 
to calculate oxidative coupling efficiency using the following ratios for each assay.   
Assay 1 
To measure the efficiency of mitochondrial coupling during oxidation of a long chain 
fatty acid (palmitoyl carnitine), the following ratio between LEAK and OXPHOS states was 
calculated:    




Equation 4.3. Oxidative coupling efficiency, assay 1 (OCE1). 
LLCFA= LEAK state for long chain fatty acid oxidation 
PLCFA= OXPHOS capacity for long chain fatty acid oxidation 
Assay 2  
 For measuring the coupling efficiency of complex I dependent oxidation, the following 
ratio between LEAK and OXPHOS states was calculated:  




Equation 4.4. Oxidative coupling efficiency, assay 2 (OCE2) 
LCi = LEAK state, complex I 
PCi = OXPHOS state, complex I 
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4.5  Study methodology   
All animal work in this study was conducted in accordance with UK Home Office 
regulations under the Animals in Scientific Procedures Act. Protocols were performed by a 
personal licence holder under a project licence, and had received prior approval from the 
University of Cambridge ethical review board.  
To investigate the role of PPARα, a PPARα genetic ablated (PPARα-/-) mouse strain 
was utilised. The first PPARα-/- mouse with a 129Ev/Sv genetic background was generated 
by homologous recombination, whereby exon 8 of the ligand-binding domain was disrupted 
(Lee et al., 1995). Mice homozygous for this mutation lack the PPARα protein and fail to 
illicit the peroxisome proliferator pleiotropic response when challenged with the PPARα 
agonist WY-14,643. They are viable, healthy and fertile suggesting PPARα is not essential 
for embryonic development. Mice used in this study were kindly donated by Professor Kieran 
Clarke (Physiology, Anatomy and Genetics, University of Oxford). 
For an overview of study design, see  
Figure 4.5 below. Male wild-type 129Ev/Sv (n= 42) and PPARα-/- (n=42) were housed 
in conventional cages from birth in a temperature (23°C) and humidity controlled 
environment with a 12h/12h light/dark cycle. 21 days (d) after birth, mice were weaned and 
pair housed. 38 ± 4d after birth, mice were provided with a standard quality-controlled diet 
RM1 (E) (65.0% carbohydrate, 13.1% crude protein, 3.5% crude fat, 10mg kg-1 NO3-, 
Special diet services) and distilled water ad libitum. 
At 6 weeks of age, mice from both genotypes were randomly assigned to receive 
drinking water supplemented either with 0.7mM sodium chloride (NaCl, Sigma 38979) or 
0.7mM sodium nitrate (NaNO3, Sigma 71752) for the remainder of the study. The former 
was used as a control to nullify the effects of the sodium intake. A concentration of 0.7mM 
was chosen as this was the same nitrate concentration shown previously to enhance β-
oxidation (Ashmore et al., 2015b) and to effectively increase plasma nitrate concentration in 
rodent models (Ashmore et al., 2015a, Ashmore et al., 2014, Ashmore et al., 2015b).  
One week following the initiation of NaNO3 or NaCl treatment, mice were again 
randomly assigned either to remain under normoxic conditions (21%O2) or be housed in 
hypoxic conditions (10% O2) in a normobaric hypoxia chamber (PFI Systems Ltd., Milton 
Keynes, UK). Mice remained in these conditions for four weeks. Nitrate treatment was 
initiated 7d prior to hypoxic exposure in order to normalise circulating nitrate levels prior to 
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hypoxic exposure. Body mass, food and water intake were measured upon initiation of 
treatment, and then weekly henceforth.   
Mice were killed 80 ± 4 days after birth by dislocation of the neck, so the use of 
pharmaceuticals was avoided. From each mouse, one soleus was excised and placed in ice 
cold biopsy preservation solution (BIOPS) (Table 4.1) ready for respirometry experiments. 
The second soleus was put into a cryovial and snap frozen in liquid nitrogen, ready for 
western blotting experiments. A drop of blood was taken from the tail vein and loaded into a 
microcuvette and haemoglobin concentration analysed using a HemoCue Hb 201 Analyzer 






Figure 4.5. A schematic of study design. 
At 6 weeks of age, PPARα+/+ (n=42) and PPARα-/- (n=42) mice were randomly assigned to 
receive drinking water supplemented either with 0.7mM sodium chloride (NaCl) or 0.7mM 
sodium nitrate (NaNO3) for 7 days, given ad libitum. This treatment was continued during 28 
days exposure to either normoxic (21%O2) or hypoxic (10%O2) conditions. Mice were 















Table 4.1. Respirometry solutions 












MES hydrate 50 











Defatted BSA  1g L-1 
 
Note: The above constituents were dissolved in distilled water. The pH was altered with 
drop-wise addition of KOH. Final solutions were filtered, divided into 35ml aliquots and 





4.5.1 Soleus muscle preparation 
Fat and connective tissue were removed and the soleus dissected into 4 thin fibre 
bundle sections in ice cold BIOPS, as shown in Figure 4.6 below. Care was taken during 









 Figure 4.6. A picture of soleus muscle dissection 
Dissection was performed in BIOPS solution on a petri dish that was placed on top of ice. 
Here, the fat and connective tissue have been removed and the muscle dissected into 4 
bundles, as indicated by the arrows. Two of these bundles were used for assay 1 and two 
for assay 2. Following dissection, the fibre bundles were transferred to cryovials for washing 
in MiR solution. 
 
 
Fibre bundles were incubated with gentle rocking for 20mins at 4°C in 1.5ml BIOPS 
supplemented with 15µl of 5mg/L-1 saponin (Sigma Aldrich, 47036) to achieve selective cell 
membrane permeabilisation, leaving the mitochondrial membrane intact (Kuznetsov et al., 
2008). Following permeabilisation, the fibres were washed three times with 1ml of fresh 
respiration medium (MirR, Table 4.1) for 5 minutes per wash at 4°C with gentle rocking.  
The wet weight of the fibre sample was measured before respirometry analysis. The 
fibre bundle was first blotted dry on filter paper before being weighed on a microbalance 
(Mettler Toledo). To ensure consistency, each bundle weighed between 0.5-1.5mg.   
4.5.2 Soleus respirometry assays 
For respirometry analysis, fibre bundles were added to 500µl atmospheric O2 




(Strathkelvin Instruments, Motherwell, UK). Respiration rates were analysed in two assays 
by substrate or substrate/inhibitor titrations. Two fibre bundles were used per assay, run 
simultaneously, 1 per chamber. Measurements taken on the Strathkelvin were normalised 
to the wet weight of the tissue and volume of fluid in the chamber.  
Assay 1 
This assay was adapted from that described previously (Heather et al., 2012), with the 
aim of examining the oxidative metabolism of long chain fatty acids and that of 
carbohydrates. JO2 was measured after addition of each of the following substrates once 
steady state was reached:    
 Malate (2mM) and palmitoyl carnitine (40µM) (LEAK) 
 Palmitoyl carnitine 
 ADP (10mM) was then added to stimulate ATP synthesis (OXPHOS).  
 Pyruvate (5mM) (OXPHOS).  
 Cytochrome c (10µM) was added in order to assess the integrity of the mitochondrial 
membrane.  
Assay 2 
This assay was again adapted from previously described protocols (Pesta et al., 2011, 
Jacobs et al., 2012), with the aim of assessing complex I and II function. JO2 was measured 
in steady state response to the addition of the following:  
 Malate (2mM) and glutamate (10mM) (LEAK at complex I) 
 ADP (10mM), ATP synthesis stimulated (OXPHOS complex I) 
 Rotenone (0.5µM), potent complex I inhibitor 
 Succinate (10mM), complex II substrate (OXPHOS, complex II).  
 Cytochrome c (10µM) 
4.5.3 Tissue homogenates preparation  
 Once the respirometry assays were complete the contents of the electrode chambers 
were combined and transferred to a beaker, this included the remaining tissue and the MiR 
solution.  The chambers were then washed in MiR to ensure all the tissue was collected. 
This was added to the beaker making a total volume of 2ml. 20mg of protease inhibitor 
(cOmplete Protease Inhibitor Cocktail, Roche) was added to this solution along with 20µl 
Triton X-100 (1%).  This was then homogenised at 25,000rpm for 30s using a Polytron (PT-
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10-35 GT Kinematic Inc. Switzerland). 1ml of the resulting homogenate was frozen at -80°C 
to be used for determination of CS activity and fibre type.  
4.5.4 Citrate synthase (CS) activity  
CS activity in the tissue remaining from respirometry experiments was measured as 
described previously (Houle-Leroy et al., 2000, Morash et al., 2013) by using a 
spectrophotometer and measuring changes in absorbance of light over specific lengths of 
time.  
CS assay  
100µl of the homogenised sample recovered from respirometry was added to 825 µl 
CS assay buffer (20 mM Tris (Fisher BP152-1), 0.1 mM 5,5’-dithiobis-2-nitrobenzoic acid 
(DTNB, Sigma D8130), pH 8.00) and 25µl of 12 mM Acetyl CoA (Sigma A2056). A magnetic 
stirrer was added to the cuvette, before warming to reaction temperature (37°C) for 3 
minutes in the spectrophotometer (Evolution 220, Thermo Scientific). Baseline 
measurements were taken for 3 mins before 50µl of 40mM oxaloacetate (40mM oxaloactete, 





𝐴𝑐𝑒𝑡𝑦𝑙 𝑐𝑜𝐴-𝑆𝐻 + 𝑂𝑥𝑎𝑙𝑜𝑎𝑐𝑒𝑡𝑎𝑡𝑒 +  𝐻2𝑂 → 𝑐𝑜𝐴-𝑆𝐻 + 𝐶𝑖𝑡𝑟𝑎𝑡𝑒 
Equation 4.5. Citrate synthase assay reaction 1. 
 
𝑐𝑜𝐴-𝑆𝐻 + 𝐷𝑇𝑁𝐵 → 𝑇𝑁𝐵2− + 𝑐𝑜-𝑆-𝑆-𝑇𝑁𝐵 
Equation 4.6. Citrate synthase assay reaction 2. 
 
Reaction 1 is catalysed by CS, thus meaning its rate is dependent on CS activity 
within the sample. This is coupled to reaction 2 as the product coASH reacts with DTNB to 
produce the absorbing substance TNB2-. This was quantified by measuring the absorbance 
of light at a wavelength of 412nm for 9 minutes following the addition of oxaloacetate. 
Recordings were taken once the reaction reached a steady state. The baseline recordings 
were subtracted from this reaction rate to calculate the enzyme-dependent rate of 
absorbance change. The following reaction was used to calculate enzyme activity:  
𝑱 =
𝒓(𝑨) × 𝑽
𝒍 ×  𝜺
 
Equation 4.7. Calculation of citrate synthase enzyme activity. 
𝐽:  Rate of reaction (μmol min-1) 
𝑟(𝐴): Rate of absorbance change (min-1) 
𝑉: Reaction volume (ml) 
𝑙: Light path length (cm) 
𝜀: Extinction coefficient (ml μmol-1 cm-1) 
The extinction coefficient, ε, was 13.6 and 6.22 ml μmol-1 cm-1 for DTNB. 
 2mM acetyl CoA was then added and measurements taken for 6 minutes to confirm 
the CS reaction had reached saturation. A negative control was performed to ensure the 
reaction was due to CS activity.  
4.5.5 Soleus muscle myosin heavy chain (MyHC) isoform 
determination 
Skeletal muscle is a highly heterogeneous tissue consisting of a variety of slow and 
fast fibre types. Major differences between fibre types, such as twitch speed and metabolic 
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substrate utilisation, are closely related to their myosin composition (Schiaffino et al., 2011). 
Myosin filaments, a key component of the sarcomere, consist of multiple myosin molecules, 
which in turn comprise of two heavy chains and four light chains. Myosin heavy chain 
(MyHC) is thus a major component of the contractile apparatus of striated muscle. It is 
encoded for by a multigene family, the expression of which is dependent upon tissue type 
and developmental stage,  with multiple MyHC genes being expressed in skeletal muscle 
(Mahdavi et al., 1987).  In mouse muscle, the spectrum of pure (non-hybrid) fibre types 
includes the following: slow type I, fast type IIA, B and X (Schiaffino et al., 2011) . 
Determining the MyHC composition of skeletal muscle is thus an informative means of 
distinguishing muscle fibre type, providing useful insight into the contractile properties of the 
muscle.   
Here, assessment of the MyHC isoform proportions of soleus muscle was performed 
on soleus muscle homogenates (prepared following respirometry experiments) using 
sodium-dodecyl-sulphate (SDS) polyacrylamide gel electrophoresis (PAGE). This technique 
separates MyHC isoforms based on molecular weight and has been used to investigate the 
fibre make up of various muscle types in previous studies. For example, mouse soleus 
muscle has been shown to constitute of predominantly type I, IIA and IIX fibres, with either 
minimal or no IIB (Kammoun et al., 2014, Brummer et al., 2013, Blough et al., 1996, Agbulut 
et al., 2003, Agbulut et al., 1996). This is compared to mouse extensor digitorum longus 
(EDL) muscle, which has been shown to constitute of predominantly IIX and IIB, with small 
or negligible amounts of IIA (Agbulut et al., 2003, Agbulut et al., 1996).  
There are many variations of the SDS-PAGE protocol in the literature and a 
significant effort was required to distinguish a protocol that was successful at resolving all 
myosin isoforms. This included variations in % acrylamide in the stack and separating gels, 
gel size, current applied, run duration and staining technique. It also involved use of EDL 
muscle as a control, known to contain IIX and IIB fibres. This was obtained from wild type 
female mice of PKS genotype, between 9-13 weeks of age, kindly donated by Professor 
Malcom Logan at King’s College London.     
  Eventually the following protocol was established that resulted in successful 
separation of type I, IIA, and IIB isoforms in mouse skeletal muscle, confirmed through 
Western Blotting. Despite attempts through Western Blotting to confirm the presence of a 
type IIX isoform, this was unsuccessful.  It is therefore possible that the type IIA band 
identified using SDS-PAGE also contains type IIX.  
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Preparation of muscle samples  
The soleus muscle homogenates prepared from the muscle bundles recovered from 
respirometry experiments (see above) were used for the detection of MyHC isoforms. For 
the MyHC to be solubilised, it was necessary for the sample to be treated with Laemelli 
sample buffer (see below) in a concentration that corresponded to the amount of protein in 
the sample. Thus, an accurate measure of protein content was required.      
Protein concentration of soleus muscle homogenates 
Protein content of soleus muscle homogenates was assessed using PierceTM BCA 
Protein Assay Kit (Thermo Scientific, Prod# 23227, Lot #OL19780), with subsequent 
detection performed using a Nanodrop™ 2000 spectrophotometer (ThermoFisher 
Scientific). Briefly, the sample was vortexed and 10µl was added to 10µl working reagent on 
a 96 well plate and heated at 60°C for 5mins. The plate was left to cool at room temperature, 
following which 2µl of the resulting solution was added to the Nanodrop and protein 
concentrations were verified using a standard curve previously established. The standards 
were prepared using bovine serum albumin (BSA) in concentrations ranging between 0.125-
2mg/ml in phosphate buffered saline (PBS) with 3% Triton X, with one standard solution 
acting as a reference, containing no BSA. Triton was added to the standards to account for 
that added to the soleus fibre bundle homogenate solution.  
The BCA assay relies on two reactions. The first is the temperature dependent 
reduction of Cu2+ ions to Cu+ by peptide bonds present in protein, with the degree of 
reduction relating to the total amount of protein present in solution. Subsequently, two 
molecules of bicinchoninic acid chelate with each Cu+, forming a purple coloured complex. 
This strongly absorbs light at a wavelength of 562nm.    
The protein concentration of the soleus homogenates ranged between 0.54-
1.65mg/ml.  
Addition of sample buffer 
 Samples were spun using a microcentrifuge for 10 minutes at 13,000rpm. The 
supernatant was tested using SDS-PAGE and found to contain no trace of myosin isoforms 
so was removed, leaving the pellet. This was re-suspended in laemelli sample buffer 
(Laemmli, 1970) at a concentration of 40µl/mg protein (or per wet weight of protein in the 




 An extra 1µl of bromophenol blue was added to the resulting sample solution to aid 
visibility when loading into the gel. Following a 2 minute vortex to ensure full mixing of 
MyHC’s with sample buffer, samples were heated at 100°C on a hotplate for 5 minutes. The 
sample was then centrifuged, again for 10 minutes at 13,000rpm so that any protein artefacts 
were contained within the pellet and not loaded into the gel. The sample was stored at -80°C 
until the gel run. 
Extensor digitorum longus (EDL) homogenisation 
EDL muscle was donated as a gift from Malcolm Logan, dissected from female wild 
type PKS mice at ~3months of age. Wet weight was obtained and sample buffer added with 
a minimum of 500μl being required for homogenisation using a gentle MACS dissociator.  
4.5.6 SDS-polyacrylamide gel electrophoresis (PAGE) 
The gels used for both coomaisse blue stain MyHC band detection and Western Blot 
analysis were cast in vertical slab mini-gels, 0.75mm.  The separating gel, left to set at room 
temperature overnight, composed of: 30% glycerol, 4% acrylamide-N-N’-methylene-bis-
acrylamide (bis) (50:1), 0.2M Tris (pH 8.8), 0.1M Glycine and 0.4% SDS. To prevent the top 
of the gel from drying out, a thin layer of 10% Sodium Dodecyl Sulphate (SDS) was sprayed 
and cling film was wrapped around the top of the plates. These protective measures were 
both removed prior to the addition of the stack gel, which consisted of: 30% glycerol, 4% 
acrylamide-bis (50:1), 70mM Tris (pH 6.7), 100mM Ethylenediaminetetraacetic acid (EDTA) 
(pH 7.0), 0.4% SDS. A 0.75mm 10-well spacer was inserted into the stack gel immediately 
after pouring. This was left to set for 1 hour before the spacer was removed and loading of 
the samples commenced. The gel constituents were prepared from stock solutions, the 
details of which are provided below. The pH of the stock solutions for both separating and 
stack gels was not adjusted after these solutions were mixed. Polymerization of both gels 
was initiated with 0.05% of NNN’N’-Tetramethylethylenediamine (TEMED) and 0.1% 
Ammonium persulfate (APS).  Details of the stock solutions along with the sources of the 
chemicals used are given in Table 4.3. 
 A protein marker (Precision Plus Protein™Kaleidoscope™, Bio-rad) was loaded 
alongside the samples. This enabled visualisation of protein migration during the gel run. It 
also enabled the molecular weight of the separated bands (~200kDa), and so identification 
of the MyHC isoforms, to be determined.  
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 The gels were run utilising the Bio-rad Mini-PROTEAN II Cell set up, which allowed 
for 2 gels to be run together. Upper running buffer, consisting of 50mM Tris, 75mM Glycine 
and 0.05% SDS was added to the space between the two gels. β-mercaptoethanol was 
required to aid the clarity of the protein bands following staining (Talmadge et al., 1993). 
Lower running buffer, containing the same constituents as the upper buffer minus β-
mercaptoethanol, was added to the tank. The gel was then run at ~4°C for 24hours at a 
constant current of 4mA (Bio-rad power supply). The temperature was maintained by placing 
the gel in an igloo, surrounding the gel set up with ice and covering with aluminium foil.  
Coomaisse blue staining 
Following completion of the SDS-PAGE run, the stack gel was removed and the 
separating gel washed in ddH2O.  To visualise and analyse the protein bands, the mini gel 
was stained with 20ml Coomaisse®G250 stain, SimplyBlue™Safestain, Invitrogen, for one 
hour on a rocker. It was then washed in 100ml ddH20 for 1 hour prior to scanning using a 
HP Scanjet 3500c Series. The bands corresponding to MyHC isoforms, located between 
150-250kDa, were analysed by gel densitometry using Fiji (ImageJ). From this, the % of 




Table 4.2. Gel constituents used for SDS-PAGE. 
 Stock solution Working solution 
Volume (ml) for 
two gels 





Sodium dodecyl sulphate (SDS) 
1M Tris  
(Tris(hydroxymethyl)amino methane) 
(pH 6.8)   
Glycerol 




















et al., 1993) 
 
100% Glycerol  
30% Acrylamide-bis (50:1) 























Stack gel 100% Glycerol 
30% Acrylamide-bis (50:1) 
Tris 0.5M (pH 6.7) 
4mM Ethylenediaminetetraacetic acid 





































Total = 200  
50mM Tris 
75mM Glycine 
0.05% SDS  
 
Note: Volumes for separating gel, stack gel, upper and lower running buffer working 




Table 4.3. Details on chemicals used for SDS-PAGE and Western blotting. 
Product/chemical name Details Source 
Acrylamide  Sigma Life Sciences, A8887.  
APS Ammonium Persulphate Electran®BDH, Prod 443073E 
Blocking grade buffer Non-fat milk Biorad, 170-6404 
Bisacrylamide NN’-methylenebisacrylamide, specially 
purified for electrophoresis 
Electran, BDH, Prod 44300 
β-Mercaptoethanol 2-mercaptoethanol Sigma Life Sciences, M3148 
Bromophenol blue Free acid Sigma B-6896 
Coomaisse Blue stain SimplyBlue™ SafeStain Invitrogen, LC6060, Lot 
1676635 
EDTA Ethlenediaminetetra-acetic acid GPR™BDH, Prod 2802145 
Glycerol  Raymond Lamb, Prod AC006D 
Glycine  Sigma Life Science, G8898  
Ponceau-S 0.1% Ponceau S in 5% acetic acid Sigma-Alrdrich Prod.P7170  
Protein maker Precision Plus 
Protein™Kaleidoscope™ 
Bio-rad, Cat 161-0375 
SDS Sodium Dodecyl Sulphate  AnalR®BDH, Prod 10807 
Sodium Chloride  GPR™ BDH, Prod 301235Q 
TEMED NNN’-Tetramethylethylenediamine Electran, Prod 443083G 
Tris Tris(hydroxymethyl)methylamine AnalR®BDH, Prod 103156X 
Trizma®Base   Sigma Life Science, T1503  





Wet transfer of proteins for Western Blot 
Following SDS-PAGE, the gel was washed in ddH2O and the separated protein was 
transferred from the gel to a Nitrocellulose membrane (Bio-Rad Trans-Blot® Transfer 
membrane, pure nitrocellulose membrane 0.2µm, Lot # BR 7257001) using a wet transfer 
technique as follows. For details on buffer and blocker constituents, see Table 4.4. The 
nitrocellulose membrane was cut to size (maximum 7.5x10.5cm) and soaked in transfer 
buffer* for 15 minutes. It was then positioned underneath the gel and both were transferred 
to the cassette (Bio-rad) to form part of the transfer sandwich, which consisted of fibre pads 
(Bio-Rad) that were wetted and filter paper (Bio-rad, Extra thick blot paper, Mini blot size (7 
x8.4 cm, 6sh). For details on the assembly of the transfer sandwich, see Figure 4.7.    
 
 
Figure 4.7. A depiction of the transfer sandwich set up used in western blotting 
procedures. 
 
To remove any bubbles that may have formed during this process, a stripette was 
rolled along the membrane filter paper prior to closing of the cassette. The cassette was 
then lowered into the transfer tank, ensuring the black side faced the black side of the tank 
to enable the transfer of protein from a negative current to positive. A stir bar was placed at 
the bottom of the tank and a cooling unit added. A litre of transfer buffer was then poured 
into the tank and the stir bar set near to maximum. The addition of SDS was required in the 
transfer buffer to aid the transfer of large proteins.  The power supply (Bio-rad) was set to 
100V/350mA for 1 hour.  Two gels, and so two cassette set ups were used per transfer run.  
Upon completion of the transfer, an initial check of its success was made by carefully peeling 











from the gel to the membrane. To visualise the successful separation of the MyHC bands 
and transfer to the membrane, a Ponceau stain was used.  
Ponceau-S staining 
Ponceau-S staining is a rapid, reversible means of visualising proteins transferred 
onto a nitrocellulose membrane following SDS-PAGE. Ponceau S is a negative stain that 
binds both to positively charged amino acid groups of the protein and to non-polar regions 
non-covalently, resulting in reddish-pink protein bands with a clear background. Transferred 
protein can be detected within the microgram range using this method.  
 Following wet transfer, the membrane was rinsed in ddH2O before being immersed 
in undiluted Ponceau S solution for 5 minutes. The ponceau was drained and retained for 
future use in a light shielded container and the membrane rinsed with ddH20. If transfer was 
successful, protein bands were visible as red vertical stripes corresponding to each column 
loaded with protein sample.  To remove the stain, the membrane was rinsed in 0.1M sodium 
hydroxide solution for ~20 seconds until the bands had fully disappeared. It was then 





Table 4.4. Buffer and blocking solution details for Western blotting. 
Solution Total volume Constituents pH 




*TRIS/glycine 1L (10x) Glycine  
Trizma® base 
N/A 
Tris Buffer Saline (TBS)  1L (10x) 24.2g Trizma® Base 
80g NaCl  
 
7.4 




Blocking buffer 200ml 10g (5%) Blocking grade buffer 
(Nonfat milk (NFM), Biorad) 
190ml TBS-T 
N/A 






Antibody staining  
 To detect MyHC type I, IIA and IIB, the following mammalian primary monoclonal 
antibodies were used respectively: BA-F8 (Immunoglobulin G, IgG), Sc-71 (IgG) and BF-F3 
(Immunoglobulin M, IgM). Each were obtained from the developmental studies hybridoma 
bank, developed by Schiaffino (Schiaffino et al., 1989). The membrane was therefore cut 
into necessary sections, to enable a separate antibody to be used on each section, and 
each section transferred to a separate, smaller container.   
 Initial blocking of the membrane sections was achieved through immersion in 50ml 
5% blocking grade buffer (non-fat milk) solution for 1 hour on a shaking table. The membrane 
was washed for 10 minutes on a shaker in TBS-T four times. The membrane sections were 
then incubated with the primary antibody diluted in blocking buffer at a concentration of 1:400 
in the fridge overnight. The same 4x10minute wash (with TBS-T) was then repeated and 
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followed by incubation with the secondary antibody for 45 minutes on a shaker at room 
temperature. In the case of Sc-71 and BA-F8 IgG antibodies, the membrane was incubated 
with goat anti-mouse IgG-horse radish peroxidase (HRP) (ECLTM Prime Western blotting 
detection reagent, RPN2232, Lot#9636827 AmershamTM) diluted in blocking buffer at a 
concentration of 1:2000. The same wash steps as stated previously were then repeated. 
Following this, the membrane was rinsed in dH2O and incubated with 4ml of ECL Prime 
Western blotting detection reagent (2ml of both solution A and B) for 5 minutes. For 
detection, the membrane image was captured using a BioSpectrum® 810 Imaging System, 
230V~50Hz UVP Bioimaging systems.   
In the case of BF-F3 IgM antibodies, the membrane was incubated with goat anti-
mouse IgM-Alkaline phosphatase secondary antibody (A9688, Sigma) diluted in blocking 
buffer at a concentration of 1:1000 for 45 minutes on a shaker at room temperature. For BF-
F3 detection the membrane was then stained with Fast red/Napthol AS-MX tablets (F4648-
50SET, Lot# 097K8211, Sigma) diluted in dH2O (1ml per tablet) targeting Alkaline 
Phosphatase, until a clear appearance of a detected band, after which it was washed with 
dH2O to minimise background.  
Attempts were made to detect MyHC IIX using mammalian primary monoclonal 
antibody 6H1 (IgM).  The same secondary antibody incubation (with goat anti-mouse IgM) 
was used as with BF-F3, only without Tween, given that 6H1 is notoriously delicate. 
Detection with Fast red/Napthol was attempted, however, no band was resolved. Further 
attempts were made, with the membrane being incubated with a tertiary reagent, extravadin 
alkaline phosphatase (Sigma, F4523) diluted in blocking buffer (with TBS) at a concentration 
of 1:500 for 45 minutes. The wash steps were then repeated, after which the membrane was 
incubated with diluted Fast red/Napthol. However, again, no band was made apparent.  
4.5.7 Western Blot analysis of metabolic proteins 
 To gain further insight into potential metabolic remodelling processes, Western Blot 
analysis was performed to detect for changes in levels of specific metabolic enzymes or 
signalling proteins. This analysis was performed in the laboratory of Dr Andrew Philp at the 
University of Birmingham.  
Muscle preparation 
Whole frozen soleus muscle was powdered using a muscle crusher and 100μl lysis 
buffer (50 mM Tris, pH 7.5, 250 mM sucrose, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 
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1 mM NaVO4, 50 mM NaF, 0.10% DTT, and 0.50% protease inhibitor cocktail) was added. 
The sample was shaken at 6.0m/sec for 40sec using a FastPrep-24TM5G (Millipore, 
Quickprep setting) and centrifuged at 4°C, 8000G for 10mins. Total protein content of the 
resulting supernatant was derived from a DCTM Biorad protein assay (Lot# 500-0113) using 
FLUOstar Omega at absorbance 750nm.  
SDS-PAGE gel run 
Laemelli sample buffer (250 mM Tris·HCl, pH 6.8, 2% SDS, 10% glycerol, 0.01% 
bromophenol blue, and 5% β-mercaptoethanol) was added prior to loading equal amounts 
of sample (19.95μg protein) onto SDS polyacrylamide gels (0.75mm thickness).  
For all antibodies excluding OXPHOS (see below), samples were boiled prior to 
loading. The separating gel constituted 12.5% acrylamide (30% acrylamide/Bis solution, Bio-
Rad, 3.3% Cross linker, Electrophoresis purity reagent) and 1.5M Tris-SDS (0.4%) pH 8.8; 
the stacking gel 5% acrylamide and 1.5M Tris-SDS pH 6.8. Polymerization of both gels was 
initiated through the addition of 0.1% APS and 0.01% TEMED and was left for 30 minutes. 
Following the addition of running buffer (0.25mM Tris Base, 2.5mM Glycine, 20% SDS), gels 
were run at a constant amperage of 23mA/gel for ~45minutes at room temperature.  
Protein wet transfer 
Following completion of the SDS-PAGE gel run, protein was then transferred to a 
pure nitrocellulose blotting membrane (PALL®, Pall Corporation, Life Sciences) at 100 V for 
1 h, with the addition of transfer buffer (0.4Mm Tris Base, 1.73mM Glycine) and ice. 
Visualisation of the protein transfer was obtained using Ponceau-S staining. 
Antibody staining 
After blocking in 3% non-fat milk in Tris-buffered saline with 0.1% Tween 20, the 
membranes were incubated overnight at 4°C with appropriate primary antibody. The 
antibodies used were: Total OXPHOS rodent WB antibody cocktail (OXPHOS) (ab110413, 
Abcam), Anti-citrate synthase (SAB2701077, Sigma), Mitofusin 2 (MFN2) (Cell Signalling 
9482), PGC1-α (AB3242, Millipore), carnitine palmitoyltransferase (CPT) 1 (CPT1MIIA, 
Alpha Diagnostics), long chain acyl co-A dehydrogenase (LCAD, a gift from Prof Jerry 
Vockley, University of Pittsburgh (Le et al., 2000)), pyruvate dehydrogenase kinase (PDK4, 
a gift from Prof Grahame Hardie, University of Dundee, (Kiilerich et al., 2010)). All primary 
antibodies were diluted 1:1000, with the exception of LCAD, which was diluted 1:5000. 
Further washes in TBS-T were followed by addition of secondary antibodies for 45 mins, 
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diluted as diluted 1:10,000 as follows:  Rabbit anti-mouse IgG (Pierce #31457, 
lot#OD1691311), rabbit anti-sheep IgG (Pierce #31480, lot#OC16810716), goat anti-rabbit 
(Pierce #31460 lot#QC214553). Immobilon western chemiluminescent HRP substrate 
(Merck Millipore) was used to quantify protein content after IgG binding.   
Western blot analysis 
Blots were visualized on a G: BOX Chemi XT4 imager using GeneSys capture 
software (Syngene UK, Cambridge, UK). Density of bands corresponding to the target 
protein were corrected to the loading control (mouse gastrocnemius) for that blot as well as 
the corresponding actin band.  
4.5.8 Statistics  
Statistical analyses were performed using R software (The R Foundation for 
Statistical Computing) and p values ≤0.05 were considered as significant. A three-way 
ANOVA was performed in order to assess effects of all 3 parameters: hypoxia, nitrate and 
PPARα. Detection of a significant two or three-way interaction identified by the ANOVA were 
investigated further using a post hoc Tukey’s test.  Interpretation of post hoc Tukey’s went 
as follows: a significant three-way interaction was considered the main outcome, any two-
way interaction was discounted in this instance. A significant two-way interaction existing 
without a three-way interaction was considered the main outcome, any significance found in 
singular parameters by the ANOVA were ignored. In both instances, Tukey’s tests on 
interactions that didn’t contain at least one repeated parameter in each of the comparison 
groups were also discounted.  
Exclusion criteria for inclusion of results in statistical analysis were respirometry 
values that deviated more than 20% from group mean values as well as those fibre bundles 
responding to the cytochrome c addition. This was employed in an attempt to remove results 
affected by day to day fluctuations in electrode sensitivity (e.g. one instance of membrane 
replacement) or by fibre damage. The number therefore varied between 6-10 per group.  
 Parametric tests, such as ANOVA’s, assume a normal, or Gaussian, distribution. 
The distribution of data can be assessed using normality tests. Whilst ANOVA’s have been 
shown to be robust to normality violation (Maxwell et al., 1990), this effect is likely reduced 
with smaller sample sizes. Indeed, the small sample size presented in this study significantly 
reduce the power of normality tests, lowering the ability to detect non-Gaussian distribution. 
Instead, a test is required to inform whether deviations from the Gaussian distribution are 
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severe enough to invalidate the statistical methods that assume a Gaussian distribution. 
Given the exclusion criteria described above, this was expected not to be of concern.  A 
normal distribution was therefore assumed.  
Graphs were generated using Graphpad Prism 6 software and follow a specific similar 
colour/pattern scheme, with white indicating normoxia, blue hypoxia and dashes indicating 
nitrate  treated groups. In addition, the wild type (PPARα+/+) are separated from the knockout 
(PPARα-/-). The majority of the data set (with the exception of body weight changes) is shown 
as box and whisker plots, so that the full data spread can be visualised, with significant links 
between groups depicted. Lines have been drawn to show significant interactions between 
groups. Black lines are indicative of interactions between genotypes (PPARα-/- vs. 
PPARα+/+), blue lines are interactions linked to O2 state (hypoxia vs. normoxia).   
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4.6 Results  
4.6.1 Effects of hypoxia and PPARα ablation on nitrate 
intake, body weight and haemoglobin 
To investigate the effects of long term, severe hypoxia, mice were exposed to either 
hypoxic (10% O2) or normoxic (21%O2) conditions for four weeks. This was preceded by 
either one week of sodium nitrate (NaNO3, 0.7mM L-1) or sodium chloride (NaCl, 0.7mM L-
1) supplementation via drinking water, which was continued for the study duration. At the 
end of the study period, the body weight of hypoxic mice was 6.7% lower (p≤0.001%) in 
comparison to normoxic mice and 4.5% lower (p≤0.01) in PPARα-/- mice in comparison to 
PPARα+/+ at the point of study completion (Figure 4.8A). The impact of PPARα genetic 
ablation upon fat metabolism was also visible with the presence of fat droplets on the liver 
of PPARα-/- mice, as described previously (Lee et al., 1995).    
Over the course of the treatment programme, nitrate intake gained from food and 
water consumption combined was 7.7 fold (p≤0.001) higher in nitrate treated mice in 
comparison to chloride treated mice (Figure 4.8B).  The severity of the hypoxic exposure 
was reflected through a two-fold increase in haemoglobin concentration (p≤0.001, all 





Figure 4.8. Mouse body weight, nitrate (NO3-) intake and haemoglobin concentrations. 
A. Average (mean) mouse body weights in each experimental group (n=10-12) in both 
PPARα+/+ and PPARα-/- genotypes measured on the first day of the week indicated, with 
dietary sodium nitrate (NaNO3) supplementation or sodium chloride (NaCl
-) beginning in 
week 1 and hypoxic treatment beginning at week 2. B. Cumulative NO3- intake from food 
and water throughout the study duration. C. Differences in haemoglobin concentration (g/L), 
derived from HemoCue analysis of a blood droplet taken from the tail vein immediately after 
sacrifice. A doubling of haemoglobin concentration was observed in the groups exposed to 
four weeks of hypoxic (10% O2) treatment. Data for B and C are presented as minimum to 
maximum box and whisker plots, with the middle line representing the median and the box 
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4.6.2 Mitochondrial respirometry 
PPARα genetic ablation impairs LEAK state respiration  
To understand how the interaction between hypoxia, nitrate supplementation and 
PPARα -/- might affect the oxidation of fat and carbohydrates, respiration rates were 
measured in permeabilised soleus muscle fibres in response to the addition of a fatty acyl-
carnitine substrate (40μM palmitoyl carnitine + 2mM malate) and a product of glycolysis 
(5mM pyruvate) respectively. In addition, flux through mitochondrial complexes 1 and 2 were 
assessed through the measurement of respiration rates in response to addition of substrates 
specific to these complexes (10mM glutamate + 2mM malate and 10mM succinate preceded 
by 0.5μM of the potent complex I inhibitor rotenone, respectively). PPARα-/- mice exhibited 
a 9.5% decrease in LEAK state respiration (O2 consumption in the absence of ADP, so not 
coupled to ADP phosphorylation) with the addition of the long chain fatty acid, palmitoyl 
carnitine (Figure 4.9A), alongside a 10.8% decrease (p≤0.05) in LEAK state respiration 
driven by complex I electron flux (Figure 4.10A).  
Hypoxia impairs oxidative capacity 
The hypoxic insult suppressed a number of measures of soleus muscle 
mitochondrial function across both genotypes. This was demonstrated through a decrease 
in respiration rates in response to addition of fatty acid substrate by 26.3% (all normoxic 
chloride vs. all hypoxic chloride, p≤0.001) in LEAK state and by 13.9% (all normoxic vs. all 
hypoxic, p≤0.01) in OXPHOS state (the latter being O2 consumption that is coupled to ADP 
phosphorylation, so in response to the addition of 10mM ADP) (Figure 4.9A, B). Pyruvate 
OXPHOS rates were also suppressed in response to hypoxia, with a 23.1% (p≤0.001) 
decrease occurring in chloride treated hypoxic groups in comparison to chloride normoxic 
groups across both genotypes (Figure 4.9C).   
Effects of hypoxia upon mitochondrial complex function were apparent through 
decreases in OXPHOS rate driven by complex II electron flux (Figure 10C), an effect again 
apparent across both genotypes with a 17.6% decrease (p≤0.01) observed in hypoxic 
chloride mice in comparison to normoxic chloride across both genotypes. Hypoxia did not 
affect flux via complex I either in the LEAK or OXPHOS states (Figure 4.10A, B).  
An insight into coupling efficiency of mitochondrial oxidation, being the proportion of 
the membrane geared towards ATP synthesis via ATP synthase relative to proton leak 
across the inner membrane, was gained from calculating oxidative coupling efficiency 
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(OCE). Calculation of OCE from palmitoyl carnitine oxidation (
𝑃𝑎𝑙𝑚𝑖𝑡𝑜𝑦𝑙 𝑐𝑎𝑟𝑛𝑖𝑡𝑖𝑛𝑒  𝐿𝐸𝐴𝐾
𝑃𝑎𝑙𝑚𝑖𝑜𝑡𝑦𝑙 𝑐𝑎𝑟𝑛𝑖𝑡𝑖𝑛𝑒 𝑂𝑋𝑃𝐻𝑂𝑆
 ) 
revealed an 18.3% decrease (p≤0.01) in hypoxic PPARα-/- relative to hypoxic PPARα+/+ 
groups (Figure 4.11A). OCE for complex I respiration (derived from assay 2) was unaffected 
by hypoxic exposure Figure 4.11B. 
Nitrate supplementation recovers aspects of hypoxic induced suppression  
The supplementation of drinking water with 0.7mM L-1 dietary nitrate - for one week 
prior to and during hypoxic exposure, was shown to attenuate two measures of hypoxic 
induced suppression of mitochondrial function, the first of which is the decrease in fatty acid 
LEAK state. As can be seen in Figure 4.9A, the decrease in palmitoyl carnitine LEAK state 
respiration is only apparent in chloride treated hypoxic mice. No such decreases were 
observed in the nitrate supplemented experimental groups, indicating a nitrate dependent 
recovery of mitochondrial function. The same pattern occurs with pyruvate oxidative 
phosphorylation, as the hypoxic induced suppression is apparent in chloride treated mice, 
but lost in the nitrate treated groups (Figure 4.9C).  Other measures of mitochondrial 






Figure 4.9. Mitochondrial respirometry results from assay 1 
Presented as oxygen flux (JO2) in pmol/second/mg, corrected to wet weight. A. Long chain 
fatty acid (palmitoyl carnitine) stimulated leak state respiration (LEAK), suppressed by 
PPARα-/- in all conditions and by hypoxia in the chloride treated animals across both 
genotypes. B. Oxidative phosphorylation (OXPHOS) of long chain fatty acid (palmitoyl 
carnitine), suppressed by hypoxia in both genotypes and across both chloride (Cl-) and 
nitrate (NO3-) treated animals. C. OXPHOS of pyruvate, suppressed by hypoxia in the 
chloride treated groups only across both genotypes. Data are presented as boxplots, with 
the box extending from 25th to 75th percentiles and displaying the median line, and whiskers 
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Figure 4.10. Mitochondrial respirometry results from assay 2 
Presented as oxygen flux (JO2) in pmol/second/mg, corrected to wet weight. A. Electron 
transfer chain (ETS) complex I driven leak state respiration, suppressed by PPARα-/- in all 
conditions. B. ETS complex I driven OXPHOS, no significant difference identified C. ETS 
complex II driven OXPHOS suppressed by hypoxia in both nitrate (NO3-) and chloride (Cl
-)  
treated conditions and across both genotypes. Data are presented as boxplots extending 
from 25th to 75th percentiles and displaying the median line, with whiskers presenting 
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Figure 4.11. Oxidative coupling efficiency (OCE). 
A. OCE for assay 1, decreased in hypoxic PPARα-/- in comparison to PPARα+/+ in both nitrate 
and chloride treated conditions. B. OCE for assay 2, no significant change across any 
treatment condition. Data are represented as boxplots extending from 25th to 75th percentiles 
and displaying the median line, with whiskers presenting minimum to maximum values n=5-
11 per experiment group. ** P≤0.01.  
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4.6.3 Metabolic proteins 
PPARα genetic ablation and hypoxia affect levels of proteins associated with 
oxidative metabolism   
Assessment of the levels of total protein related to β-oxidation in the soleus revealed 
decreases in levels of the β-oxidation enzyme long chain acyl co-A dehydrogenase (LCAD) 
and in the shuttle carnitine palmitoyltransferase 1 (CPT1) by 15.6% and 17.0% respectively 
(p≤0.05, PPARα-/- vs PPARα+/+) (Figure 4.12A,B). This is alongside a hypoxic induced 
decrease in CPT1 protein levels by 17% across both genotypes (p≤0.05) (Figure 4.12B).  
The hypoxic induced changes in proteins may thus relate to the decrease in fatty 
acid oxidation capacity outlined in the respirometry results. This was not the case for 
carbohydrate oxidation as the hypoxic induced abrogation of pyruvate OXPHOS was not 
accompanied by changes in protein levels of a key mediator of pyruvate entry into the TCA 
cycle, pyruvate dehydrogenase kinase 4 (PDK4) (Figure 4.12C).  
4.6.4 Myosin heavy chain (MyHC) isoforms 
Hypoxic exposure induces a shift in myosin heavy chain isoform proportions 
 Assessment of soleus muscle MyHC isoforms indicated that hypoxia induced a shift 
in proportions towards a fast type isoform makeup, with a 34% increase in type II isoforms 
alongside an 11.1% decrease in type I fibres (p<0.01) (Figure 4.13). Relationships between 
fibre type proportions and mitochondrial respirometry were investigated. However, no 





Figure 4.12. Total protein levels assessed by Western Blot. 
A. Levels of long chain 3-hydroxyacyl-coenzyme A dehydrogenase (LCAD) B. Carnitine 
palmitoyltransferase 1 (CPT1) C. Pyruvate dehydrogenase kinase 4 (PDK4). Data are 
presented as boxplots extending from 25th to 75th percentiles and displaying the median line, 
with whiskers representing minimum to maximum values. Values are relative to the actin 
band and gel loading control, n=3-5 per experiment group. *P≤0.05 D. Western blot pictures 
with corresponding actin band derived from a ponceau stain. Given that LCAD and CPT1 
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Figure 4.13. Myosin heavy chain isoform type proportions in the soleus. 
These were examined, with separation of fibre type specific bands of the soleus (SOL) 
shown alongside those of the extensor digitorum longus muscle (EDL) to demonstrate 
differences in muscle composition. This was quantified using SDS-PAGE (A), with 
identification of type I, IIA, IIB isoforms confirmed using western blotting (B). For graph 












4.6.5 Measures of mitochondrial density 
PPARα genetic ablation decreases PGC1α 
 From the aforementioned functional respirometry measurements, it is unclear 
whether the downregulation of oxidative processes that were observed in both hypoxia and 
PPARα-/- groups were due to remodelling of mitochondrial pathways or to a loss in 
mitochondrial density. In other words, was the suppression due to mitochondria functioning 
less efficiently or because fewer mitochondria were present resulting from alterations in the 
mitochondrial network? Equally, was nitrate supplementation acting to recover mitochondrial 
function in hypoxia through changes to the mitochondrial network or through improving the 
efficiency of oxidative pathways?   
This question was investigated further by measuring total protein levels of factors 
closely related to mitochondrial content and that have been shown previously to be indicative 
of alterations in mitochondrial networks. One such measure is a key regulator of 
mitochondrial biogenesis, PGC1α. Whilst no significant changes were observed in PGC1α 
with nitrate or hypoxic treatments, differences were identified between genotypes, with a 
19.8% decrease (p≤0.05) in PPARα-/- in comparison to PPARα+/+ (Figure 4.14A). Alongside 
this was a lack of change in the mediator of fusion between mitochondrial outer membranes, 
mitofusin 2 (MFN2) (Figure 4.14B).    
PPARα genetic ablation and hypoxia impair citrate synthase (CS) activity with 
chloride, but not nitrate, treatment 
Another measure closely correlated to mitochondrial density is the activity of the TCA 
cycle enzyme CS  (Larsen et al., 2012). As shown in Figure 4.14D, CS activity measured in 
soleus homogenates was suppressed in the hypoxic chloride treated groups by 23.9% in 
comparison to normoxic chloride (p≤0.01). This occurred alongside a 17.5% decrease 
(p≤0.05) in CS activity in PPARα-/- chloride in comparison to PPARα+/+ chloride groups. No 
significant decreases were observed in the nitrate treated groups, indicating that this 
treatment maintained CS activity.  
 However, the changes in CS total protein were unaffected across all treatment 
conditions Figure 4.14C. Similarly, no change was observed in protein levels of 




Figure 4.14. Total protein levels of PGC1α (A), MFN2 (B), Citrate synthase (CS) (C) and 
CS activity (D). 
Data are represented as boxplots extending from 25th to 75th percentiles and displaying the 
median line, with whiskers presenting minimum to maximum values. Values are relative to 
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Figure 4.15. Total protein levels of all five mitochondrial complexes, assessed by 
Western blot.  
The corresponding blot picture is presented on the following page. Data presented as 
boxplots extending from 25th to 75th percentiles and displaying the median line, with whiskers 
presenting minimum to maximum values. Values are relative to the actin band and gel 
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Figure 4.16. Summary diagrams of key changes identified in 
mitochondrial function and related protein content. 
A. Addition of pyruvate. Hypoxia attenuated oxidative 
phosphorylation (OXPHOS, with addition of ADP) in both 
genotypes, an effect recovered with nitrate supplementation.  B. 
Addition of Palmitoyl Carnitine. PPARα
-/- 
and hypoxia both 
cause attenuation of leak state (LEAK) respiration (no addition of 
ADP). The hypoxic induced suppression was alleviated by nitrate 
supplementation. C. Protein changes. PPARα
-/- 
attenuated long 
chain acyl CoA dehydrogenase (LCAD) protein levels. Both 
hypoxia and PPARα
-/- 
induced suppression of 
carnitine palmitoyl transferase 1 (CPT1) in addition to citrate 









In this study, four weeks of hypoxic exposure was demonstrated to impair several 
measures of mass corrected mitochondrial respiration in the mouse soleus muscle. This 
included a decrease in OXPHOS respiration rates of pyruvate, complex II driven electron 
flux and long chain fatty acids, with the latter also being impaired in LEAK state. These 
effects were observed to a similar same degree in both PPARα+/+ as well as PPARα-/-, thus 
indicating it is a response elicited independently of PPARα. The impairment of pyruvate 
OXPHOS and long chain fatty acid LEAK state respiration rates did not occur in mice 
supplemented with dietary nitrate (Figure 4.16A and B respectively). This affect was 
apparent in both genotypes (PPARα+/+ and PPARα-/-). This thus suggests nitrate treatment 
partially recovered the hypoxic induced suppression of skeletal muscle mitochondrial 
function and that this again occurred via mechanisms independent of PPARα. To the 
author’s knowledge, this is the first time that the interaction between dietary nitrate and 
PPARα in hypoxia has been explored to this depth in skeletal muscle. The results suggest 
that nitrate supplementation holds promise as a potential therapy for alleviating hypoxic 
induced stress in skeletal muscle, which is relevant for various disease states where skeletal 
muscle impairment is associated with hypoxia (Killian et al., 1992a, Puthucheary et al., 
2013), and also in the context of high altitude physiology (Levett et al., 2012).   
A key question remaining is the mechanism by which nitrate treatment is acting to 
recover these specific aspects of mitochondrial function. Given that the biologically active 
element of dietary nitrate supplementation, NO, is a potent vasodilator, it is possible that the 
improvements in mouse mitochondrial function reported in this chapter are a result of 
increased skeletal muscle blood flow, as has been demonstrated in response to acute 
dietary nitrate supplementation in subjects sojourning to high altitudes (Bakker et al., 2015). 
As analysis was focused upon in vitro measures in this chapter and mouse tissue blood flow 
was not measured, this cannot be ruled out. However, if this was the case, it would perhaps 
be expected to be reflected through global improvements in mitochondrial function as 
opposed to the specific improvements discussed. In addition, enhanced oxidative capacity 
in response to nitrate treatment has been demonstrated in cultured myocytes (Ashmore et 
al., 2015b), which is thus an effect occurring independently of an increased O2 delivery 
resulting from NO induced vasodilation. 
In some respects, it may appear surprising that PPARα genetic ablation had so little 
effect upon skeletal muscle oxidative metabolic function in hypoxic conditions. This is 
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especially interesting in light of recent findings on the role of PPARα in the hypoxic 
adaptation of the heart (Cole et al., 2016). Indeed, Cole and colleagues reported that the 
changes evoked by PPARα genetic ablation ensured these mice had already undergone the 
required adaptive cardiac metabolic changes to maintain function in hypoxia. The 
contradiction between this and the present chapter, which instead suggests a minimal role 
of PPARα in hypoxia induced skeletal muscle metabolic remodelling, may be due to tissue 
specific differences. The heart has a higher metabolic rate and mitochondrial density in 
comparison to skeletal muscle and also relies heavily upon fat oxidation for ATP generation 
(Neely et al., 1972). Modulation of fat oxidation indeed appears to be a crucial aspect of 
cardiac hypoxic adaptation (Cole et al., 2016). The dependence upon this adaptation may, 
at least in part, explain why these apparent discrepancies between the tissue specific 
responses exist and in turn why a decline in muscle energetics is reported in the heart, but 
not skeletal muscle. Unlike skeletal muscle, where the PCr half-life is maintained in hypoxic 
exposure (Edwards et al., 2010), the PCr/ATP ratio is reported to be impaired in the human 
heart (Holloway et al., 2014, Holloway et al., 2011). It would therefore make sense for 
skeletal muscle to have other avenues of metabolic adaptation aside from PPARα 
dependent mechanisms. This would be of interest for future studies to pursue.  
Other effects of PPARα ablation upon mouse physiology were largely expected, 
given previous reports. This included weight loss and the presence of fatty droplets on liver, 
the latter being an indication of the necessity of PPARα for the regulation of hepatic liver 
metabolism (Lee et al., 1995), alongside reduced expression of recognised PPARα targets 
CPT1 and LCAD (Figure 4.16C) (Morash et al., 2013, Lee et al., 1995).  
PPARα genetic ablation will undoubtedly cause alterations to key positive effectors 
of inner mitochondrial membrane uncoupling proteins (UCP’s): free fatty acids (Woyda-
Ploszczyca et al., 2016).  This may go to explain the observed decrease in LEAK state in 
PPARα-/- mice. Moreover, the member of the UCP family, UCP3,  has been identified as a 
PPARα target (Cole et al., 2016).  The effects on complex I flux appears to be a novel finding 
and its relation to the other responses mentioned are not clear.   
The severity and longevity of the hypoxic insult in this chapter was reflected through 
several measures. This included the two-fold difference in the haemoglobin concentrations 
of those mice exposed to hypoxia in comparison to their normoxic counterparts, a response 
unaffected by nitrate treatment. This is contrary to previous findings whereby nitrate 
treatment was shown to decrease haemoglobin concentrations in both hypoxic and 
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normoxic conditions (Ashmore et al., 2015a), a disparity that may result from the prolonged 
nitrate treatment duration in this chapter (18 days (Ashmore et al., 2015a) vs. 35 days 
(present study)).  
Hypoxia was also found to alter MyHC isoform proportions, which were indicative of 
a shift towards a fast type (glycolytic) fibre phenotype. This is in line with previous reports of 
HIF-1α mediating increases in expression of glycolytic enzymes in response to hypoxic 
exposure within skeletal muscle (Kim, 2006, Green et al., 1989, Firth et al., 1995). This result 
is therefore perhaps expected, especially given that the time course of the present chapter 
is beyond the time frame required to induce fibre type shifts in rodent soleus muscle, which 
has been reported to occur after as little as 7 days following hind limb suspension (Stevens 
et al., 1999).   
An aspect of metabolic remodelling that has been shown repeatedly in  response to 
environmental hypoxia is a shift away from oxidation of fatty acids (Horscroft et al., 2014). 
Measures of mitochondrial oxidative respiration presented in this chapter support this 
concept, as oxidation of long chain fatty acid (palmitoyl carnitine) in both LEAK and 
OXPHOS states were attenuated by hypoxic exposure. The impact upon β-oxidation is 
further supported by the suppression of CPT1 protein levels in response to hypoxic exposure 
(Figure 4.16C). This has been reported previously and has been associated with a 
downregulation of PPARα expression (Morash et al., 2013). Given that this effect occurred 
in both PPARα+/+and PPARα-/- mice, this suggests other signalling mechanisms may play a 
role in the regulation of CPT1 levels, for instance through PPARβ/δ compensation (Wahli et 
al., 1995).  
 The suppression of β-oxidation reported here is thus in accordance with the general 
consensus that environmental hypoxia induces a shift away from the highly O2 demanding 
oxidation of fatty acids (Horscroft et al., 2014). However, the hypoxic induced suppression 
was not exclusive to β-oxidation as pyruvate oxidation was also shown to be attenuated.  
The causes of this decline in carbohydrate oxidation are unclear. Previous studies have 
reported induction of pyruvate dehydrogenase kinase (PDK) isoforms in response to hypoxic 
exposure, which in turn inhibits pyruvate dehydrogenase thus blocking the conversion of 
pyruvate to acetyl CoA, causing a shunting of pyruvate from entry into the TCA cycle. The 
upregulation of PDK1 is  HIF-1α mediated in a human B lymphocyte cell line and mouse 
embryo fibroblasts (Kim, 2006). In cardiac muscle, mediation of a hypoxic induced increase 
in PDK4 expression has been linked to PPARα (Cole et al., 2016). However, the assessment 
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of PDK4 protein levels in mouse skeletal muscle revealed no change across the treatment 
groups, neither in hypoxia or PPARα-/-. This discrepancy may again be explained by 
differences in tissue type, as skeletal muscle may exhibit different mechanisms to concert 
this suppression of pyruvate oxidation.   
The impact of hypoxic exposure upon mitochondrial complex function, as with most 
other measurements of mitochondrial function mentioned, has shown confusing results in 
previous studies. For instance, short term exposure (9-11days) to hypobaric hypoxia 
(4,559m) has been shown to have little effect upon complex I and II function (Jacobs et al., 
2013). However, significant suppression of function was demonstrated following a 28 day 
exposure to 3,454m (Jacobs et al., 2012), and specifically in complex I dependent OXPHOS 
in rodents (Gamboa et al., 2012).  In the present chapter, hypoxia was not reported to affect 
complex I function, but did induce a decline in complex II dependent OXPHOS. This is in 
line with previous findings taken from metabolic profiling of human plasma, which revealed 
a 158% increase in succinic acid concentrations in response to hypoxia (Tissot van Patot et 
al., 2009). Given that succinic acid (succinate) is the substrate of complex II/succinate 
dehydrogenase, its accumulation is indicative of a concerted downregulation of complex II 
function. In cardiac tissue, the accumulation of succinate in response to ischemia is reported 
to have a toxic effect and has been directly linked to the production of mitochondrial ROS 
from complex I (Chouchani et al., 2014).  
Alongside measurements of mitochondrial respiration were investigations into 
possible changes occurring to the mitochondrial network. This included the surrogate 
measure of mitochondrial density, CS activity (Larsen et al., 2012), which was decreased in 
response to hypoxia and PPARα-/- in chloride treated groups. This thus suggests the hypoxic 
and PPARα-/- induced suppression of mouse mitochondrial function reported in the 
respirometry measures may have been linked to a decrease in mitochondrial density as 
opposed to mass specific changes, as has been reported in previous studies examining long 
term hypoxic exposure (Horscroft et al., 2014). Given that this affect was restricted to 
chloride treated animals, this indicates that the potential decrease in mitochondrial density 
was recovered with nitrate treatment. Indeed, induction of mitochondrial biogenesis 
triggered by nitrate supplementation has been suggested previously in adipose tissue 
through increasing levels of a major driver of mitochondrial biogenesis, PGC-1α (Roberts et 
al., 2015). However, changes in CS activity were not reflected through alterations in the 
protein levels of CS, which were unaffected across all treatment groups. Equally, no change 
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was observed in PGC-1α or in mitochondrial complexes I-IV in response to hypoxic 
exposure. This could suggest either that measures of CS activity are perhaps not as closely 
related to changes in mitochondrial density as has been recorded previously (Larsen et al., 
2012), or that the sensitivity of Western Blotting is not sufficient to detect discrete 
modifications across treatment conditions. It may also be that alterations in protein levels of 
these molecules are not apparent at the time point at which these measurements were 
taken, following 4 weeks of hypoxic exposure. It may be that these changes are occurring 
at a more acute phase of the hypoxic exposure.  
 A response that did match was the decline in CS activity observed in chloride treated 
PPARα-/- mice in comparison to PPARα+/+ along with a corresponding fall in PGC-1α total 
protein in PPARα-/- mice. Both of these results indicate a decline in mitochondrial content 
and biogenesis, which may also contribute to the decline in LEAK state respiration observed 
in response to PPARα ablation.  
 Another indication of possible changes occurring to the mitochondrial network in 
response to hypoxia is that of fission, a process required to remove damaged mitochondria, 
which is mediated in part by membrane anchored dynamin family members MFN1 and 
MFN2 (Youle et al., 2012). A decrease in MFN2 levels have been shown in hypoxic mouse 
models, whereas inducing MFN2 overexpression has been suggested to attenuate hypoxia-
induced apoptosis (Peng et al., 2015). In this chapter, however, protein levels of MFN2 were 
unchanged across treatment groups.  
 Nitrate supplementation has recently been demonstrated to induce skeletal muscle 
fibre type switching towards from fast glycolytic to slow oxidative fibre type (Roberts et al., 
2016). However, results of the present chapter do not indicate any effect of nitrate treatment 
upon MyHC isoform proportions. Although the nitrate dosing used by Roberts and 
colleagues was the same as used in the present chapter (0.7mM), their treatment was in the 
absence of a hypoxic insult, which may be severe enough to counteract influences of nitrate 
treatment upon fibre type.  
4.8  Conclusions 
This study has confirmed previous reports of hypoxic induced suppression of 
mitochondrial function in skeletal muscle. Hypoxia impaired numerous measures of mass 
specific respiration rates in the mouse soleus muscle, including long chain fatty acid LEAK 
and carbohydrate OXPHOS capacities. These significant decreases were recovered in 
227 
 
nitrate supplemented mice, indicating a nitrate dependent recovery of mitochondrial 
function. As this nitrate effect was observed in both PPARα+/+ and PPARα-/- mice, it suggests 
the effect is not dependent upon PPARα. In conclusion, results of this study indicate that 





5 Chapter 5 (Study 4): Effects of acute 
dietary nitrate supplementation upon 
metabolism and exercise performance in 
COPD: a double blind, placebo-controlled, 
randomised controlled pilot study. 
 
5.1  Introduction 
As outlined in the literature review (section 1.2.6), COPD is a highly prevalent 
disease and exercise limitation is a common symptom amongst patients. Previous findings 
suggest that tissue O2 delivery, intramuscular O2 transport and mitochondrial dysfunction 
may all contribute to exercise limitation in COPD. Approaches that reduce the O2 cost of 
exercise may thus be of therapeutic benefit and current knowledge suggests nitrate 
supplementation may be beneficial in conditions where O2 delivery to the muscles is reduced 
(section 1.2.7).  
A number of studies have demonstrated a decrease in the O2 cost of submaximal 
exercise in healthy young individuals in response to nitrate supplementation (Larsen et al., 
2007, Lansley et al., 2011, Bailey et al., 2009, Vanhatalo et al., 2010), an effect associated 
with improvements in exercise tolerance and performance (Bailey et al., 2010, Vanhatalo et 
al., 2010, Murphy et al., 2012). The majority of these studies use beetroot juice as the nitrate 
source, with the O2 sparing effect being dependent largely on nitrate itself, as nitrate-
depleted beetroot juice fails to illicit the same effect (Lansley et al., 2011).   This O2 sparing 
effect is also apparent in healthy subjects exposed to conditions where O2 delivery to the 
muscle is reduced due to high altitude exposure (5000m) (Masschelein et al., 2012) or a 
reduced inspired FIO2 (14%) administered via a gas mask (Vanhatalo et al., 2011). These 
studies demonstrated a nitrate dependent improvement in arterial and muscle oxygenation 
in both rest and exercise (Masschelein et al., 2012); also an improved exercise tolerance 
(Masschelein et al., 2012, Vanhatalo et al., 2011) occurring  alongside a reduction in markers 
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of  muscle fatigue (Vanhatalo et al., 2011). The work presented in the previous chapter on 
mouse skeletal muscle is in line with these findings by demonstrating the nitrate dependent 
partial recovery of mitochondrial function in hypoxia.   
Prior evidence therefore indicates that nitrate supplementation could potentially have 
considerable benefits for improving exercise tolerance in chronically hypoxic COPD patients. 
Whilst this has been investigated in COPD cohorts previously, these studies have produced 
confounding results likely due to limitations in study design. For instance, although benefits 
of nitrate supplementation have been demonstrated in COPD patients through increasing 
exercise time, these studies did not use a robust placebo (Berry et al., 2015, Kerley et al., 
2015). Other groups have failed to produce these results when using a robust placebo 
(Shepherd et al., 2015, Leong et al., 2015), however, in these studies, the nitrate dosing 
was below that which has been shown to enhance exercise performance in healthy subjects 
(Wylie et al., 2013). In the case of Leong and colleagues (Leong et al., 2015), testing was 
performed one hour post dosing, which is prior to the time taken for plasma nitrite levels to 
peak (Wylie et al., 2013).  
In addition to poor study design, an area lacking in these previous studies that could 
provide significant insight into the effects of nitrate supplementation on this complex disease 
population is metabolomic analysis.  NMR-based metabolomic assessment of plasma in 
COPD patients has been shown previously to uncover phenotypic information based upon 
a combination of systemic effects and lung-function parameters (Ubhi et al., 2012b). For 
instance, it has been used to distinguish between subtypes of COPD patients, with a cohort 
of 21-38 per patient phenotype. Amongst the distinguishing features were specific changes 
in amino acid metabolism in those patients additionally suffering from cachexia (Ubhi et al., 
2012a). The metabolomics approach thus presents as a means of accounting for the 
heterogeneity of this complex disease and it has been adopted by numerous studies to 
further disease characterisation. For example, it has been used to elucidate differences in 
metabolic profile in COPD patients (n=18) vs. controls (n=12) in response to exercise at 70% 
maximal work rate, which include differences in the levels of valine, alanine and isoleucine 
(Rodríguez et al., 2012). Endurance training was demonstrated to have a significant impact 
upon the metabolic profiles of healthy subjects that were not replicated in COPD patients, in 
whom the only training-induced effect was a decrease in lactate (Rodríguez et al., 2012). 
Given these significant advances made through employment of metabolomics techniques, 
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it thus makes sense to adopt this approach in the examination of nitrate dosing in these 
patients.   
5.2 Aims  
In this pilot study, the effects of a higher, acute dosing of dietary nitrate on exercise 
performance and plasma metabolites in COPD patients were investigated. The latter was 
achieved through targeted metabolomics using 1H-NMR.    
5.3 Hypothesis 
Nitrate supplementation would improve exercise performance by increasing 
endurance time and the effects would be apparent in changing plasma metabolites, 
providing an insight into the mechanisms of nitrate action.  
5.4  Methods 
5.4.1 Patient selection  
This study was approved by the Bromley Research Ethics Committee (reference 
13/LO/0372) and conducted in line with the principles of the Declaration of Helsinki. All 
participants provided written informed consent prior to enrolment in the study.  
COPD patients of GOLD stage II-IV (Rabe et al., 2007) were considered for inclusion 
in the study and were recruited through outpatient clinics at the Royal Brompton Hospital 
and through public outreach events such as World COPD day. Recruitment began on 24th 
June 2013 and was completed on the 28th April 2014, with follow-up completed on 3rd June 
2014. This study was registered prospectively on a publicly accessible database 
(www.iscrn.com/ISRCTN66099139) and all ongoing and related trials for this investigation 
were also registered.  
Detail on the recruitment process is depicted in Figure 5.1. Exclusion criteria for the 
study included patients taking nitrate-based medications or phosphodiesterase V inhibitors, 
those with other medical conditions likely to benefit from nitrate supplementation (including 
ischemic heart disease and peripheral vascular disease) and patients on long-term O2 
therapy or antibiotic therapy (whether on an acute of prophylactic basis). Patients 
considered clinically unstable (defined as being within one month of pulmonary 
exacerbation), suffering from hypotension or significant renal impairment 
(eGFR<50ml/min/1.73m2) were also excluded from the study.  
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5.4.2 Study design and randomisation  
 This study was a double-blind, cross-over, placebo-controlled trial. Beverages were 
allocated using computer-generated randomisation in blocks of 4. This was devised by an 
independent statistician with consecutive numbers linked to preparations of either placebo 
or active nitrate treatment. Researchers involved in the enrolment of patients or outcome 
measurements remained separate from the randomisation process and were blinded 
throughout the study and data analysis. The principle investigator who was not involved in 
any patient visits (Dr Hopkinson) held the randomisation list and indicated the order of 
patient assignment.  
 Nitrate supplementation was expected to induce a rise in plasma nitrate and nitrite 
levels, with nitrite being further reduced to NO. Increases in NO were in turn expected to 
induce vasodilation, to be observed as a decrease in blood pressure. In response to 
exercise, nitrate supplementation was hypothesised to increase time to exhaustion during 
symptom-limited cycle ergometry at 70% peak workload as assessed on an incremental, 
maximal, symptom-limited cardiopulmonary exercise test. Given previous reports of NO 
decreasing VO2, it was additionally hypothesised that nitrate supplementation would alter 
the area under the VO2 curve. As exercise test duration varied considerably for some 
subjects between the treatment and placebo exercise tests (irrespective of treatment 
condition), VO2 analysis was restricted to the time shared between the two tests. This 
approach, defined as exercise isotime, ensured discrepancies in exercise test duration did 
not affect analysis.  Changes in exercise performance with nitrate dosing were expected to 
be reflected through changes in metabolic profile, thus providing an indication of the 
potential mode of nitrate action.  
5.4.3 Intervention 
 140ml of BEET-IT Sport Stamina Shot (James White Drinks, Ipswich, UK) containing 
0.8g nitrate and 140ml of a matched placebo of beetroot juice specifically depleted of nitrate 
were used as the active and placebo preparations respectively.  The placebo preparation 
was identical in appearance and taste (Lansley et al., 2011), and also produced beeturia.  
The dose chosen was intended to provide a bolus of nitrate (12.9mmoles) exceeding that 
necessary to reduce O2 consumption during submaximal exercise in young healthy subjects 
(Wylie et al., 2013), and was selected as a convenient dosing method (2x 70ml bottles) 
which was readily acceptable and easily ingested.  
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Subjects were requested to avoid foods naturally high in nitrate in the 48hour period 
prior to the dosing visit and were asked to match food and caffeine consumption on the two 
days of testing.  Subjects were additionally asked to avoid use of mouthwash and chewing 
gum in the 48hour period prior to testing as this has previously been shown to reduce oral 
bacterial nitrate reductase activity (Govoni et al., 2008).  Subjects were also advised to avoid 
heavy exercise in the 24 hours prior to each dosing visit. 
5.4.4 Study conduct 
Following successful screening, the subjects attended the laboratory for 
measurement of baseline characteristics during which several parameters were recorded 
including vital signs, anthropometric measures, full pulmonary function testing and an 
incremental maximal symptom-limited cycle ergometry test was performed.  
On the dosing visits, conducted at the Royal Brompton & Harefield NHS Trust, subjects 
arrived in the morning. Following a 10 minute rest period, blood pressure measurements 
and baseline plasma samples were obtained, after which the patients were dosed.  3 hours 
later, both blood pressure measures and blood sampling were repeated prior to endurance 
cycle ergometry at a constant work rate (70% peak workload achieved on prior maximal 
incremental testing).  The cycle test was conducted at the same time on each occasion. 
Further blood draws were taken at peak exercise.  After a minimum wash-out period of 7 
days the protocol was repeated with the crossover beverage.  See Figure 5.1 for an outline 

























Figure 5.2. Blood samples timeline. 
Sampling was conducted at 4 time points throughout the study day. Example of blood 
sample being taken at peak exercise. 
  
Figure 5.1. Flow diagram of the double-blinded, placebo-controlled, cross-over single 
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5.4.5 Baseline characteristics  
Blood pressure and anthropometrics  
Blood pressure was measured using an automated blood pressure monitor (Omron 
M6, Omron Healthcare Europe, Hoofddorp, Netherlands).  Measurement was made in the 
seated position with the subject’s arm supported.  A mean of three measurements was 
recorded.  Height (cm) without shoes was measured using a wall mounted measure, and 
weight (kg) measured using standardised scales.   
Pulmonary function testing 
 Measurements were made in the lung function department of the Royal Brompton 
Hospital according to international guidelines and with rigorous quality assurance in place 
with a Jaeger master lab system (CompactLab system, Jaeger, Wurzburg, Germany).  
Spirometry, gas transfer and plethysmographic lung volumes were also measured in 
accordance with European Respiratory Society (ERS)/ American Thoracic Society (ATS) 
guidelines(Miller et al., 2005, Macintyre et al., 2005, Wanger et al., 2005).  Standardised 
lung function testing reference equations were based on the European Coal and Steel 
Community (ECSC) reference values(Gibson, 1993).  Capillary blood gas samples were 
taken at rest.   
5.4.6 Cycle ergometry 
A symptom limited incremental exercise test was performed at baseline on a bicycle 
ergometer (Ergoselect 100, Ergoline, Bitz, Germany) with metabolic measurements 
collected using a mouthpiece (Masterscreen CPX metabolic cart, CareFusion, Basingstoke, 
UK) and analysed using JLAB software (JLAB Lab Manager version 5.32, Jaeger, 
CareFusion, Basingstoke, UK) (See Figure 5.3).  Following a 2 minute rest period and 2 
minute free cycling workload increased by 5 Watts every 30 seconds with subjects being 
asked to maintain a speed of 60-70 revolutions per minute.  Measurements were taken of 
peak workload, VO2, VCO2, minute ventilation, respiratory rate and tidal volume.  Peak 
workload was defined as the greatest workload that the subject could maintain for a 30 
second period.   
To evaluate the effects of the intervention, endurance cycle ergometry testing was 
performed 3 hours following dosing at 70% peak workload.  This is within the time period at 
which it has been shown for plasma nitrite levels to peak in plasma following nitrate dosing 
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(Wylie et al., 2013). The endurance time was calculated as the time from the beginning of 
loaded cycling to the point of test cessation due to symptom limitation.  Breath-by-breath 
data was obtained and rolling 8-breath averages were used in the isotime analysis. Exercise 
isotime is defined as the time shared between the treatment and placebo exercise tests for 
each subject. This ensured discrepancy in the exercise test duration, which were 





Figure 5.3. A subject undertaking the submaximal cycle ergometry test performed at 
70% maximal workload until exhaustion. 





5.4.7 Plasma sample processing   
 All plasma samples (baseline, 3 hours post dosing, peak exercise and recovery) 
were obtained by venesection in lithium heparin tubes and immediately spun for 10 minutes 
at 520g at 4◦C.  The resulting supernatant was pipetted into 2ml polypropylene cryotubes, 
taking care to avoid any contamination from the buffy coat containing the white cells/ 
platelets atop the erythrocyte pellet, and immediately frozen at -80◦C. These samples were 
used both for nitrate/nitrite measurements and plasma metabolomics. 
 Unlike EDTA, the anticoagulant heparin gives only weak and very broad NMR 
resonances from polysaccharide moieties, thus having a limited effect upon the resulting 
spectra (Barton et al., 2010).  
Plasma nitrate/nitrite measurements 
Plasma samples were analysed from the following time points: baseline, post 
dosing/pre-exercise and peak exercise. 
Nitrate and nitrite plasma levels were assessed using a post-column diazo coupling 
reaction (Griess reaction) in combination with high-performance liquid chromatography 
(HPLC) (Eicom NOx analyser, ENO-20, San Diego, USA) (Rassaf et al., 2002).  Nitrate and 
nitrite were first separated on the analytical column (Figure 5.4).  Nitrite then reacted with 
the Griess reagent generating diazo compounds, with absorbance measured at 540nm 
using a spectrophotometric detector.  Nitrate passed through the reduction column and was 
further reduced to nitrite before undergoing the same diazo coupling reaction.  The peak 
areas of absorption of solutions of know standard concentrations were then compared to 





Figure 5.4. Instrumentation used to discern plasma nitrate and nitrite values. 
Nitrate and nitrite were firstly separated using high performance liquid chromatography 
(analytical column visible in A and B). Nitrite, followed by nitrate (which is firstly reduced to 
nitrite), then reacts with Griess reagent generating a red diazo compound, the absorbance 
of which was measured at 540nm using a spectrophotometric detector (bottom diagram) 
(C). 
 






Plasma metabolomics 1H-NMR 
Sample preparation for NMR spectroscopic analysis  
Plasma samples were defrosted at room temperature and centrifuged 
(13,000rpm/16,000g for 10mins). An aliquot of 300µl was then mixed with 300µl of NMR 
buffer (double distilled water containing 8% D2O). The resulting mixture was transferred to 
5mm NMR tubes within a 96-tube rack.  
NMR spectral acquisition 
1H-NMR spectra of plasma samples were obtained as described in Chapter 2 
(section 2.4.3). As in this section, samples were analysed on a subject by subject basis, 
meaning plasma taken from the same subject at all 4 time points was defrosted and 
prepared at the same time and run within the same NMR experiment. This was to ensure 
any daily differences in experimental procedure were removed from analysis when data 
between time points were compared.    
NMR data processing 
Data were Fourier transformed using an exponential window function with a line 
broadening of 0.3Hz in the frequency domain. Spectra were phased automatically using 
zero-order phase correction and baselined in Topspin 3.0 (Bruker Biospin, Karlsruhe, 
Germany) before being imported into Matlab (Mathworks, Natick, MA) at full resolution. All 
chemical shifts were manually referenced to formate (δ = 8.44 ppm). Following this, spectra 
were normalised using PQ normalisation (Dieterle et al., 2006) and binned using adaptive 
intelligent binning (De Meyer et al., 2008), both in Matlab.  
NMR Data Analysis  
The analysis strategy for this data set was a targeted approach focused upon 
assessment of specific metabolites that have been previously associated with exercise and 
with COPD sufferers (Rodríguez et al., 2012, Nobakht M. Gh et al., 2015). This included: 
lactate, alanine, acetate, glucose, β-hydroxybutyrate, L-arginine, citrate and isoleucine. 
Lactate, glucose and isoleucine are particularly relevant in this thesis, given their association 
with progressive hypobaric hypoxic exposure unveiled in chapter 2.    
The ppm values for the discernible peaks of these metabolites were identified. The 
corresponding binned value, and so spectral region containing this peak(s), was taken 
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forward for analysis. The focus was upon the change in these metabolites between 
treatment conditions from peak exercise compared to pre (post dosing).  The difference 
between time points was therefore calculated (peak-pre) and a paired students’ t-test was 
subsequently performed to assess differences between the treatment and placebo groups.   
The patient cohort included a range of disease severities clearly distinguished by 
differences in GOLD stage. Previously metabolite changes (specifically perturbations in 
amino acid metabolism), identified through targeted metabolomics, have been shown to 
distinguish between sub-categories of COPD patients (Ubhi et al., 2012a). Therefore, 
analysis was taken further to separate those of GOLD stage I-II from III-IV and distinguish 
whether metabolite changes between these two sub-categories could be identified.   
5.4.8 Data analysis and statistics  
A convenience sample of 25 was studied to offer a good chance of identifying a 
clinically meaningful effect, with 21 of these subjects fully completing the study protocol.  
Data are presented as mean ± standard deviation and were analysed using GraphPad Prism 
version 7.0 for Windows (GraphPad Software, San Diego, California, USA).  
Repeated measures analysis of variance (ANOVA) was used to compare plasma 
nitrate metabolites between treatment conditions and at each specific time-point. To 
compare O2 consumption between study conditions, individual cardiopulmonary exercise 
test data periods were expressed as percentiles of isotime (the duration of the shorter of the 
two tests) and the individual responses grouped to allow analysis of VO2 against percentage 
of isotime (plotted at the midpoint of each 10th percentile of isotime).  The area under this 
curve was assessed for each subject and the two conditions then compared using a paired 
student t-test.  Resting and isotime measurements between treatment conditions were 
compared using paired t-tests, or the appropriate non-parametric test for data that was not 
normally distributed. In the case of endurance times, which did not fit a normal distribution, 
a Wilcoxon test was used to compare median values between the two treatment groups.  
For all results, a p-value of <0.05 was considered to be statistically significant. 
Correlations were mapped to assess whether changes in nitrate handling were 
responsible for changes in physiological parameters induced by nitrate dosing. For this, Δ 
nitrate and nitrite pre (post dose): peak exercise was correlated with the following:  ΔVE, 
ΔVO2, Δ power/VO2. A large degree of variability was also observed in exercise endurance 
time between subjects, therefore this was also correlated to Δ. To assess whether this 
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variability was related to changes in nitrate handling, the change in endurance time between 
treatments was also correlated to plasma nitrate/nitrite changes. Lastly, the subject cohort 
had a distinct variation in GOLD stage. Therefore, to examine whether the variability in 
nitrate handling was influenced by disease severity, a measure of airway obstruction, FEV1, 
was plotted against plasma nitrate/nitrite changes. 
Data that were normally distributed (tested using D’Agostino-Pearson (omnibus K2) 
normality test) were analysed using Pearson correlation coefficients, with two tailed P 
values. Otherwise, Spearman Correlation was used for data that was not normally 
distributed.  Again, a p-value <0.05 was considered to be statistically significant. Linear 
regression was subsequently performed if this was the case.  
5.5  Results  
5.5.1 Subjects 
Of the 25 subjects enrolled in the study, 21 completed the full study protocol (Figure 
5.5). Recruitment began in June 2013 and the trial was completed by June 2014, by which 
time the 25 enrolled subjects had either completed or been withdrawn from the study. 
Baseline characteristics that are relevant for the purposes of this thesis are presented in 
Table 5.1. All patients were 100% compliant with the dosing protocol and no adverse effects 
























Note: (n=21), presented as mean +/-SD. BP-blood pressure; BMI-body mass index; FEV1- 
forced expiratory volume in 1 second; RV- residual volume; TLC-total lung capacity, PaO2 – 
partial pressure of arterial O2; VO2 – pulmonary oxygen uptake, GOLD – Global initiative for 
chronic obstructive lung disease.   
Measurement Mean SD (+) 
Sex (male:female) 16:5 
 
Age (years) 68 7 
Systolic BP (mmHg) 137 19 
Diastolic BP (mmHg) 79 7 
BMI (kg/m2) 25.2 5.5 
FEV1(L) 1.33 0.58 
FEV1 % predicted  50.1 21.6 
RV % predicted 167 53 
TLC % predicted  119 14 
RV/TLC ratio (%) 52.3  8.7 
PaO2 (kPa) 10.7 1.2 
Peak power on cycle (Watts) 71.9 30.8 
Peak VO2 (ml/min/kg) 18.0 5.9 
GOLD I/II:III/IV 12:9 
 
Figure 5.5. CONSORT recruitment diagram for enrolment and study recruitment. 
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5.5.2 Venous nitrate and nitrite measures  
Alterations in plasma nitrate at each time point are presented in Figure 5.6. As 
expected, significant increases in plasma nitrate levels were observed post dosing with 
nitrate-rich beetroot juice (37.0 + 16.4µM baseline vs. 820.2 + 187.7µM post dosing, 
p˂0.0001). Levels remained elevated at peak exercise, although a greater variability was 
observed between subjects (917.1 + 291.6 µM) (Individual values plotted in Figure 5.7A). 
No significant changes were observed in plasma nitrate with placebo treatment (45.7+ 
15.8µM baseline vs. 45.3µM + 16.5µM post dosing).  
For changes in plasma nitrite, levels at baseline for all bar 3 subjects were below the 
quantifiable limit (0.2µM) to be detected.  The representation of changes from baseline to 
pre and post exercise levels are therefore only presented for plasma nitrate. Plasma nitrite 
levels remained at this level for the placebo treatment, but underwent a significant increase 
following nitrate supplementation to 1.57 + 0.98µM. Despite the slight decrease in value, 
this level was retained at peak exercise (1.37+ 0.65µM) (Figure 5.7B).  
These results thus demonstrate that the nitrate dosing altered plasma levels of 
nitrate metabolites (nitrate and nitrite), but that there was a large degree of variability 
between subjects. Baseline measurements of plasma nitrate ranged from 16-70µM. 
Changes in nitrate levels from baseline to post dosing ranged from 483.7-1217.4µM and 
post dosing plasma nitrite levels ranged from 0.5-4.0µM. To investigate whether a 
relationship existed between the individual degree of change in nitrate and nitrite following 
nitrate dosing, these two variables were correlated (Figure 5.8). However, no significant 
correlation was revealed.  
Further investigation into possible inter-individual differences in nitrate handling are 

















































Figure 5.6. Alterations in plasma nitrate following dosing. 
Plasma nitrate concentrations assessed prior to dosing at baseline, post dosing (pre exercise) 
and at peak exercise. This includes the initial post dosing/pre-exercise time point, taken 3 
hours following placebo/nitrate beverage consumption, and peak exercise, taken at the point 
of exhaustion following submaximal endurance cycle ergometry testing. *Significantly different 




Figure 5.7. Plasma nitrate (A) and nitrite (B) levels post dosing (pre-exercise) and at 
peak exercise represented as individual values. 




Figure 5.8. Correlation of the Δ nitrate pre (post dosing): peak exercise against Δ 
nitrite. 









































































5.5.3 Blood pressure  
 Changes to systolic, diastolic and mean arterial blood pressures at 3 hours post 
dosing in comparison to baseline measurements are presented in Figure 5.9. Diastolic 
blood pressure underwent a significant decrease with nitrate dosing, with the nitrate treated 
group undergoing a 7 + 8 mmHg reduction from baseline (p = 0.008) in comparison to a 1 + 
8mmHg reduction with placebo treatment. Neither systolic nor mean arterial pressures 
(MAP) underwent any significant alterations with nitrate treatment, however, MAP did 
display a numerical decrease although this was not statistically significant (7 + 8 nitrate vs. 
3 + 8mmHg placebo, p=0.07).  
5.5.4 Endurance exercise time during 70% max workload 
 Individual cycle ergometry endurance exercise times at 70% max workloads are 
presented for both treatments in Figure 5.10.  No significant difference was found in median 
endurance time between the treatment groups (5.65 (3.90-10.40) nitrate vs. 6.40 (4.01-9.67) 
minutes placebo, p=0.50). A treatment order effect was tested for, but again, no significant 
difference was observed between the Δ endurance time if the placebo was administered 






Figure 5.9. Blood pressure changes following nitrate dosing. 
Blood pressure parameters including systolic blood pressure (sBP), diastolic blood pressure 
(dBP) and mean arterial blood pressure (MAP)) are presented as 3hr post dose (pre-




Figure 5.10. Endurance time during cycle ergometry.  
This was performed at 70% maximal workload assessed in both placebo and nitrate dosing 
conditions. No significant difference in endurance time was found between the two 

































































5.5.5 Rest and isotime analysis of cardiopulmonary 
exercise test parameters 
Mean values for all cardiopulmonary parameters at both rest and isotime (being the 
longest time of equivalent exercise completed under either study condition) are presented 
in Table 5.2. At isotime, significant decreases were observed in minute ventilation (VE) (4.5 
(±10.6) %, p=0.029), pulmonary O2 uptake (VO2) (3.3% (±9.1) %, p=0.043) and relative O2 
pulse (2.3 (± 11.9) %, p=0.043) (Figure 5.11 A-C). A numerical improvement was observed 
in the power/VO2 relationship with a 4.3 (± 9.7) % increase, which was close to significance 
(p=0.053) (Figure 5.11D). No significant changes were observed in any other parameter 
presented in table 2 at either rest or isotime, including: heart rate, breathing frequency, tidal 
volume, exhaled carbon dioxide production and peripheral arterial O2 saturation. In addition, 
no alteration was reported in the rating of perceived exertion with exercise, as the average 
Borg scale values for dyspnea at peak exercise were 5 (± 3) and for legs 3 (± 2) across both 




Table 5.2. Cardiopulmonary exercise testing presented as rest and isotime 
 
Note: Data are presented as mean (SD). *p˂0.05. Abbreviations: HR – heart rate, BF – 
breath frequency, VT – tidal volume, VE – minute ventilation, VO2 – pulmonary oxygen 
uptake, VCO2 – exhaled carbon dioxide production, SpO2 – peripheral oxygen saturation.   
 
   




Difference (+SD) P 
value 
HR (bpm) Rest 85 (11) 87 (11) 2 (7) 0.063 
HR (bpm) Isotime 122 (17) 121 (20) -1 (10) 0.30 
BF (breaths/min) Rest 16 (4) 17 (4) 1 (3) 0.095 
BF (breaths/min) Isotime 32 (8) 32 (5) 0 (7) 0.48 
VT (L) Rest 0.93 (0.43) 0.87 (0.25) -0.06 (0.26) 0.33 
VT (L) Isotime 1.44 (0.39) 1.40 (0.47) -0.04 (0.18) 0.12 
VE (L/min) Rest 13.27 (3.90) 13.37 (3.95) 0.10 (2.29) 0.34 
VE (L/min) Isotime 43.85 (13.94) 41.88 (14.85) -1.97 (4.52) 0.029* 
VO2 (ml/min/kg) Rest 4.5 (1.2) 4.4 (1.3) -0.1 (0.9) 0.32 
VO2 (ml/min/kg) Isotime 17.2 (6.0) 16.6 (6.0) -0.6 (1.48) 0.043* 
VCO2 (ml/min/kg) Rest 4.2 (1.2) 4.2 (1.3) 0.0 (0.82) 0.49 
VCO2 (ml/min/kg) Isotime 17.1 (6.0) 16.7 (6.3) -0.4 (1.74) 0.14 
SpO2 (%) Rest 95 (2) 96 (2) 0 (2) 0.26 
SpO2 (%) Isotime 92 (4) 93 (4) 1 (2) 0.15 




0.051 (0.014) -0.002 (0.010) 0.15 
Relative oxygen 
pulse(ml/beat/kg) 
Isotime 0.143 (0.039) 0.138 (0.036) -0.0005 (0.014) 0.043* 




Figure 5.11. Cardiopulmonary isotime exercise test parameters presented in the 
placebo and nitrate treated conditions 
A. Minute ventilation (VE), B. Pulmonary O2 uptake (VO2), C. Relative O2 pulse, D. 
Power/VO2 relationship. Calculated by dividing the power output (W) at 70% VO2 max by 






















































































































VO2 curves to isotime 
 The average VO2 curve to isotime is presented in Figure 5.12. A separation is visible 
between the two treatment conditions. This is reflected in the 7.3 (±0.8) % drop (p=0.027) in 
the amplitude of area under the curve (AUC) with nitrate treatment, which is displayed in 
Figure 5.13.  
 
5.5.6 Plasma metabolomics using 1H-NMR 
 Analysis of select plasma metabolites, assessed using 1H-NMR, presented in Figure 
5.14, revealed no significant difference in abundance between pre-exercise (post dosing) to 
peak exercise between the two treatment conditions. Separation of the patient cohort by 
GOLD stage also did not reveal any significant differences.  
5.5.7 Correlation analysis 
 As presented above, a large inter-individual variability in both plasma nitrate and 
nitrite levels were observed in the response to exercise following nitrate dosing. To 
investigate the presence of subgroups in response to nitrate dosing (i.e. responders vs. non-
responders), the difference in plasma nitrate and nitrite from pre-exercise (post dosing) to 
peak exercise were correlated with the following exercise parameters: ΔVE, Δ VO2, Δ AUC 
VO2 Δ power output/VO2 and Δ endurance time. No significance was observed in the 
correlations with Δ plasma nitrate (Figure 5.15) or Δ plasma nitrite (Figure 4.16). The large 
spread of data that can be observed in these correlation plots highlights the complexity of 
this patient cohort. To investigate the effects of a measure of disease severity upon plasma 
nitrate/nitrite changes, Δ plasma nitrate/nitrite was correlated with FEV1 (Figure 5.17). 
Whilst no correlation was observed with Δ plasma nitrate, significance was observed with Δ 
plasma nitrite (Figure 5.17B). This is despite a weak r2 displayed from linear regression 
analysis (p = 0.0486, r2= 0.189).  
It has been demonstrated previously that resting plasma nitrate levels in healthy 
subjects correlate with maximal power output (W) (Jungersten et al., 1997). This association 
between physical fitness and nitrate metabolism was investigated in this cohort (Figure 






Figure 5.12. Average isotime VO2 analysis. 
VO2 is presented at each 10
th percentile of isotime (n=21). 0% represents the initiation of 
loaded cycling at 70% maximal workload (as assessed by incremental cycle ergometry). For 
reasons of visibility, error bars are not included.   
 
 
Figure 5.13. Area under the curve to VO2 isotime (AUC) presented as individual 
responses to placebo and nitrate treatments. 
A significant decrease occurred between placebo and nitrate treated groups *p=0.027, as 
assessed using a Paired T test. n=21.  
 













































Figure 5.14. Plasma metabolite changes in placebo and nitrate conditions 
Metabolites expressed as pre (post dosing): peak exercise ratio, with a value of 1 indicative 
of no change. Paired t-tests were utilised to compare metabolite levels between treatment 





































































Figure 5.15. Correlations between changes in plasma nitrate (pre (post dosing) to 
peak exercise) and changes in exercise parameters to placebo and nitrate treatment. 
This includes: A. Minute ventilation (VE), B. Pulmonary O2 uptake (VO2), C. the power/VO2 
ratio and D. Endurance time, E. Area under the curve (AUC) VO2. n=21. No significant 
correlation was identified.  
  













































Figure 5.16. Correlations between changes in plasma nitrite (pre (post dosing) to peak 
exercise) and changes in exercise parameters between placebo and nitrate treatment. 
This includes: A. Minute ventilation (VE), B. Pulmonary O2 uptake (VO2), C. the power/VO2 
ratio and D. endurance time, E. Area under the curve (AUC) VO2. n=21. No significant 
correlation was identified. 












































Figure 5.17. Correlations between changes in plasma nitrate and nitrite at pre (post 
dosing) and peak exercise and forced expired volume in 1 second (FEV1). 
A significant negative correlation was observed using Pearson correlation coefficient) in Δ 
plasma nitrite vs. FEV1, (P=0.0486), n=21 
 
 
Figure 5.18. Correlation between baseline plasma nitrate (taken as an average across 
both study arms) and maximal power (W). 
No significant correlation was identified. n=21 
  

















 = 0.1895, P = 0.0486
Y= -0.3206*X  + 1.266



















5.6  Discussion 
 In this chapter, the effects of acute nitrate supplementation (12mM nitrate vs. 
placebo ingested 3hours pre-exercise) upon endurance exercise time and related metabolite 
changes were investigated in COPD patients (n=21, age 68+7 years, GOLD I-IV). The 
nitrate-rich beetroot juice dose had the expected response of increasing circulating plasma 
nitrate within 3 hours of dosing, occurring alongside increases nitrite formed via reduction. 
The biological activity of this nitrate dose, thought to be mediated via NO, was reflected 
through changes in diastolic blood pressure at rest. In addition, decreases were observed 
in both oxygen consumption (VO2), minute ventilation (VE) and relative O2 pulse at exercise 
isotime with nitrate treatment. However, no effect was observed upon endurance time and 
so exercise performance, between the two treatments. In addition, no changes were 
observed in plasma levels of metabolites associated with exercise and COPD 
pathophysiology.   
5.6.1 Effective dosing with nitrate-rich beetroot juice 
shown through plasma nitrate/nitrite levels  
Inherent variabilities have been reported in previous studies to nitrate treatment, with 
even elite athlete populations displaying subgroups of ‘responders’ and ‘non-responders’ 
that are suggested to be linked to inter-individual differences in oral nitrate reductase activity 
(Hultström et al., 2015). The combined effects of advanced age along with the complex 
pathophysiology of COPD upon digestion, enterosalivary circulation and activity of oral 
commensal bacterial upon dietary nitrate intake are unknown. Consequently, the capacity 
of subjects to respond to nitrate treatment was also uncertain. This is on the background of 
a lack of consensus amongst previous studies examining the effects of nitrate 
supplementation upon COPD patients, with some showing no beneficial effects (Shepherd 
et al., 2015, Leong et al., 2015). A key concern with the current chapter therefore was that 
nitrate metabolism may be impacted in this population and that the nitrate dose administered 
would not translate to a subsequent increase in biologically active NO.  
Baseline recordings of plasma nitrate, and so endogenous levels, were within the 
range (16.0-70.2uM) of those reported in healthy subjects with varying physical capacities 
(Jungersten et al., 1997). Endogenous plasma nitrate levels are thought to be the major 
inactive pool of NO, resulting from a reaction with Hb to form NOHb, followed by subsequent 
conversion to nitrite and finally nitrate (Yoshida et al., 1980). Whilst this measure does not 
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give insight into the degree of NO stored within S-nitrosylated proteins or the tissue 
localisation of NO production, it does give an indication of endogenous NO production and 
so suggests that this is within normal range. A further assessment of endogenous NO activity 
can be gained through correlation between plasma nitrate levels and maximal power output, 
as in healthy cohorts, increasing resting plasma nitrate levels are shown to correlate with 
increasing maximal power output (Jungersten et al., 1997). However, this relationship was 
not apparent in the data, which may indicate that the association between physical fitness 
and NO production reported in healthy subjects may be affected in this disease population. 
In response to dosing, plasma nitrate levels achieved with dosing (22-fold increase) 
exceeded those produced by administration of a higher dose of nitrate in healthy young 
individuals (Wylie et al., 2013). A concomitant rise in plasma nitrite was accompanied by 
decreasing dBP, a parameter mediated via NO action. This observation is in line with 
previous studies on healthy subjects (Larsen et al., 2006, Webb et al., 2008)  and COPD 
patients (Berry et al., 2015, Kerley et al., 2015). Interestingly, the range of plasma nitrate 
concentrations was greater at peak exercise compared to pre-exercise, with the average 
concentration being numerically (although not significantly) higher. This may be explained 
by the conversion of biologically active NO to the nitrate storage pool.  
Whilst these results go to suggest that the reduction of dietary nitrate in the patient 
cohort was unaffected in comparison to healthy subjects (Larsen et al., 2006, Carlstrom et 
al., 2010), correlation analysis demonstrated that an increase in airway obstruction (FEV1) 
may be associated with lower plasma nitrite levels. This may suggest that nitrate reduction 
could be implicated in more severe cases of COPD.   
It can therefore be concluded that this patient cohort displayed similarities in nitrate 
metabolism with healthy populations and were responsive to nitrate dosing. However, 
certain aspects of the response to nitrate dosing may be affected and are worthy of note for 
future investigations in this complex disease population.   
Of potential concern relating to the plasma analysis were baseline levels of nitrite, 
which fell below the quantifiable limit in the vast majority of subjects. There are two 
explanations for this, one being the presence of a small interfering peak thought to originate 
from beetroot juice. The second is that samples were not treated with thiol-blocking agent 
prior to centrifugation. This treatment prevents flux of nitrite across blood cell membranes, 
which may act to lower plasma concentration. Although we were unable to observe baseline 
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nitrite production, high levels of plasma nitrites were readily measured following nitrate 
dosing.   
In this chapter, nitrate dosing occurred in the absence of any adverse side effects, 
aside from beeturia.  A singular, higher dose of nitrate is therefore both safe and biologically 
active in the COPD patient population. The unchanging nitrate levels in the placebo 
treatment from baseline also confirmed that the placebo was robust.  
5.6.2 Effects of nitrate dosing upon exercise physiology  
 Contrary to the study hypothesis, nitrate dosing did not improve endurance exercise 
performance, as no significant difference in endurance time was observed between 
conditions. This occurred along with unchanged levels of perceived exertion, either in the 
legs or in the level of dyspnoea. These results thus indicate exercise tolerance was 
unaffected with nitrate treatment. This is in spite of a reduced O2 requirement of exercise, 
shown through a decrease in pulmonary O2 uptake by 3.3%, which is a similar magnitude to 
that recorded in healthy individuals in response to nitrate treatment (Wylie et al., 2013). 
Alongside this was a fall in minute ventilation and a numerical (close to significant) increase 
in the power/VO2 relationship. Correlation analysis did not reveal any significant trends 
between these exercise parameters and the change in plasma nitrate/nitrite during exercise, 
indicating that inter-individual variation in nitrate metabolism did not affect the degree of 
physiological change observed. Indeed, the spread of data in these plots demonstrate the 
heterogeneity of this population.    
 Decreasing O2 uptake during exercise occurred in the absence of impairment in 
power output, which is a well-recognised response to nitrate supplementation in healthy 
humans (Larsen et al., 2011, Larsen et al., 2007, Bailey et al., 2009, Vanhatalo et al., 2010, 
Lansley et al., 2011), but has not been reported previously for COPD patients. The 
mechanisms behind this response are not clear, but may involve a combination of enhancing 
the following: changes in blood flow to working muscles (Cosby et al., 2003, Bentley et al., 
2014), effects upon energy consuming processes required for  skeletal muscle contraction 
(Evangelista et al., 2010, Ishii et al., 1998) and  improved efficiency of mitochondrial 
oxidative phosphorylation. The latter may be best explained through the action of NO at the 
respiratory chain, as it has been demonstrated to be an inhibitor of complex IV activity, which 
is the site of O2 consumption (Brudvig et al., 1980, Brown et al., 1994). However, unlike the 
outcome measures from prior studies involving healthy human studies (Bailey et al., 2009, 
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Cermak et al., 2012, Wylie et al., 2013), the drop in VO2 was not accompanied by 
improvements in submaximal exercise performance.  
There are a number of possible explanations for failing to see any change in 
submaximal endurance time, a key factor being the large degree of variability in exercise 
time. This is somewhat expected, given the day-to-day symptom variability in COPD 
(Kessler et al., 2011). But the extent of variability was surprising as it was beyond what has 
been observed in previous endurance cycle ergometry tests at 75% peak workload in a 
similar population (O’Donnell et al., 2011). It is possible that familiarising subjects to the 
endurance test through a trial run could improve consistency. However, this is improbable 
given that no order affect was identified. It is also possible that incorporating a larger sample 
size may have given a positive result through improving statistical power, however, this is 
unlikely given that exercise time was numerically shorter in the nitrate treated group. The 
desired effect of improving endurance capacity in these subjects would not likely be 
achieved through an increase in nitrate dosing, although this may further alter plasma NO2- 
and the O2 cost of moderate intensity exercise (Wylie et al., 2013).  
It may simply be that the small improvements in the O2 cost of exercise observed 
with nitrate treatment do not affect the rate limiting parameters of exercise in ventilatory 
limited patients. It may also be the case that effects upon exercise performance with nitrate 
dosing become more apparent in patients who are more severely affected by COPD, in 
which case this chapter focused upon the wrong patient group as patients on O2 
supplementation were not included. It may be possible that a reduction in the O2 cost of 
exercise offers the greatest benefit in this patient phenotype.  
Lastly, it has been shown that the effects of dietary nitrate upon skeletal muscle 
contractile processes, including increasing contractile force and intracellular [Ca2+], is most 
prominent in fast twitch type II fibres (Hernández et al., 2012). Beneficial effects of nitrate 
supplementation may therefore become more apparent in response to short duration, high 
intensity exercise requiring recruitment of this fibre type.   
5.6.3 Unchanging metabolite levels indicate no 
compensatory increase in anaerobic glycolysis 
The analytical strategy adopted towards plasma metabolite analysis was for a 
targeted approach of select metabolites, either those known to be affected by exercise or 
those previously reported through metabolomics approaches to be affected in this disease 
260 
 
population (Rodríguez et al., 2012, Nobakht M. Gh et al., 2015).  Whilst no significant 
changes were observed in any of the targeted metabolites between treatments, these results 
do still provide an interesting insight. The lack of change in plasma lactate as well as glucose 
is an indication of no alteration in anaerobic metabolism, given that glucose is the substrate 
and lactate the metabolic end-product of anaerobic glycolysis. This is in line with previous 
reports that demonstrate decreasing VO2 induced via nitrate supplementation is not 
compensated for by an increase in anaerobic means of ATP generation (Bailey et al., 2009, 
Larsen et al., 2007).  
Equally, the lack of change in other metabolites assessed indicate that the nitrate 
effects happen independently of associated pathways. This includes: TCA cycle activity 
indicated by the key components/intermediates acetate (from which acetyl CoA is derived) 
and citrate; ketone body metabolism indicated by β-hydroxybutyrate; as well as amino acid 
metabolism demonstrated by alanine, L-arginine and isoleucine.  
5.7  Conclusion 
 Acute oral administration of nitrate did not alter median endurance time nor targeted 
metabolomic analysis in COPD patients. However, the nitrate dose was associated with a 
decrease in VO2 and VE with submaximal exercise. This was not accompanied by increasing 
plasma lactate or decreases in plasma glucose, indicating these effects occurred in the 
absence of a compensatory rise in anaerobic glycolysis. Further investigation into the 
potential of nitrate supplementation as an ergogenic aid for COPD sufferers should 
encompass different durations of supplementation and exercise intensities and should 






6 Chapter 6: General Discussion 
6.1  Summary of findings 
The work presented in this thesis encompassed two overarching themes:  
1. To further understanding of metabolic acclimatisation in healthy humans in the face 
of environmental hypoxia 
2. To elucidate the potential for dietary nitrate supplementation to alleviate hypoxic 
induced metabolic stress.  
This first theme was approached through examination of plasma and serum metabolic 
(and lipidomic) profiles obtained from healthy humans exposed to high altitude of differing 
durations and severity. In Chapter 2 (study 1), plasma metabolic and lipid profiles were 
assessed in a large subject cohort exposed to progressive hypoxia through a strictly 
controlled ascent to EBC. The results were indicative of a shift towards anaerobic glycolysis, 
mobilisation of fat stores and impairment of de novo lipogenesis with ascent. This was 
alongside an indication of changes to lipoprotein transportation. In Chapter 3 (study 2), 
plasma metabolic profiles were assessed alongside various physiological measures in a 
small number of subjects exposed to chronic hypoxia and extreme cold during a 33-week 
attempted crossing of Antarctica in winter time. Results revealed a shift in metabolic profile, 
with an increased reliance upon carbohydrates during exercise post expedition. This was 
alongside alterations to body composition, with loss of fat tissue, and a decline in spine BMD.  
 The second overarching theme of this thesis was approached firstly at the mechanistic 
level in Chapter 4 (study 3), through use of a mouse model in which a master regulator of 
β-oxidation, PPAR-α, was genetically ablated. Here, prolonged dietary nitrate 
supplementation recovered decreases in pyruvate OXPHOS and long chain fatty acid LEAK 
state respiration induced by 4 weeks severe hypoxic exposure (10% O2). However, 
mechanisms of nitrate action remain unclear, although they do appear to be induced 
independently of PPARα. The potential for nitrate supplementation to aid hypoxic 
acclimation was further examined in a clinical (COPD) population in Chapter 5 (study 4). 
The desired result of increasing performance through improvements in endurance time were 
not observed. However, VO2 decreased in the absence of a compensatory increase in 






Figure 6.1. Summary of thesis study findings. 
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6.2  Metabolic remodeling induced by environmental 
hypoxia 
As already outlined in depth, the controversy surrounding metabolic remodelling in 
response to hypoxic exposure calls for more stringent investigation.  The work in this thesis 
highlighted several metabolic pathways and potential biomarkers of interest in healthy 
humans affected by environmental hypoxia.  
The work presented in Chapters 2 and 3 identified clear alterations to carbohydrate 
metabolism. In response to acute, progressive hypoxia experienced in Chapter 2, the 
increased circulating lactate along with decreased glucose were indicative of an increased 
reliance upon anaerobic glycolysis for ATP generation. The fall in plasma glucose was also 
associated with a decrease in body weight. The role of carbohydrate metabolism appeared 
equally important in long term exposure, as demonstrated in Chapter 3, whereby decreases 
in plasma glucose were accompanied by increases in RER during exercise. These 
responses align with previous reports of either maintenance or enhancement of glycolytic 
capacity in the face of hypoxic exposure (Horscroft et al., 2014, Cole et al., 2016).  Whilst 
the results in this thesis do not provide detailed insight into glycolytic pathway changes with 
regards to transporter protein or enzyme activity changes, they did confirm the importance 
of carbohydrate metabolism in response to both acute progressive and chronic hypoxic 
exposure.   
Alongside increasing reliance upon carbohydrate oxidation, a body of evidence goes to 
suggest that this is accompanied by a shift away from O2 costly fatty acid metabolism 
(Horscroft et al., 2014). Examination of lipid metabolism is therefore of utmost importance 
when considering high altitude adaptation. This was addressed in most depth in Chapter 2, 
whereby lipidomic analysis of plasma revealed substantial alterations to TG storage and 
mobilisation, with accompanying increases in free fatty acids, alongside changes to lipids 
that are crucial to membrane composition with ascent. The rise in unsaturated fatty acids 
was associated with the loss in body weight. To the author’s knowledge, this was the first 
time plasma lipid profile changes have been examined in such a large study cohort 
undergoing altitude ascent. Comparison to prior altitude studies is therefore limited and 
consideration of potential causes of these changes, for instance through the sympathetic 
nervous system responses, was largely speculative. However, it did highlight that the 
dynamics of adipose tissue and the transportation of fat are crucial in hypoxic induced 
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metabolic remodeling.  The results also highlighted the importance of lipids acting as 
indicators of membrane structural changes. The body composition changes outlined in 
response to prolonged hypoxic exposure experienced in Chapter 3, with body fat decreasing 
post expedition, suggest changes in lipid metabolism may be sustained over longer periods. 
An aspect of metabolism often overlooked in high altitude investigation is that of amino 
acids. The substantial decrease in isoleucine levels with ascent observed in Chapter 2 was 
thus a novel finding. The role of BCAA’s in metabolism is gaining increasing interest, with a 
growing body of evidence supporting their role as metabolic regulators in protein, lipid and 
glucose metabolism (Zhang et al., 2017). Plasma isoleucine levels may therefore present 
as an important biomarker for induction of metabolic remodeling in hypoxia, particularly 
hypoxic scenarios whereby nutrient uptake and preservation of muscle mass are severely 
compromised, for instance in critical care patients  (Ackland et al., 2000, Puthucheary et al., 
2013).  
Interestingly, measures of SpO2 reported in Chapter 2 did not correlate with changes in 
any of the identified metabolites/lipids. This thus suggested that inter-individual differences 
in the degree of O2 delivery to the tissues may not directly impact the metabolic 
acclimatisation processes.  
6.3  Dietary nitrate as a potential alleviator of 
hypoxic induced metabolic stress 
Much debate surrounds the field of nitrate supplementation. The reported actions upon 
O2 delivery and consumption at the level of the mitochondria make nitrate supplementation 
appear an ideal candidate for aiding metabolic acclimatisation to hypoxic exposure. The 
investigation into the mechanisms of nitrate action in hypoxia and the effects of nitrate 
supplementation on performance as was conducted in this thesis was therefore warranted.  
In Chapter 4, nitrate supplementation was found to enhance very specific aspects of 
skeletal muscle mitochondrial function. In spite of previous reports of the dependence of NO 
action upon PPARα signaling (Ashmore et al., 2015a), these affects were found to occur 
independently of PPARα, as demonstrated through the use of PPARα genetic ablation. It 
may be that mechanisms alter depending on the degree and duration of hypoxic exposure, 
with the prolonged period examined in Chapter 4 allowing sufficient time for compensatory 
mechanisms to be initiated. For instance, the role of PPARδ in this model required more in-
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depth investigation. In addition, comparison to the responses of other tissues would be 
beneficial to determine whether the observations are specific to skeletal muscle. It would 
also be beneficial to investigate the possible translation of these effects at a whole-organism 
level and in response to an exercise challenge.   
In Chapter 5, a decreased VO2 during submaximal exercise was reported with nitrate, 
yet endurance time did not undergo a significant change. The implications of a fall in O2 
requirement were thus unclear. The absence of a rise in plasma lactate was indicative of an 
absent compensatory increase in anaerobic glycolysis, as has been reported previously 
(Bailey et al., 2009, Larsen et al., 2007). However, neither the consequences upon the O2 
cost of ATP production (so mitochondrial P/O ratio) (Larsen et al., 2011) nor the ATP cost 
of force production (Bailey et al., 2010) can be determined. Further investigation is therefore 
required to outline any potential benefits of such dietary intervention upon the exercise 
capacity of this hypoxic patient cohort.  
There are a number of factors that could be included into the study design of future work 
into dietary nitrate supplementation in the COPD patient cohort. This includes the choice of 
exercise intervention, for instance a lower % of peak may prove to be more tolerable for this 
patient group. Another possibility is altering the focus away from endurance towards 
recruitment of type II fibres through short exercise bursts at a higher intensity. In addition, 
the dosing regimen could be extended to examine effects beyond an acute bolus dose. 
Finally, focusing on a specific subtype of this patient population, for instance upon GOLD I/II 
or GOLD III/IV rather than including both within the same study may help to improve 
homogeneity of responses between subjects.  
6.4  Critique of methodology 
6.4.1 Critique of metabolomics/lipidomics 
Both metabolomics and lipidomics have the capacity to provide a highly sensitive 
measure of biological phenotype and to unveil potential biomarkers related to perturbations 
such as environmental hypoxia. Employment of these techniques can thus present as a 
powerful analytical tool, particularly when used in conjunction. For the purposes of this 
thesis, the adoption of these techniques was aimed at identifying potential biomarkers that 
could be examined in more detail in future investigations. The lack of consensus surrounding 
metabolic remodelling in hypoxia means that further investigation into this field lends itself 
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to untargeted and hypothesis generating approaches, as was adopted with the 
metabolomics experiments performed in this thesis.  
The profiling approach does have limitations, however, particularly when examining a 
small diverse cohort. In the instance of Chapter 5, a small cohort with a large range of 
pathological complications were examined. A targeted approach to metabolomic analysis 
was therefore adopted. This analysis had limitations given that key patterns of change in 
metabolic profile are omitted. Despite the low subject numbers, patterns related to the 
experimental intervention were identified in the metabolic profile of subjects in Chapter 3. 
The importance of this observation was realised when relating it to other physiological 
parameters along with dietary recordings. Together this highlighted that some caution is 
required when adopting such -omics approaches to pilot studies and that maximal 
interpretation can be gained when combining this with other functional measures.  
 The processing, analysis and interpretation of -omics data presents as a significant 
challenge. In spite of attempts made to standardise such procedures (Sumner et al., 2007), 
much discordance exists amongst previous studies. Whilst there are clear precautions to 
consider, there is no set ‘right’ way to proceed. The approaches adopted in this thesis 
attempted to adapt accordingly both to the nature of the data set produced and the initial 
experiment aims.  
 One clear limitation that remained with the interpretation of metabolomics/lipidomics 
data set regardless of the choice of analysis method was the inability to define for certain 
whether changes in a metabolite are a result of changes in production/supply or 
consumption. In essence, this technique provides a highly sensitive insight into a snapshot 
in time. Even when associated with other metabolite changes, in addition to other 
physiological measures, a degree of speculation is required. A way to confirm the impacts 
and relevance of the findings highlighted in this thesis would be through metabolic flux 
analysis, for instance through 13C flux (Wiechert, 2001). This has the potential to provide far 
greater insight into the remodelling of relevant pathways highlighted in this thesis.  
6.4.2 Critique of field work approach 
A key component of Chapters 2 and 3 of this thesis was field work, in both instances 
occurring in extreme environmental conditions. This work therefore extended beyond the 
standardised, controlled laboratory environment, as was utilised in Chapters 4 and 5. Whilst 
considerable effort was made to ensure accuracy and subjectivity did not impair measures 
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taken, the limitations in equipment and resources undoubtedly made this difficult.  Measures, 
such as body weight data or the diary analysis presented in Chapter 3 thus need to be 
interpreted with a degree of caution.  
Another factor lacking with this approach is the inclusion of a control group. In order to 
isolate the effects of hypoxia, this would require exposure to the same external factors minus 
hypoxia.  Indeed, a key issue with high altitude investigation is in attributing the effects of 
high altitude exposure solely to hypoxia. Whilst hypoxia has been recognised to be the major 
contributor to the physiological responses observed at altitudes (Woolcott et al., 2015), there 
are undoubtedly influences from other factors. For instance, when investigating metabolic 
alterations, dietary changes were an important consideration and were lacking in Chapter 2. 
The analysis approach attempted to address this concern. By looking at extreme changes 
occurring with ascent across the 5 altitude locations, this directed focus upon the altitude 
effect. However, this stringent approach did limit metabolite/lipid identification. This was 
particularly apparent in the metabolomic results whereby only 3 metabolites were taken 
forward for Bayesian modelling. Such a compromise was considered worthwhile to ensure 
confidence in the results.  
For future investigations into progressive acute or chronic hypoxic exposure, numerous 
measures could be adopted to minimise the influence of external factors. This would include 
the use of a hypobaric chamber, more frequent blood withdrawals as well as accurate 
recordings of daily dietary intake.   
6.5 Concluding remarks 
The work presented in this thesis outlines metabolic remodelling processes occurring in 
response to environmental hypoxia. The results confirm those of prior studies and unveil 
novel findings. The specific metabolites identified may be viewed as biomarkers for such 
exposure and highlight potential metabolic pathways to be examined in future studies. In 
addition, the work delved into the mechanisms of nitrate action and its potential as a therapy 
for sufferers of disease where hypoxia is a known comorbidity. Whilst mechanisms remain 
unclear, in vitro results indicate dietary nitrate supplementation may act as an aid to 
metabolic acclimatisation in hypoxia. However, the effectiveness of nitrate supplementation 
on alleviating hypoxic stress in vivo, and so its use as a potential therapy in a clinical context, 
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